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SUMMARY 
RESUMEN 

SUMMARY 
Ocular hypertension, although not considered a disease itself, it leads to glaucoma 
which eventually cause irreversible vision loss. Consequently, glaucoma therapeutic 
approach is to lower intraocular pressure (IOP). Nonetheless, anti-glaucoma drugs come 
often with several side effects that can lead to treatment withdrawal in some cases. In this 
context, melatonin and its analogs emerges as potential complimentary/alternative 
treatment, offering the advantage of hypotensive and antioxidant properties. 
 The present PhD thesis aim to investigate endogenous melatonin content in the 
aqueous humor and describes mechanisms involved in detecting increased IOP, along with 
a focus on the possibility of melatonin receptors to interact with different receptors with 
the intention to find a more effective combined therapeutical approach. Finally, to study 
the attribution of the crystalline lens to the aqueous humor melatonin content and to 
discover the regulation of its synthesis in this ocular structure. 
 Results showed a correlation between melatonin levels in the aqueous humor and 
IOP. Melatonin levels were found higher in patients with elevated IOP. Using a 
glaucomatous animal model (DBA/2J) it was possible to corroborate our findings. In vitro 
assays pointed to the participation of the TRPV4 channel, which is sensitive to pressure, 
among other stimuli. Activation of the mentioned channel in human immortalised non-
pigmented ciliary body epithelial cells resulted in an increment of melatonin secretion 
through the increase of aralkylamine N-acetyltransferase (AANAT) expression, the first 
enzyme in melatonin synthesis. In addition, short term assays showed that the TRPV4 
activation leaded to AANAT phosphorylation through a cascade of intracellular events that 
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involves the participation of calmodulin and calcium-calmodulin dependent protein kinase 
II. This phosphorylation activates AANAT and therefore melatonin synthesis is stimulated. 
 From the other hand, finding increased levels in ocular hypertensive cases has 
raised some questions, such as the reason behind the inability of endogenous melatonin to 
lower IOP, suggesting some alteration in melatonin receptors along with the development 
of glaucoma. Our results confirmed a decline in melatonin receptors expression when 
glaucoma is developed. More importantly, we introduced the concept of receptor 
heteromerization, using different techniques such as the technology of bioluminescence 
resonance energy transfer (BRET), we confirmed that heteromerization exists between 
both melatonin receptors and α1A-adrenergic receptors. Different assays were done to study 
the intracellular mechanism resulting from the activation of both heteromers showing that 
they are functional, and they present a cross antagonism in the case of healthy subjects. On 
the contrary, in vivo studies showed that melatonin instillation after blocking α1A-
adrenergic receptor with prazosin was more effective in lowering IOP than melatonin 
alone. Findings offers an effective combined therapy for glaucoma.  
 Finally, the discovery of melanopsin presence in the human crystalline lens was 
proved using immunolabelling in human lens tissue and crystalline epithelial cells, as well 
as by western blot. Such findings lead to the study of melatonin regulation in the 
crystalline lens, results showed an increment of AANAT, and its activity to produce 
melatonin under darkness condition. 
 Melatonin release to the aqueous humor from different structures showed clearly 
its importance in regulating IOP, thus, suggesting a possible mechanism to control 
pathologies such as glaucoma. 
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RESUMEN 
 La hipertensión ocular, aunque no se considera una enfermedad en sí, es un factor 
de riesgo para desarrollar glaucoma, que eventualmente causa pérdida irreversible de la 
visión. En consecuencia, el enfoque terapéutico más habitual en el glaucoma es reducir la 
presión intraocular (PIO). No obstante, los fármacos anti-glaucomatosos presentan varios 
efectos secundarios que pueden conducir a la retirada del tratamiento en algunos casos. En 
este contexto, la melatonina y sus análogos emergen como un tratamiento complementario/
alternativo, ofreciendo la ventaja de poseer propiedades hipotensoras y antioxidantes. 
 La presente tesis doctoral tiene como objetivo investigar el contenido de la 
melatonina endógena en el humor acuoso y describir los mecanismos implicados en la 
detección de los cambios en la IOP. Igualmente se estudia la capacidad de los receptores de 
melatonina para interactuar con otros receptores con la intención de encontrar un enfoque 
terapéutico combinado más eficaz. Finalmente, esta tesis también estudia la contribución 
del cristalinoen su aporte de melatonina al humor acuoso. 
 Los resultados han mostrado una correlación entre los niveles de melatonina en el 
humor acuoso y la PIO. Los niveles de melatonina se encontraron más altos en pacientes 
con PIO elevada. El uso de modelo animal glaucomatoso (DBA/2J) corroboró nuestros 
hallazgos de una manera consistente. Por otro lado, los ensayos in vitro señalaron la 
participación del canal TRPV4, proteína que es sensible a la presión,como principal 
activador de la sintesis de la melatonina.  De este modo, la estimulación de este  canal en 
células epiteliales del cuerpo ciliar no pigmentadas inmortalizadas humanas dio como 
resultado un incremento de la secreción de melatonina a través de un aumento de la 
expresion de la Aralquilamina N-acetiltransferasa(AANAT), la primera enzima en la 
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síntesis de melatonina. Además, los ensayos a corto plazo mostraron que la activación de 
TRPV4 induce a la fosforilación de AANAT, y su activación, a través de una cascada de 
eventos intracelulares implica la participación de la calmodulina y la calmodulina quinasa 
II dependiente de calcio-calmodulina. 
 Por otra parte, encontrar niveles aumentados en los casos de hipertensión ocular ha 
planteado algunas incógnitas. El motivo detrás de la incapacidad de la melatonina 
endógena para bajar la PIO, sugiere una cierta alteración en los receptores de melatonina 
paralelo al desarrollo de glaucoma. Nuestros resultados confirmaron una disminución en la 
expresión de receptores de melatonina cuando se desarrolla glaucoma. Más importante 
aún, introdujimos el concepto de heteromerización de receptores, utilizando diferentes 
técnicas como la tecnología de transferencia de energía de resonancia de bioluminiscencia 
(BRET), y confirmamos que la heteromerización entre los receptores de melatonina y el 
receptor α1A-adrenérgico exsite. Se realizaron diferentes ensayos para estudiar el 
mecanismo intracelular resultante de la activación de ambos heterómeros mostrando que 
son funcionales, y presentando un antagonismo cruzado en el caso de sujetos sanos. Sin 
embargo, los estudios in vivo demostraron que la instilación de melatonina después de 
bloquear el receptor α1A-adrenérgico con prazosin era más eficaz en la reducción de la PIO 
que la melatonina sola. Este hecho sugiere la posibilidad de una nueva terapia combinada 
eficaz para el glaucoma. 
 Finalmente, el descubrimiento de la presencia de melanopsina en el cristalino fue 
demostrado usando inmunomarcaje en tejido humano y células epiteliales del cristalino, 
así como mediante inmunotransferencia. Estos hallazgos conducen al estudio de la 
regulación de la melatonina en el cristalino, los resultados mostraron un incremento de 
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AANAT, y un aumento en su actividad para producir melatonina bajo condiciones de 
oscuridad. 
 La liberación de melatonina al humor acuoso de diferentes estructuras mostró 
claramente su importancia en la participación en la regulación de la PIO, sugiriendo un 
posible mecanismo de control en patologías como el glaucoma. 
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Chapter I: General aspects 
“Wisdom begins in wonder”  
Socrates 
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The eye: complexity makes our window to the outside world 
The eye is the organ of photo-reception, a process of transforming the light energy 
of the environment by producing changes in specialized nerve cells in the retina, leading to 
nerve action potentials reaching the brain through the optic nerve, where the information is 
processed and consciously appreciated as vision. This is the main physiological function of 
the eye. 
 The eye is a round sphere organ 2.5 cm in diameter and formed by two segments of 
different size and curvature, the anterior segment, the cornea; which is smaller and more 
convex, and the posterior segment with a greater radius of curvature; the sclera. The 
anterior segment of the eye is divided in turn, forming two internal cavities, the anterior 
and the posterior chamber, while the spherical shape of the posterior segment forms the 
vitreous cavity (Fig. 1.1) (John V. Forrester, 2015).
Figure 1.1. Schematic diagram of the human eye in horizontal section showing the major 
components and the arrangement of ocular structures (Image taken from Henry Gray, 
1918). 
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  It is made up of three basic layers or coats, often known as tunics. These are the 
fibrous (corneoscleral) coat, the vascular coat (composed of choroid, ciliary body and iris), 
and the neural layer (retina). The coats surround the contents, namely the lens and the 
transparent media (aqueous humor and vitreous body).  
 The cornea and the sclera envelop the eye in a way which forms protection of the 
ocular structures, as well as being an important structural support for the attachment of 
extraocular muscles. The cornea, is covered from the outside with the tear film, and it is 
responsible for most of the refraction of the eye. Its transparency is the most important 
property for vision and it is achieved in several ways; its avascularity; the regularity and 
smoothness of the covering epithelium; and the regular arrangement of the extracellular 
and cellular components in the stroma, which is dependent on the state of hydration, 
metabolism and nutrition of the stromal elements (John V. Forrester, 2015).  
 The uveal tract, the middle vascular pigmented layer of the eye, consists of three 
components, the iris, ciliary body, and the choroid. All are connected and have an initial 
opening in the pupil, and latterly at the optic nerve canal. The iris is a thin, pigmented, 
contractile disk which separates the anterior and poster chambers through the pupil 
opening, and is surrounded by the aqueous humor. The size of the pupil regulates the 
amount of light entering the eye and is dependent on the state of contraction of the intrinsic 
pupillary muscles, the dilator and sphincter pupillae  (Davis-Silberman and Ashery-Padan, 
2008). The ciliary body is a wide ring of tissues that extends from the scleral spur 
anteriorly to the ora serrata posteriorly. It is divided into an anterior zone called pars 
plicata (corona viliaris) and posterior, pars plana zone and it performs several functions 
such as accommodation, aqueous humor production and the lens zonule production. The 
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last ocular structure of the middle ocular layer is the choroid, which is the posterior part of 
the vascular coat of the eye. It is a thin, highly pigmented, vascular, loose connective tissue 
situated between the sclera and the retina, whose principal function is to nourish the outer 
layers of the retina (Nickla and Wallman, 2010). It also acts as a conduit for vessels 
travelling to other parts of the eye. Furthermore, absorption of light by choroidal pigment 
prevents unwanted light from reflecting back through the retina, something which occurs 
in some nocturnal species that possess a tapetum (Banerjee et al., 1992; Chinnery et al., 
2017). 
 The third and innermost coat of the eye is the retina and the retinal pigment 
epithelium. The retina is responsible for converting the images from the external world 
into neuronal impulses which are transmitted to the brain for analysis. it consists of the 
inner neurosensory retina and the outer simple epithelium, the retinal pigment epithelium 
(RPE). The neural retina is firmly attached only at its anterior termination, the ora serrata, 
and at the margins of the optic nerve head (Martinez-Morales et al., 2004).  
 The three tunics that make up the structure of the eyeball are arranged in such a 
way that within the eye delimit different cavities, we can find the lens, vitreous humour 
and aqueous humour (Fig. 1.1). 
The crystalline lens 
 The crystalline lens is located in the anterior segment of the eye, historically, it was 
reported that ancient Greco-Roman authors believed that the lens was located in the exact 
centre of the eye, however, studies showed that the centrality of the lens was an influential 
and enduring notion which seems to have originated with the ninth-century Arabic authors 
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in Mesopotamia, since ancient scientist used to dissect the eye and earlier photos showed 
the right location of the lens (Leffler et al., 2016).
 The lens is a biconvex avascular and transparent structure that is located between 
the iris and the vitreous humor. It is the second main structure in the refractive function of 
the eyeball after the cornea. Its main characteristic is its elasticity, being able to modify its 
curvature during the process of accommodation, like a lens in a camera, the basic function 
of the eye lens is to transmit and focus light onto the retina (Fig. 1.2) (Hejtmancik and 
Shiels, 2015).
Figure 1.2. Image of the anterior part of the eye showing the location of the crystalline 
lens (Image modified from David G. Cogan opthalmic collection, National Eye Institue). 
Structure and cells of the crystalline lens 
 The lens comprises three parts: the capsule; lens epithelium; and the lens fibers. 
The lens capsule completely envelops the lens and acts as a barrier to diffusion and 
contributes to shaping the lens during accommodation. It is a thickened, smooth, 
collagenous membrane which is composed mainly of type IV and XVIII collagens, 
laminin, entactin, perlecan, heparin sulfate proteoglycan, and fibronectin (Cammarata et 
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al., 1986; Parmigiani and McAvoy, 1984). The lens capsule is first detectable at 5–6 weeks 
of gestation in humans and is produced continually throughout life firstly by the cuboidal 
epithelium and then more slowly by the fiber cells (Fisher and Pettet, 1972).
 Lens epithelium is restricted to the anterior surface of the lens, where the mitotic 
division in the lens occurs. The anterior epithelial cells are connected by gap-junctions, 
allowing the passing of low-molecular weight metabolites and ions. They present few or 
no tight junctions that would make the extracellular spaces impermeable to these 
molecules. The anterior epithelium is also rich in organelles and contains large amounts of 
cytoskeletal proteins, such as microtubules, spectrin, ƒ-actinin, actin, myosin, and 
vimentin, presumably to help stabilize the cell structures during accommodation (Fig. 1.3).
Figure 1.3. A: Meridional section through the lens; 1. lens capsule; 2. lens epithelium; 3. 
transition of the epithelium into the fibers; 4. lens fibers (Image taken from the handbook 
of physiology, 1890). B and C: Scanning electron micrograph illustration the tightly 
packed mass of fiber cells in the human lens ( Image taken from Al-Ghoul KJ, Nordgren 
RK et al, 2001).
The cells become more columnar at the equator. As they elongate, the apical 
portion comes to lie deeper than other, more superficially positioned, lens cells. These 
elongated lens cells are known as lens ‘fibers’. The cell nucleus and cell body sink deeper 
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into the lens as further cells are laid down externally. Mitotic activity is maximal in the 
pre-equatorial and equatorial lens epithelium, known as the germinative zone, where the 
mitotic division in the lens occurs  (Goodenough et al., 1980).
 At birth, the lens weight is about 65 mg, at the age of 10 the human lens weight 
increases to about 160 mg and it continues growing substantially slower so that it weighs 
about 250 mg by the age of 90 (Augusteyn, 2007). Of the total mass of the lens, 60% is 
made up of proteins, much higher than almost any other tissue (Wistow and Piatigorsky, 
1988). The lens is surrounded by a collagenous capsule which acts as a barrier to diffusion 
and contributes to shaping the lens during accommodation (Atchison, 1995; Fisher and 
Pettet, 1972). 
 The crystalline lens is composed of a single cell type which follows a 
developmental pattern,  starting as a member of the germinative zone in the single layer of 
anterior epithelial cells overlying the fiber cell mess. These epithelial cells migrate 
laterally towards the equator, where they elongate and invert to form secondary fibers. To 
increase light transmission, organelles such as mitochondria, Golgi bodies, and both rough 
and smooth endoplasmic reticulum (ER) are degraded in the differentiating lens fiber cells 
so that they are absent from the nuclear fiber cells (Hejtmancik and Shiels, 2015).  As the 
cells elongate newer cortical fiber cells are layered over them so that they are moved 
toward the lens nucleus, stretching anteriorly from the cuboidal epithelial cells posteriorly 
to the posterior capsule. Transcriptional control plays a significant role in the differential 
synthesis of lens crystallins (Piatigorsky, 1987). The distribution of β-crystallin mRNAs in 
chickens and the β- and γ-crystallin proteins and mRNAs in rats provides examples of the 
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spatial and temporal control of crystallin gene expression during lens development (Clark 
and Huang, 1996; Hejtmancik et al., 1985; Muchowski et al., 1997).  
Transparency and aging 
 The main optical function of the lens is to transmit light to the retina through the 
cornea. It fine-tunes the focusing of light to the retina, and by changing shape, it adjusts 
focal distance (accommodation) (Pasta et al., 2004). 
 The human lens is colorless at birth; its transparency is due to its highly organized 
structure. However, during the earlier part of the sixth decade the color intensifies, and this 
is primarily confined to the nucleus, causing the effect on color perception (Petrash, 2013), 
probably due to the production of 3-hydroxykynurenine and other metabolites of 
tryptophan that filter UV light (Regini et al., 2007). Since the change is gradual, it 
generally goes unnoticed (Pescosolido et al., 2016). The limit of visual perception is about 
720 nm, the lens transmits light of wavelength up to 1200 nm efficiently, and a very little 
light below 390 nm. The lens absorption makes blue objects seem dull and grey unless 
they are very bright blues whereas green (made from mixing blue with yellow) appears 
yellow (Fig. 1.4) (Hejtmancik and Shiels, 2015). 
 As discussed previously, the architecture and cellular contents of the lens are 
critical for its transparency. The transparency and high-refractive index of cells in the lens 
result from the tight packing of their proteins, providing a constant refractive index over 
distances approximating the wavelength of the transmitted light. For several reasons, such 
as ageing or diabetes, the proteins in the lens aggregate resulting in the clouding of the lens 
and the formation of cataracts. As the light cannot pass clearly through the lens, there is 
some loss of vision. Since new cells cover the outside of lens, the other cells are 
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compacted into the centre of the lens, resulting in the cataract. The cataract ultimately 
results in the loss of vision in people over the age of 40 years. The most recent estimates 
from World Health Organization (WHO) reveal that 47.8% of global blindness is due to 
cataracts, making this pathology one of the top causes of reversible blindness (Cook et al., 
1994; Croft et al., 2001; Kaur et al., 2017).
Figure 1.4. A series of scaled changes in lens equatorial and polar dimensions with ageing.
The ciliary body 
 The ciliary body is a complex, highly specialized tissue that comprises several cell 
types. It is hidden behind the iris, which makes it impossible to visualize simply when 
someone looks at an eye. It is a wide ring of tissue that extends from the scleral spur 
anteriorly to the anterior border of the retina (ora serrata) posteriorly. It is divided into two 
zones, an anterior pars plicata (corona ciliares) and a posterior pars plana. On cross-
section, it have a shape of a triangle, and its base faces the anterior chamber and the apex 
blends posteriorly with the vascular choroid. The surface of the ciliary body (pars plicata) 
is elaborated into a series of ridges and consists of 70 radially arranged folds known as 
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ciliary processes, each is approximately 2 mm in size. The pars plana is an approximately 
4 mm wide zone stretching from the posterior limits of the ciliary processes to the ora 
serrata, the sharp serrated or dentate junction where non-pigmented ciliary epithelium 
undergoes a sharp transition to become the neural retina (Fig. 1.5) (Delamere, 2006).
Figure 1.5. The ciliary body location (taken from The Commoner diseases of the eye, 
how to detect and how to treat them, Casey Albert Wood ,1904). 
 The ciliary body can be divided histologically into the ciliary epithelium, ciliary 
body stroma and ciliary muscle, and its function can be divided into accommodation, 
aqueous humor production and production of the lens zonules, vitreal glycosaminoglycans 
and vitreal collagen. The base of the ciliary body is home to the ciliary muscle, the 
contraction of which causes the lens to assume a more rounded shape. This is because the 
lens is suspended by fine ligaments, called zonules that attach to the ciliary body. When 
the ciliary muscle contracts, the anchoring point of the zonules moves slightly inward, 
relaxing tension on the zonules, and the natural elasticity of the lens causes it to take on a 
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more spherical shape. This is how our focus shifts. It is the process of accommodation 
(Croft and Kaufman, 2006). When the ciliary muscle relaxes, there is a slight outward 
motion that tightens the zonules and flattens the lens (Croft and Kaufman, 2006). 
The ciliary processes 
The ciliary processes have a radial orientation with each ridge pointing toward the 
pupil. Each of the 70-80 processes is densely vascularized and covered by an epithelial 
lining of highly active, secretory cells to comply with the function of the ciliary processes; 
the aqueous humour production (Tamm and Lutjen-Drecoll, 1996). The covering epithelial 
layers is, in fact, a bilayer made up of two different epithelial cell types, the cell layer 
farthest from the anterior of the eyeball is developmentally related to the retinal pigment 
epithelium. It is named the pigmented epithelium (PE) and it is composed of cuboid cells 
with numerous melanosomes, and a small number of mitochondria and rough endoplasmic 
reticulum.This layer is separated from the stroma by Bruch’s membrane which contains 
collagen and elastic fibers. The other half of the ciliary epithelium bilayer, the non-
pigmented layer (NPE), is developmentally related to the neural retina. Unlike the EP 
cells, the NPE cells do not present melanin, however the amount of mitochondria and 
rough endoplasmic reticulum is much higher in these cells. This increase is even greater in 
the anterior cells of the pars plana, which is indicative of a higher metabolic rate 
(Delamere, 2006; Do and Civan, 2004).  
 The NPE is also composed of cuboid cells. These cells present a remarkably large 
number of invaginations and folds on that part of their surface. The basement membrane 
faces the aqueous humor. In addition to the existence of a basement membrane, there is an 
internal limiting membrane. This invagination of what is the basolateral membrane of the 
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non-pigmented ciliary epithelium, appears to be another anatomical feature, providing the 
ciliary body with an enormous surface area available for fluid secretion. There are other 
side interdigitations, close to which, the existence of enzymes can be detected: ATPase Na
+-K+ (potassium sodium pump) and carbonic anhydrase (CA), whose presence is also 
observed in the apical area (Civan and Macknight, 2004).
Figure 1.6 Schematic representation of a sagittal section of the eye, a focus on the bilayer 
of the ciliary epithelium, which constitutes the blood-aqueous barrier.
 The union of the two epithelial layers is established by desmosomes. These bonds 
are permeable, and allow the transit of water and ions between the two cell types. There 
are also gap junctions that regulate the intercellular transport of small molecules by 
opening channels with diameters of approximately 1.5 nm.
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 The ciliary processes, through the specific transport of substances, are responsible 
for the formation of aqueous humor. This transparent fluid is essential for the maintenance 
of ocular structures and their nutrition (Freddo, 2013; Kaufman, 2011). 
Aqueous Humour 
 The aqueous humour is a clear transparent fluid which bathes the anterior and 
posterior chambers of the eye. It is similar to blood plasma, composed mainly of water, 
electrolytes and substances of low molecular weight. Its ionic composition varies between 
different species (Adler, 1933; Civan and Macknight, 2004; Davson et al., 1936).  
 Some intraocular structures such as the iris, lens, and corneal endothelium 
contribute to the final composition of AH, however the formation of AH occurs mainly as 
an active process of secretion in the ciliary processes. After its secretion in the ciliary 
processes towards the posterior chamber, the aqueous humor circulates through the pupil 
towards the anterior chamber, where it drains (Bill, 1966b). The circulation of the aqueous 
humor from the posterior to the anterior chamber is directly related to its functions, such as 
providing oxygen and nutrients to the cornea, lens and trabecular meshwork, as well as 
removing waste substances from cellular metabolism, it also maintains a certain volume, 
giving the eye a certain intraocular pressure (IOP), which is essential for the correct 
functioning of the visual system, and it transports ascorbic acid to the anterior segment, 
where it acts as an antioxidant removing free radicals, and facilitates the immune response 
at the local level during an inflammatory process (Krupin et al., 1986). 
 In humans, the total aqueous humor volume is about 250 µl and it is produced at 
around 2-4 µl/minute (Toris et al., 1999). 
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Aqueous humor formation and drainage  
 The formation of the aqueous humour is a complex process which requires three 
steps to be carried out. First, the blood flow must reach the ciliary processes in the anterior 
uvea. From the plasma from these capillaries, an ultrafiltrate is generated towards the 
stroma, within the interstitial spaces between the vessels and the ciliary epithelium. The 
solutes of the ultrafiltrate cross the ciliary epithelium into the posterior chamber, and 
finally, they are accompanied by a passive flow of water following an osmotic gradient. 
The movement of solutes through the ciliary epithelium can be carried out through three 
interdependent physiological mechanisms, first, diffusion which is defined as the passive 
movement of solutes through the ciliary epithelium in response to a concentration gradient. 
In addition, substances with a high liposolubility coefficient are those that pass through the 
cell membrane more easily. Second is the ultrafiltration, which is the passive movement of 
water and water soluble substances through cell membranes as a result of hydrostatic and 
osmotic pressures and is produced as a result of the difference in pressures between the 
capillary blood pressure of the ciliary processes and the intraocular pressure. It represents 
the flow of most of the blood plasma through the endothelium of the fenestrated capillaries 
into the ciliary stroma. Finally, the active secretion which involves the movement of 
solutes through the ciliary epithelium against a gradient with energy consumption, and is 
the major mechanism in the aqueous humor formation. Aqueous humor formation through 
the active transport mechanism has been reported to be greater than by ultrafiltration and/
or diffusion, and is considered to be responsible for 80% of aqueous humor formation 
under normal conditions (Fig. 1.7) (Brubaker, 1991; Cole, 1977; To et al., 2002). 
 After the formation of the aqueous humor by the ciliary processes and its secretion 
to the posterior chamber, it passes through the iris and passes into the anterior chamber, 
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from where it will be drained to the level of the iridocorneal angle by some escape routes. 
Two main drainage routs exist inside the venous circulation: the conventional one through 
the trabecular meshwork, and the non-conventional route which is the uveoscleral 
pathway.
Figure 1.7. Aqueous humor pathway. The aqueous homor formation takes palce in the 
ciliary processes and it drain by the pathways describes in the test (photo taken for the 
National Eye Institute). 
1- Trabecular pathway: 
 The trabecular meshwork is the main pathway through which the aqueous humour 
is drained. Approximately 80-90% of the aqueous humour is evacuated through the 
trabecular pathway. For its drainage, the AH crosses different layers that constitute the 
trabecular meshwork: uveoscleral, corneoescleral and cribiform, until reaching the 
Schlemm canal. From here, the AH reaches the collecting channels, whereby it is drained 
into the intraclass and episcleral veins (Bill, 1966a; Weinreb et al., 2002). 
 The transcellular pathway is the main way in which the aqueous humor is 
transferred into the canal. The particularity of the structures of the transcellular pathway is 
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its regulation by means of pressure mechanisms. Thus, an increase in IOP results in an 
increase in the number of these structures; Almost disappearing when it decreases (Bill, 
1966a). Thus, in a range of normal pressures, the increase in IOP will be accompanied by a 
linear increase in HA evacuation; However, after a certain pressure limit, the drainage 
decreases due to the compression of the trabecular meshwork and the canal, which 
increases resistance to fluid passage (Brubaker, 1975, 1991) . 
2- Uveoscleral pathway 
 It is considered a minor pathway for the aqueous humor outflow, with 
approximately 10-20% drainage rate in humans. The lack of an epithelial barrier between 
the anterior chamber and the ciliary muscle favors the entry of AH into the ciliary body 
from the iridiocorneal angle. The fluid flows freely between the muscle bundles and enters 
the suprachoroid and supraciliar spaces, from where the sclera can be reached. The 
uveoscleral pathway is relatively insensitive to pressure increases (Pederson and Toris, 
1987; Suguro et al., 1985). 
 Intraocular pressure (IOP) is the force that supports intraocular tissues. It is 
maintained within stable values due to a complex and dynamic balance between the 
constant production of the aqueous humor and its drainage. Small variations in either 
direction cause changes in IOP, the main factors that affect IOP are circadian rhythms, 
episcleral vein pressure, the ratio between production and drainage of aqueous fumes, and 
the influence of hormones and nerves (cranial nerves V and VII). As for circadian rhythms, 
the IOP undergoes small variations throughout the day, being maximal first thing in the 
morning and reaching its minimum values at night. In humans, the rate of HA formation 
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was 2.61 µl / min during daytime and 1.08 µl / min during nights (McCannel et al., 1992). 
In terms of IOP , healthy human eyes presents a diurnal fluctuation which varies between 
3-5 mm Hg, being significantly greater in glaucomatous eyes (Asrani et al., 2000). 
 The IOP is considered to be elevated when it exceeds the values corresponding to 
the 97.5 percentile of the population, which in humans is usually established in values 
greater than 21 mm Hg. However, it is not considered a pathological process per se, 
although it constitutes an important risk factor in the development of certain ocular 
pathologies such as glaucoma (Casson et al., 2012a). 
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Melatonin: a great discovery reveals a multitasking molecule 
 Melatonin is an indoleamine (N-acetyl-5-methoxytryptamine) first discovered and 
described in the pineal gland by the dermatologist Aaron Lerner (Lerner et al., 1960). It 
derives from an important neurotransmitter called serotonin and it is mainly known to be 
responsible for regulating the circadian rhythm; one of the most relevant characteristics of 
melatonin is its variable synthesis throughout the day. Melatonin synthesis is increased 
during the night and reduced at day time  (Pevet, 2002, 2014; Tosini and Fukuhara, 2003; 
Zawilska et al., 2002). Since the discovery of melatonin, a diversity of functions for 
melatonin has been defined. One of the initial uses of melatonin in humans was to 
minimize the circadian disruption resulting from jet lag (Arendt, 1988). Endogenous 
nocturnal peak of melatonin is followed by a drop in body temperature, and a reduction in 
both systolic and diastolic blood pressure (Simko and Pechanova, 2009). On the other 
hand, bright light exposure at night, which inhibits melatonin rise, leads to an elevation of 
body temperature, higher level of performance, reduced sleepiness and an absence of 
blood pressure reduction. Exogenous melatonin intake promotes sleepiness among a series 
of proven body reactions enhancing the opening of the sleep gate (Krauchi et al., 2006; 
Nishiyama et al., 1997). 
 Melatonin have several functions apart from transducing photoperiod information. 
One of these functions is regulating seasonal reproductive activity in photoperiodic 
animals. Changes in the melatonin cycle, according to variations of ambient photoperiod 
duration, for instance, long nights during the winter, compared to shorter nights thus less 
melatonin during summer period, function as a calendar rather than just a clock providing 
the internal organs information about the time of year. Melatonin message is a signal 
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which allows seasonal breeders to anticipate the changing seasons and make the necessary 
adjustments in advance of the actual breeding period  (Arendt et al., 1995; Brainard et al., 
1982; Gupta and Haldar, 2014; Li and Zhou, 2015).  
 Significant evidence points towards the role of melatonin in suppressing 
carcinogenesis. Many tumours develop following damage to nuclear DNA when it goes 
unrepaired, as injuries of the DNA are frequently a result of free radicals. Since melatonin 
neutralizes free radicals, it protects DNA from the oxidative damage, besides melatonin 
may help in repairing the already damaged DNA. Melatonin can limit tumour progression 
by acting as anti proliferation, anti metastasis, proapoptotic, and prodifferentiation 
substance (Assayed and Abd El-Aty, 2009; Cerutti et al., 1994; Karbownik et al., 2000a; 
Karbownik et al., 2000b; Mao et al., 2016; Sliwinski et al., 2007). Currently, light at night 
is being examined as a causative factor for the elevated breast cancer in women and 
prostate cancer in men, giving the high incidence of breast and prostate cancer in human 
population and that light exposure after darkness onset alters biological rhythmicity and 
supresses melatonin (Fig. 1.7) (Karasek and Pawlikowski, 1999; Reiter et al., 2007a; 
Stevens, 2005, 2009a, b; Zamfir Chiru et al., 2014). 
 Melatonin ability to quench the devastatingly reactive and toxic -OH was first 
proven (Poeggeler et al., 1993; Tan et al., 1993) and then followed by the confirmation that 
melatonin is able to detoxify different damaging oxidizing agents like O2, H2O2, ONOO-, 
and HCIO (Reiter et al., 2008; Reiter et al., 2003; Reiter et al., 2007b). Melatonin is 
considered one of the best FDA-approved drugs as part of the Neurodegeneration Drug 
Sreening Consortium of the National Institute of Neurological Disorders and Stoke 
(NINDS) because of its ability to reduce cytochrome c discharge from mitochondria, 
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beside its capacity to easily cross the blood-brain barrier and its virtual absence of toxicity 
(Wang, 2009; Wang et al., 2013).Melatonin is of special importance in the ocular system.
Figure 1.8. Some of the numerous actions of melatonin in mammals from pineal 
and extra-pineal sources. 
 The eye is the window of our body to the outside world, informing us of the time of 
the day in order to regulate melatonin, starting from the retina. Independently of regulating 
light/dark cycles starting from the eye, melatonin contribute in numerous functions within 
several ocular structures. The cornea is the most superficial part of the eye and therefore it 
is likely to suffer accidents like foreign body entrance or inadequate contact lens wearing 
among others. Corneal health and transparency is of great importance to maintaining clear 
vision. Melatonin accelerate corneal wound healing, and it has been possible to 
demonstrate that the effect of melatonin is to increase the rate of cell migration rather than 
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mitosis (Crooke et al., 2015). And last but not least, melatonin acts as an antioxidant 
protecting ocular structures against free radicals. It have been proved to reduce intraocular 
pressure by decreasing the rate of aqueous humour secretion by the non-pigmented ciliary 
epithelium, resulting in a modulation of IOP (Fig. 1.8) (Wiechmann and Wirsig-
Wiechmann, 2001). 
Melatonin synthesis 
 Melatonin is synthesized primarily from tryptophan which hydroxylates to 5-
hydroxytryptophan, this amino acid is then decarboxylated by I-aromatic amino acid 
decarboxylase to form the biogenic amine serotonin (Axelrod, 1974). 5-25% of produced 
serotonin is then converted to N-acetylserotonin (NAS) through acetylation, which has 
been discovered to be involved in melatonin biosynthesis by the enzyme called 
arylalkymine N-acetyltransfrerase (AANAT). Finally, to convert NAS to melatonin, an 
enzyme called hydroxyindole-O-methyltransferase (HIOMT) is responsible for the O-
methylation step of NAS (Fig. 1.9) (Axelrod and Weissbach, 1961).  
 At night, an increment of melatonin synthesis is stimulated by electrical signals 
originated from neurons present in the suprachaismatic nucleus (SCN). These neurons 
receive inputs from the eyes and send inputs through the paraventricular nucleus (PVN) 
and then the spinal cord to the superior cervical ganglia (SCG) of the sympathetic nervous 
system, the fibres terminating adjacent to pinealocytes (Moore and Klein, 1974). 
 Norepinephrine (NE) is the neurotransmitter at the postganglionic sympathetic 
nerve terminal. It binds to α- and β- adrenergic receptors on the pinealocyte membrane and 
triggers a numerous of intracellular signalling. 
!28
Figure 1.9. Diagramatic resprestentation of melatonin synthesis in the pineal gland
(on the left).  On the rigth, a demonstration of daily rhythm in pineal indoles. Serotonin 
levels are hight during the day and decrease at night (dark panel) because of an increase in 
AANAT protein and activity. AANAT transfers an acetyl group from acetyl CoA to 5-HT. 
The increase in AANAT activity results in an increase in the intracellular concentration of 
N-acetylserotonin which is converted to melatonin by hydroxyindole-O-methyltransferase 
(modified after Klein,1974). AANAT, arylalkylamine N-acetyltransferase; AC, adenylate 
cyclase; HIOMT, hydroxyindole-O-methyltransferase; cAMP, cyclic adenosine 
monophosphate; CREB, cAMP response element-binding protein;NAS, N-acetyl 5-
methoxytryptamine; NE, norepinephrine; PKA, protein kinase A.
 When „- receptors are activated it stimulates guanine nucleotide binding protien 
(G-protein) which activates adenylate cyclase. ATP is hydrolyzed and intracellular cAMP 
levels rise, which enhance cAMP dependent protein kinase. This activates mRNA 
expression to synthesize AANAT or boost its activity. In parallel with the increment of 
cAMP levels and AANAT activity at night, there is a peak activity of phosphodiesterase 
which hydrolyses cAMP (Klein et al., 1997; Klein et al., 1992; Minneman and Iversen, 
1976). 
 Stimulation of ƒ- receptors activate a G-protein-linked to phosphotidylinositol 
cascade process involving phospholipase C (PLC), diacylglycerol (DG), and protein kinase 
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C (PKC). PKC in turn activates adenylate cyclase resulting in the enhancement of AANAT 
activity and melatonin synthesis (Fig. 1.8) (Ho et al., 1988). 
 Arylalkymine N-acetyltransferase, also known as serotonin N-acetyltransferase. It 
catalyzes the transfer of acetyl group from acetyl-CoA to serotonin resulting in the 
synthesis of NAS. This is the rate limiting step in melatonin production, with an activity in 
rat pineal gland showing a 24 hours rhythm with a nocturnal peak of 20- to 100 fold 
greater than daytime levels, which explain the higher melatonin levels during night 
(Reiter, 1993). 
 Hydroxyindole-O-methyltransferase is a cytosolic protein which constitutes 2 to 
4% of total soluble proteins in the pineal gland. This enzyme catalyses the O-methylation 
of NAS by S-adenosyl methionine to form melatonin. In mammals, pineal HIOMT activity 
is high and appears to exhibit no diurnal variation (Sugden, 1989). 
AANAT: the key enzyme in melatonin regulation ¨THE TIMEZYME¨ 
 Briefly after Aaron Lerner reported melatonin isolation, Weissbach reported studies 
describing an enzyme in pineal extracts which transfers a methyl group from S-
adenosylmethionine to N-acetylserotonin, and he described the presence of an enzyme in 
rat liver and beef pineal gland which could acetylate serotonin in the presence of acetyl-
CoA-generating system. Since beef pineal extracts also contained hydroxyindole-O-
methyltransferase, it was possible to show the conversion of serotonin to melatonin as a 
process performed in two steps (Weissbach et al., 1960). 
 Arylalkylamine N-acetyltransferase, AA-NAT, HGMW-approved symbol AANAT; 
EC 2.3.1.87. is of special interest because of its daily fluctuations indicating an  important 
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role, which is the molecular interface between the clock-driven regulatory systems and 
melatonin production (Fig. 1.9) (Klein, 1985; Klein et al., 1992). 
AANAT localization and Characteristics 
 The portion of AANAT gene encoding the mRNA transcript is approximately 2.5 
kb, 1.9 kb, 3.8 kb in human, sheep, and chicken respectively (Coon et al., 1996; Klein et 
al., 1996) .  
 The human AANAT gene is localized at 17q25. Studies done by Coon,1996 
suggested that AANAT have a single locus in the human genome using several techniques 
like PCR of a somatic cell hybrid panel or Fluorescence in situ hybridization (FISH) in 
addition to genomic Southern blots. In addition, it does not appear to be linked to any 
known genetic disease (Coon et al., 1996). The AANAT sequence contains conserved 
putative acetyl CoA binding motifs at AANAT121-140  and AANAT165-177 (Tercero et al., 
1992). Motifs A and B, which are located between these sites, may play a role in acetyl-
CoA binding or acetyl group transfer. The term motif A\B refers to two conserved 
sequences that identify family members, this is indicated by evidence that all proteins with 
these motifs are acetyltransferases, that point mutations in these motifs block activity 
(Namboodiri et al., 1980b; Tercero et al., 1992) and that similar structures are involved in 
nucleotide binding (Schulz et al., 1990). 
 A conserved histidine-rich region which includes motif A, within AANAT112-146. 
This region contains approximately 50% of the histidine although the sequence represents 
15% of total AANAT. Some of these histidine could function as a catalytic site based on 
the ability of the imidazole group to catalyze acetylation of indolamines (Klein et al., 
1976). Finally, the six conserved cysteines in mammalian AANAT can play a role in 
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protein thiol:disulfate exchange inactivation of the enzyme (Namboodiri et al., 1981; 
Namboodiri et al., 1980a).
Figure 1.10. Structure of arylalkylamine N-acetyltransferase (AANAT) Vertebrate 
AANATs are organized into a central catalytic core, which alone has enzymatic activity, 
and flanking regulatory regions, each of which has a PKA site. Phosphorylation of the N-
terminal PKA site converts the 6-residue sequence containing the PKA site into a 14-3-3 
binding motif: RRHTLPAN † RRHpTLP. The arylalkylamine-binding domain 
characterizes the AANAT family. The AcCoA binding domain is similar to that found in 
the acetyltransferase superfamily identified as the ‘Motif A/B’ superfamily, reflecting two 
highly conserved motifs in the AcCoA binding domain, or, as the ‘GNAT’ superfamily, 
reflecting membership of an important enzyme, GCN5. The structure and function of this 
superfamily are reviewed in detail in Dyda et al. (2000).
 Interestingly, 100% conservation is kept among the species examined (human, rat, 
sheep) in peptide sequences AANAT48-59, AANAT72-85, and AANAT90-100. these sites might 
be involved in binding arylalkylamine substrates (Klein et al., 1996). 
 Human AANAT deduced amino acid sequence defines a 23.2 kDa protein (Coon et 
al., 1995). The specificity of the substrate, Km values and stability of expressed and of 
partially purified ovine AANAT are similar. The degree of similarity to humans is the 
following: monkey (97%), sheep (84%), rat (90%), and chicken (76%). Closer observation 
of the sequence revealed similarity not uniformed, with the lowest level of conservation at 
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the extreme N-terminal portion of the molecule, and the remarkably conserved regions are 
found within a core that extends from the N-terminal PKA site to the end of motif A (Fig. 
1.10). Interestingly, within that region a 81% conservation is found among all available 
sequences. Furthermore, closer examination reveals a number of highly conserved 
characteristic features, including a number of stretches of 10 or more (example: 
AANAT48-59, AANAT72-85, and AANAT90-100) which is 100% identical amino acids in 
human, rats, and sheep, these sites might be involved in binding arylalkylamine substrates 
(Klein et al., 1997; Klein et al., 1996). 
 Conserved putative protein kinase A/protease regulatory regions are present at the 
C- and N-termini (RRXT/S). Moreover, a conserved protease cleavage site (RR) is present 
in the human sequence at amino acid 154, as well as conserved putative casein kinase 
phosphorylation site and a single putative protein kinase C phosphorylation site are present 
in human AANAT  (Coon et al., 1996). These phosphorylation sites are of a special interest 
since cAMP is known to regulate the activity of the enzyme (Klein et al., 1992); a drop in 
cAMP is thought to be the signal for the rapid turn-off in activity (Klein, 1978). cAMP acts 
on AANAT in several ways, most commonly is the prevention of proteosomal proteolysis 
(Gastel et al., 1998). AANAT protein binds to a member of an unfamiliar proteins called 
14-3-3 in which they form dimers. Studies showed that the N-terminal PKA site is 
embedded within a sequence that becomes a consensus 14-3-3 binding motif upon 
phosphorylation (RRHTLPAN︎RRHpT LPAN ; where pT is phosphothreonine) (Muslin et 
al., 1996; Petosa et al., 1998). A complex formation is triggered at night by cAMP-
dependent phosphorylation of the enzyme resulting in activation and protection against 
proteolysis. This complex is formed only if AANAT is phosphorylated and it is reversed 
and prevented by a 14 amino acid phosphopeptide that includes the N-terminal 
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PKA-14-3-3 binding motif of AANAT, which, in turn, binds to an amphiphathic groove of 
14-3-3. The 14-3-3 binding restricts the flexibility of loop 1 and stabilize binding pockets, 
leading to a decrease of the Km and, as a consequence, a reduction of Vmax, for 
arylalkymines by 10 folds. This can be especially good for the cells since they can 
maintain the enzyme, thereby helping melatonin production when serotonin levels are low, 
like the case at night when acetylation lowers total serotonin levels as much as 95% (Fig. 
1.9). 
 The regulation of AANAT protein by cAMP is a balance between destruction and 
protection. When cAMP is absent, AANAT does not bind to 14-3-3, therefore it is rapidly 
destroyed by proteasomal proteolysis. cAMP shifts the balance by directing 
phosphorylation of AANAT (pAANAT), which triggers binding to 14-3-3, thus protected. 
However, this binding is reversible by the drop of cAMP levels, because existing 
molecules of pAANT disassociate from the complex and re-association is blocked by 
dephosphorylation by protein phosphatase (PP), AANAT is then destroyed (Klein et al., 
2003). 
 Specificity is characterized by high selectivity for some arylalkylamine; like 
serotonin, tryptamine, methoxytryptamine and mescaline, but not for all, as in the cases 
of , histamine, norepinephrine and dopamine. The selectivity of the enzyme is further 
emphasized by the high activity towards tryamine and very low activity toward 5-
hydroxytyramine (dopamine). This selectivity, together with the number of potential 
arylalkylamine substrates in vertebrates, limits the physiological function of AANAT to 
serotonin acetylation (Klein et al., 1996). 
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 Studies first done in rats indicated that the nocturnal increase in enzyme activity is 
controlled by the 24-hour clock in the suprachiasmatic nucleus (SCN), that is linked to the 
pineal gland by a neural circuit which is activated at night, resulting in the release of 
norepinephrine from sympathetic nerves in the pineal gland which finally elevate cAMP 
levels which increase serotonin N-acetylation through a mechanism which requires 
membrane hyperpolarization, protein synthesis, and N-acetyling enzyme stabilization 
(Namboodiri et al., 1985; Namboodiri et al., 1983). 
Hydroxyindole-O-Methyl Transferase (HIOMT) :last step in melatonin synthesis  
 The final step in melatonin synthesis the conversion of N-acetylserotonin to 
melatonin, is catalyzed by the enzyme Hydoxyindole-O-methyltransferase (HIOMT).   
 Hydroxyindole-O-methyltransferase (HIOMT, EC 2.1.1.4.) is a cytosolic protein 
which constitutes 2 to 4% of the total soluble proteins in the pineal gland. This enzyme 
catalyses the O-methylation of NAS by S-adenosyl methionine to form melatonin. it was 
isolated and purified from bovine pineal gland and it appears to be formed of a dimer of 
two 39-kDa subunits. Nevertheless, human isolated HIMOT revealed a deduced amino 
acid sequence of 373 residue with a predicted pI of 5.7 and size of 41.6 kDa. Studies using 
western blot and immunodetection analysis confirmed the mass of human HIOMT to be 
about 42 kDA, which is larger than bovine HIOMT. Avian HIOMT has extra amino acids 
after residue 9 compared to the one of mammalian. The deduced amino acid sequences of 
bovine and avian HIOMT are 70% and 57% identical to the human HIOMT  (Donohue et 
al., 1993; Donohue et al., 1992). 
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 Computer analysis of human HIOMT sequence indicates several potential sites for 
secondary modification. two sites are conserved among the three sequences: the casein 
kinase II phosphorylation site at Ser-149 and the myristoylation site at Gly-216. In 
addition, 7 cysteines are conserved and it is possible that these form disulfide bonds or 
participate in protein thiol:disulfide exchange. 
 Analysis of a sample of 14 human individuals pineal gland homogenates indicated 
that all contained HIOMT with evident variability between individuals (As melatonin 
levels varies remakably between individuals). 
 When the question of the photoneural regulation of melatonin synthesis in the 
pineal gland was first examined, emphasis was placed on this enzyme, thinking that it was 
¨the¨ key enzyme in melatonin synthesis because of its narrow specificity and limited 
distribution. However, this view started to change when it was realized that HIOMT did 
not have a large daily rhythm while pineal serotonin and melatonin did. In addition, it 
became clear that adrenergic agonists could stimulate melatonin production without 
changing HIOMT activity. Altogether, this made the focus shift towards acetylation as the 
key regulating step in melatonin pathway (Sugden, 1989). 
Melatonin biosynthesis in extrapineal tissues 
 For several years after melatonin was discovered, it was considered to be 
exclusively produced by the pineal gland and only related to the control of the circadian 
and circannual rhythms. Afterwards, the presence of melatonin-related enzymes was 
subsequently discovered in the retina and the cerebellum (Bubenik et al., 1974). This was 
followed by its identification in many other peripheral tissues and organs (Reiter et al., 
1983; Stefulj et al., 2001). 
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 After melatonin synthesis was detected in the retina, Vlahakes and Wurtman 
discovered the presence of melatonin synthesizing enzymes in the rat harderian gland. 
Moreover, studies on pinealectomized rats were done and melatonin presence was found in 
the retina, cerebellum, and the harderian gland The expression of AANAT and HIOMT 
using more specific molecular technology revealed its presence in various tissues and 
organs including the retina (Olcese and Moller, 1989), iris, ciliary body (Aimoto et al., 
1985), crystalline lens (Abe et al., 2000; Quay, 1984), Harderian gland (Djeridane et al., 
1998) and the lacrimal gland (Mhatre et al., 1988), spleen, heart, skeletal muscle, liver, 
stomach, gut, placenta, testes, ovaries, cerebral cortex and striatum (Sanchez-Hidalgo et 
al., 2009). 
 Focusing on the eye, the retina was the first identified structure where melatonin is 
synthesized extrapineally after discovering the expression of AANAT and HIOMT in 
several retinal layers. First, it was thought that melatonin was synthesized in the 
photoreceptors, in the outer nuclear layer of the retina. However, different studies 
suggested that the photoreceptors are not the only place in the retina which produces 
melatonin. AANAT levels have been detected in the inner nuclear layer containing cell 
bodies of amacrine, horizontal, bipolar, and muller cells and in the ganglion cell layers as 
well (Coon et al., 2002; Liu et al., 2004). In the ciliary epithelium of the ciliary body, 
reports have indicated that these cells rhythmically synthesize melatonin and secrete it to 
the aqueous humour (Martin et al., 1988; Martin et al., 1992). AANAT and HIOMT 
activity have been detected in the human ciliary body (Martin et al., 1992). Specifically, 
the non-pigmented ciliary epithelium ,which is the one facing the aqueous humour, is the 
main area responsible for producing melatonin (Brubaker, 1991; Cole, 1977; Edelman et 
al., 1994; Rowland et al., 1986; Smith and Gregory, 1989). AANAT and HIOMT activity 
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have been also detected in the rat and rabbit lens. While AANAT activity showed a 
rhythmic behavior with peak levels during the night, HIOMT activity did not appear to 
fluctuate (Abe et al., 1999; Abe et al., 2000). Immunohistochemistry studies revealed that 
AANAT is localized in the lens cortical fiber cells. 
 Variation of melatonin synthesis in a day-night manner does not necessarily occur 
in all extrapineal synthesizing tissues, suggesting different signalling pathways from the 
photoperiod regulation of melatonin production. Furthermore, many extrapineal tissues 
have higher melatonin concentration than plasma throughout the 24 hours, and the 
intracellular melatonin from these tissues is not generally released into the circulation. All 
these observations suggest that extrapineal melatonin acts locally, possibly protecting cells 
from oxidative and inflammatory damage (Venegas et al., 2012). However, there are 
several exceptions to this assumption, for example, oral overload with tryptophan in rats 
and chicks induced a dose-dependent increase of melatonin in serum. Melatonin 
production was related to the enterochromaffin cells of the gastrointestinal tract (Huether 
et al., 1992). In other conditions, peripherally generated melatonin seem not to enter the 
circulation. 
Melatonin degradation  
 Unlike melatonin synthesis, melatonin metabolism is less thoroughly understood. It 
was believed for several decades that melatonin had only one metabolite, 6-
hydroxymelatonin, which is now considered the classical hepatic way of degradation 
(Facciola et al., 2001). However, melatonin metabolism is a highly complex process and 6-
hydroxymelatonin is only one of its metabolites. Melatonin is metabolized by either an 
enzymatic process, a pseudoenzymatic process or via its interaction with ROS and NOS.  
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 In the classical melatonin metabolism pathway, the liver CYP P450 enzymes 
CYP1A1, CYP1A2, and CYP1B1 metabolize melatonin to 6-hydroxymelatonin, which is 
then conjugated with either sulfate or glucuronide and secreted in the urine (Arendt, 1988; 
Facciola et al., 2001; Ma et al., 2005).    
 The alternative indolic pathway involves melatonin being metabolized to 5- 
methoxytryptamine by melatonin deacetylase (Grace et al., 1991; Rogawski et al., 1979; 
Semak et al., 2005). 5-Methoxytryptamine is then converted by monoamine oxidase to 5-
methoxyindoleacetaldehyde, which is further enzymatically metabolized to either 5-MIAA 
or 5-MTOL by aldehyde dehydrogenase and alcohol dehydrogenase, respectively. Recent 
studies performed on the liver have indicated, however, that both mitochondrial and 
microsomal cytochrome P450s metabolize melatonin predominantly by 6-hydroxylation, 
with O-demethylation representing a minor metabolic pathway (Semak et al., 2008).  
 In the kynuric pathway, cleavage of the pyrrole ring of melatonin by indoleamine 
2,3- dioxygenase yields AFMK, which is further metabolized by arylamine formamidase 
to form N1-acetyl-5-methoxykynuramine (AMK) (Hardeland et al., 1993; Hirata et al., 
1974). The kynurenic acid degradation pathway can also be executed by other enzymes, 
including peroxidase, and myeloperoxidase (Slominski et al., 2008). The free radical 
species have also been shown to be involved in a non-enzymatic kynurenic pathway (Tan 
et al., 2000; Tan et al., 2007). The additional route of melatonin degradation in 
mitochondria to AFMK by cytochrome C was also described  (Semak et al., 2005).  
Melatonin Receptors 
 Melatonin shows its effects by several mechanisms in mammals. First, by binding 
to melatonin receptors in plasma membrane, or to orphan nuclear membrane. Another 
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mechanism is biding to intracellular proteins such as calmodulin, calreticulin and tubulin. 
Finally comes the antioxidant effect (Pandi-Perumal et al., 2008). 
 In mammals, melatonin receptors are found in many body structures and tissues, 
such as the brain, retina, cardiovascular system, skin, immune system cells, kidney, 
platelets among many other sites. Melatonin receptors MT1, MT2 have been cloned and 
characterized, while the putative MT3 was pharmacologically characterized, and in some 
animal models it has been suggested that it is the quinone reductase 2 enzyme (QR2) 
which plays a role in preventing oxidative stress and presenting features of melatonin 
receptors. Apart from the three receptors, a melatonin related orphan receptor has been 
found in mammals, GPR50, which surprisingly does not bind melatonin (Li et al., 2013). 
Finally, a different orphan nuclear hormone receptor RZR/ROR α has also been described 
(Pozo et al., 2004; Rafii-El-Idrissi et al., 1998). 
Nuclear receptor 
 Melatonin is a ligand for a retinoid related orphan nuclear hormone receptor (RZR/
ROR α; human gene ID: 6095). theses receptors include three subtypes (a, b, d) and four 
splicing variants of the a-subtype (Becker-Andre et al., 1993). The structure of nuclear 
receptors consist of an N-terminal domain, a DNA binding domain that contains a zinc 
double finger, a hinge region, and a ligand binding domain included in the C-terminal 
(Lardone et al., 2009; Smirnov, 2001). Little is known about the interaction between 
melatonin and these nuclear receptors, and whether they interact directly has been a source 
of controversy. Some studies theorized that melatonin interacts with the nuclear receptors 
of the retinoic acid family of orphan receptors (Becker-Andre et al., 1993; Carlberg and 
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Wiesenberg, 1995). However, others propose that melatonin indirectly regulates nuclear 
receptors through MT1 membrane receptor (Ram et al., 2002). 
Membrane receptors 
 Most of melatonin actions are mediated by its membrane receptors. Melatonin 
receptors are members of the 7-transmembrane G protein-coupled receptor family 
(GPCRs). Both MT1 and MT2 receptor subtype belong to the class A of rhodopsin-like 
GPCRs (www.gpcr.org/7tm) and contains 7 hydrophobic transmembrane helices.  
 The MT1 receptor is formed by 350 amino acids, and it has a calculated molecular 
weight of 39 kDa. The chromosome location for MT1 receptor is 4q35-1(Navajas et al., 
1996). The MT2 receptor is formed by 362 amino acids with a 40 kDA molecular weight 
and it is located in 11q21-22 (Reppert et al., 1995). Both receptors share 60% homology.  
 The existence of 3 extracellular loops alternating with 3 intracellular loops to link 
the 7-transmembrane regions suggests the presence of potential sites for glycosylation and 
phosphorylation. The MT1 melatonin receptor has 2 potential glycosylation sites in the N-
terminal region and it may exist in more than one glycosylated form, while MT2 receptor 
has one potential glycosylation site in the N-terminal region (Navajas et al., 1996; Reppert 
et al., 1996b).  
 An orphan receptor called the melatonin related receptor GPR50 is encoded by a 
gene located on the X chromosome (Xq28) and it has 45% amino acid homology to 
melatonin receptors (Dufourny et al., 2008). Despite this homology, melatonin does not 
bind to GPR50 and the identity of its real ligand is unclear (Reppert et al., 1996a). 
However, GPR50 has been shown to heterodimerize with both MT1 and MT2, but it only 
!41
interferes with MT1; deletion of the large C-terminal tail of GPR50 abolishes the inhibitory 
effect of GPR50 on MT1 without affecting heterdimerization (Li et al., 2013). 
Receptors heteromerization: A new era involving melatonin receptors 
 G protein-coupled receptors (GPCRs) are the largest class of cell surface receptors 
in mammalian genome. Approximately 1000 genes thought to encode GPCRs in humans, 
around 300 to 400 of these genes mediate the effects of endogenous ligands, with the 
remainder being sensory receptors. Almost half of all current prescription drugs act 
through GPCRs. All these facts taken together point towards the importance this class of 
receptors has from a pharmacological point of view (Drews, 1996; Prinster et al., 2005). 
 GPCRs have traditionally been thought to act as monomers. iInterestingly, a new 
era emerged in 1979-1980 when Luigi F. Agnati and Kjell Fuxe hypothesized that an inter-
membrane interaction between neuropeptide and monoamine receptors could occur. The 
first observations were published in 1980, showing that substance P could modulate the 
high-affinity serotonin binding sites in spinal cord membrane preparations using 
biochemical binding   techniques (Agnati et al., 1980). This idea has been challenged over 
the past few years by accumulating pharmacological and biochemical data, all indicating 
that the primary functional GPCR signaling unit may actually consist of dimers or 
oligomers of receptors (Angers et al., 2002; George et al., 2002; Jordan and Devi, 1999; 
Marshall, 2001). Although the idea did not gain wide acceptance until more than a decade 
later, early evidence for GPCR dimerization came from unexplained cooperativity 
observed in ligand binding assays and unexpectedly large estimates of the size of receptor 
complexes on gel filtration columns (Agnati et al., 2003; Angers et al., 2002). 
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 Multimerization of GPCRs was originally based on studies investigating the 
possibility of certain GPCRs to dimerize with themselves (homodimerization). Currently, 
there is a growing list of receptors that have been found to associate with other receptors 
(heterodimerization). The reports of heterodimerization suggest a potential level of 
receptor complexity that could explain previously unexpected pharmacological profiles. In 
addition to fundamentally changing our views on the structure and activation processes of 
GPCRs, the concept of homo- and heterodimerization could have dramatic impacts on 
drug development and screening (Prinster et al., 2005). 
 With the challenge of such a discovery, a concern in the field that GPCRs 
heterodimerization might be an artifact of receptor over-expression and/or a result of the 
techniques used to study receptor associations has been addressed. This issue appeared 
clearly since studies are normally carried out in heterologous cells, nevertheless, new 
techniques and approaches are being tested. To best address this issue we need to consider 
the evidence that these receptor-receptor interactions are specific versus non-specific and 
that they are functionally important versus physiologically irrelevant (Prinster et al., 2005). 
A number of new approaches has made it possible to obtain credible evidence of 
homomers of many types of GPCRs, such as complimentary chimeras, co-
immunoprecipitation with differentially epitope-tagged receptors, the use of sodium 
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), often in combination 
with covalent cross- linking, and biophysical methods, namely bioluminescence resonance 
energy transfer (BRET) and fluorescence resonance energy transfer (FRET), and finally, a 
novel in situ proximity ligation assays (PLA)(Agnati et al., 2003; Soderberg et al., 2006). 
 Concerning melatonin receptors, a study was conducted to investigate the possible 
interaction between MT1 and MT2 melatonin receptors. An experiment to investigate the 
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existence of constitutive homo and hetero-oligomerization among MT1 and MT2 was 
carried out in HEK 293 cells expressing physiological levels of both receptors using BRET 
approach among other techniques. The putative oligomerization of MTs receptors was 
assessed using co-oimmunoprecipitation assays, the results indicating that both MT1 and 
MT2 homo-oligomers can be formed. Also, western blot analysis of membrane derived 
from HEK 293 cells expressing tagged melatonin receptors revealed three groups of 
immunoreactive bands with a similar migration pattern, suggesting the presence of 
monomeric, dimeric, and higher oligomeric states for other GPCR (Ayoub et al., 2002). 
 Investigation showed that MT1 and MT2 are predominantly expressed as dimers in 
living cells, such results are consistent with the assumption that they represent functional 
signaling units. Thus, although receptor dimerization is not modulated by ligand binding, 
dimers may still be necessary for biological function (Ayoub et al., 2002).  
 Melatonin receptors, as other GPCR receptors, can interact with different types of 
receptors. Recent studies showed that both MT1 and MT2 receptors and serotonin receptor 
5-HT2C form heteromers.  Within both heteromers, melatonin showed the ability to activate 
different cellular cascades, the former Gi/cAMP in the case of MT2 homomer, as well as 
Gq/PLC pathway by transactivation of the 5-HT2C promoter. This transactivation was 
unidirectional and it was not observed for the MT2 protomer upon 5-HT stimulation.  
Whereas melatonin activates both pathways, other ligands have a more restricted profile 
using either the direct activation or transactivation mode. Interestingly, the clinically active 
antidepressant agomelatine shows functional properties on MT2/5-HT2C heteromers that 
are biased toward the Gi /cAMP pathway and thus distinct from those of melatonin- and 5-
HT2C-specific antagonists (Kamal et al., 2015). 
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 Heteromerization behavior of GPCR class of receptors, in this case melatonin 
receptors, could be an important therapeutic target for several pathologies, specially 
because of melatonin’s diverse functions in several body organs. Many questions and 
observations are still to be addressed on this regard.   
Signalling pathways 
 A well established classical intracellular pathway for MT1 and MT2 receptors has 
been canonically accepted . In the classical way, MT1 and MT2 stimulation would lead to 
adenylate cyclase (AC) inactivation in a Gαi subunit process of the G protein coupled to 
the membrane receptor (von Gall et al., 2000). When AC is inactivated, it would lead to a 
decrease in intracellular cAMP concentration, and finally a decrease in activated protein 
kinase A (PKA). The action of these receptors has been shown to inhibit forskolin-induced 
cAMP formation (Vanecek, 1998). 
 However, depending on the tissue, organ or species studied, the MT1 and MT2 
receptors are capable of activating very different signaling cascades. In the HEK293 cell 
line the MT1 receptor has been implicated in the activation of the phospholipase C-α 
(PLC-α) (Brydon et al., 1999); While MT2 receptor, in addition to classical inhibition of 
AC, has been described in the inhibition processes of the enzyme guanylate cyclase (GC) 
(Petit et al., 1998). 
 The plasticity in signal transduction demonstrated by melatonin receptors is at least 
partially related to their ability to associate with different types of G proteins. It is known 
that the cloned melatonin receptors are capable of binding Gi proteins to subtypes of 1 -3, 
Gz and possibly Gs (Tslm et al., 1996). In fact, Gs activation has recently been confirmed 
for the MT1 receptor in human prostate epithelial cells. Signal transduction of receptor-
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mediated antiproliferative action of melatonin on human prostate epithelial cells involves 
dual activation of G!(s) and G!(q) proteins (Shiu et al., 2010). Similarly, MT1 and MT2, 
have demonstrated the ability to associate to G16 protein in transfected COS-7 cells (Lai et 
al., 2002; Mody et al., 2000). Activation of phospholipase C (PLC) by melatonin 
stimulation also suggested a possible association of these receptors with Gq, G11 or G14 
protein (New et al., 2003). Activation of Gq has been demonstrated for the MT1 receptor in 
gastrointestinal smooth muscle, associated with PLC activation and increased intracellular 
Ca2+ and phosphatidylinositol (PI) hydrolysis (Ahmed et al., 2013). Similarly the MT2 
receptor is able to activate PKCζ in a process associated with the activation of Gq in 
mesenchymal cells (Lee et al., 2014). 
Signalling pathway through adenylate cyclase 
 Adenylate cyclase is an enzyme, belonging to the group of lyases, which catalyzes, 
from ATP, the synthesis of cAMP. It acts as a second messenger in multiple intracellular 
pathways, the most studied being the activation of PKA. 
 Ten different isoenzymes, called type 1 to 10, have been described, differing 
mainly in their sensitivity to the different types of Gα, Gβγ and CaM subunits (New et al., 
2003). 
 Mediation of pertussis toxin-sensitive G protein, and its action on the accumulation 
of intracellular cAMP, induced by melatonin receptors, was already described by Carlson 
et al in 1989 (Carlson et al., 1989). Inactivation of this pathway by pertussis toxin clearly 
indicated the involvement of Gi protein as a mediator in transduction. In 1995, the 
coupling of Mel1c to Gi protein, and the direct action of the Gαi subunit on adenylate 
cyclase and the consequent decrease in cAMP (Yung et al., 1995) was demonstrated. 
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 However, this is not the only way in which melatonin receptors modulate AC 
action. This is due to the large number of different isozymes and the ability of melatonin 
receptors to be associated with different types of G protein. The Gαi and Gαz subunits are 
able to inhibit type 1 AC to 6, whereas Go has not been shown to inhibit ACs types 2,4,5 
and 6 (Lee et al., 2014). The Gβγ subunits are capable of inhibiting type 1 AC; However, 
they act as activators of type-2 and 6-type ACs when they have been pre-activated by Gαs 
or phosphorylated by PKC. This phenomenon has been observed in the model of renal 
embryonic cells transfected with Mel1c receptor and overexpression of type 2 AC. In this 
model melatonin was able to increase the accumulation of intracellular cAMP (Yung et al., 
1995) through a melatonin receptor coupled to Gi and Gz, via Gβγ subunit. 
 This model could explain apparent contradictions such as the potentiation that 
produces melatonin in the accumulation of cAMP-induced vasoactive intestinal peptide in 
human leukocytes (Lopez-Gonzalez et al., 1992). Independently of the aforementioned 
mechanisms, CaM is capable of inhibiting AC activation type 5 and 6 (Taussig and 
Gilman, 1995). Thus, melatonin by direct action on CaM, preventing the binding of Ca2+ 
to calmodulin, would be able to deactivate the inhibition on these two types of AC, and 
thus increase the intracellular concentrations of cAMP. In contrast, type 1 and 2 CAs are 
activated by CaM (Taussig and Gilman, 1995); So that inhibition of it, would result in a 
decrease in cAMP levels (Fig. 1.11). 
 Another possible pathway for the regulation of CA involves its activation by 
phosphorylation mediated by PKC. Type 1-8 CAs present this type of regulation (Taussig 
and Gilman, 1995). As previously discussed, melatonin receptors may activate this 
signaling pathway by different mechanisms. Activation of PKC and phosphorylation of 
!47
type 1 AC to 8 would therefore promote increased intracellular cAMP concentrations 
(New et al., 2003). 
Figure 1.11. Scheme showing membrane signalling by melatonin receptors MT1 and MT2, 
both G-protein coupled receptors. On the right is shown the interaction of Gi with adenyl 
cyclase (AC) to decrease cAMP levels and therefore cyclic AMP-dependent protein kinase 
activity (PKA). On the left is shown the interaction of Gq with phospholipase C (PLC) 
leading to the cleavage of phosphatidyl inositol diphosphate (PIP2) into inositol 
triphosphate (IP3) and diacylglycerol (DAG). These second messengers stimulate 
increased intracellular Ca2+ and protein kinase C (PKC), respectively. The downstream 
effects of these events at the membrane vary with cell type.
 Therefore, the final response triggered by melatonin and its receptors, will depend 
on the different combinations between G proteins, activated signalling pathway and the 
majority presence of the different isoenzymes belonging to that pathway present in each 
cell type. 
 This variety in the transduction of different intracellular signals makes it difficult to 
study the melatonin receptors, even more so, when the same receptors besides regulating 
different second messengers can regulate the same transduction pathway positively or 
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negatively, according to the conditions environmental or cell type studied (New et al., 
2003). 
PLC / PKC signaling pathway 
 PLCβ is an enzyme involved in the metabolism of phosphatidylinositols (PI) and 
intracellular signaling measured by Ca2+. Activation of this enzyme has been associated 
with different G protein subunits: Gαq, Gα11, Gα14, Gα15, Gα16, and Gβγ subunits (Rebecchi 
and Pentyala, 2000). There is extensive literature demonstrating the activation of this 
pathway mediated by melatonin, in various cell models (Benitez-King et al., 2001; Eison 
and Mullins, 1993; Mullins et al., 1997; Popova and Dubocovich, 1995). As we have 
already mentioned, recent work in this field has shown that the interaction between 
melatonin receptors and PLC is mediated by the Gq protein (Ahmed et al., 2013). This 
pathway of activation binds the already reported mediated by G16. However, these are not 
the only mechanisms that enable PLC / PKC activation. Prior to the discovery of the 
association of melatonin receptors with Gq protein, an alternative mechanism mediated by 
Gβγ subunits was postulated (New et al., 2003). There are multiple examples of activation 
of this pathway mediated by Gβγ subunits of Gi protein-associated receptors. In fact, there 
are systems in which the activation of the PLC/PKC pathway by melatonin receptors is 
abolished by the action of the pertussis toxin, which directly implies the intermediation of 
a Gi protein (MacKenzie et al., 2002; McArthur et al., 1997). In the same way, an effect 
described in the literature is the potentiation of activation of the PLC, pre-activated by Gq, 
mediated by Gi protein (Chan et al., 2000). This effect has been observed in HEK-293 cells 
in which a potentiation of PLC activation has been observed when MT1 receptors and P2Y 
receptors coupled to Gq protein are stimulated simultaneously (Roka et al., 1999). 
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Transient Receptor Potential Ion Channels (TRP) 
 TRPs are a super-family of non-selective cation channels which play critical roles 
in the responses to various environmental changes and stimuli. TRP channels derive their 
name from a Drosophila trp mutant that was unable to respond to repeated or constant 
bright light stimulation (Cosens and Manning, 1969). Twenty years later, molecular 
cloning and functional analysis led to the discovery that the defect lies in a gene encoding 
for a cation channel known as TRP in Drosophila (Montell and Rubin, 1989). Up to date, 
28 mammalian TRP channels are known, divided into 6 subfamilies: canonical (TRPC), 
vanilloid (TRPV), melastatin (TRPM), mucolipin (TRPML), polycystic (TRPP) and 
ankyrin (TRPA).  
 TRP channels are tetrameric proteins with subunits having six transmembrane 
domains, with varying sizes of cytoplasmic C- and N- terminal tails. Depending on the 
family branch, the cytoplasmic amino-terminal domain contains different numbers of 
ankyrin repeats, ranging from zero to twenty nine, which have been seen to be involved in 
a range of interactions (Gaudet, 2008). The majority of functionally characterized TRP 
channels are permeable to sodium, chloride, potassium and calcium, but each of them has 
unique characteristics for ion permeability, conductance, voltage dependence and gating 
(Ramsey et al., 2006). 
 Many TRPs are sensitive to physical stimuli like temperature, pH, shear stress and 
other mechanical forces such as stretch and hypoosmolarity. Furthermore, many TRPs are 
ligand gated and voltage sensitive. For example, in high temperatures greater than 420 C 
and caspaisin (the spicy component of chilli peper), the channel TRPV1 is opened. 
!50
Meanwhile, TRPM8 is opened by low temperatures, below 230 C, and by cooling agent 
like menthol and icillin (Caterina et al., 1997; Peier et al., 2002a). 
 TRP channels are widely distributed through the body, expressed in a vast number 
of different cell types. They are specially abundant in sensory receptor cells, and play a 
critical role in vision, hearing, taste, pain and temperature sensation. 
 TRP channels mediate the transmembrane flux of cations down their 
electrochemical gradients, thereby raising intracellular Ca2+ and Na2+ concentrations and 
depolarizing the cell. Transmembrane voltage changes underlie neuronal action potential 
propagation and muscle contraction, and direct the driving force for calcium entry through 
plasma membrane channels in non-excitable cells, as well as controlling the gating of 
voltage-dependent Ca2+, K+, and Cl- channels. TRPs are well positioned to regulate [Ca2+]i, 
[Na2+]i, and Vm in both excitable and non-excitable cells (Ramsey et al., 2006). 
TRPV4 
 The TRPV4 cation channel (GenBank accession number NM_022017) was first 
described in 2000, by cloning cDNAs with homology to the conserved coding regions of 
mammalian TRPV1 and TRPV2 and Osm-9, the osmosensor from C. elegans (Liedtke, 
2007) and was identified as the possible sensor for osmolarity in the kidney, liver and heart 
(Strotmann et al., 2003).   
 TRPV4 gene is located in the long (q) arm of chromosome 12 at position 24.1, 
being located from the base pair 109,783,086 to base pair 109,833,406 on chromosome 12 
as commented. The TRPV4 protein is known to compose 871 amino acid residue and 
normally assembled as a homotetramer. Each TRPV4 monomer has six transmembrane 
helices (S1-S6) stretching across the lipid bilayer, together with the re-entering loop 
!51
known as the pore loop, found between S5 and S6. The transmembrane region is found to 
be similar to that of TRPV1. NH2 and COOH termini are localized in the cytoplasm  (Fig. 
1.12) (Stewart et al., 2010). Heterotetramers have been also reported with TRPC1 and 
TRPP2, as well as heteromeric TRPV4-TRPC1-TRPP2” complexes (Du et al., 2014).
Figure 1.12. The TRPV4 protein is composed of a cytosolic N-terminal region and six 
transmembrane domains, including the pore region and an intracellular C-terminal tail. 
The N-terminal region contains the ankyrin repeat domain, which consists of six ankyrin 
repeats
 TRPV4 is a polymodal channel which can be activated either by sensitization or 
opening by intracellular signalling. Besides its former exclusively known function as 
osmoregulator,it is also sensitive to moderate heating ranging between 25–34 °C (Guler et 
al., 2002; Watanabe et al., 2002). Studies in mice knock out (TRPV4-/-) exhibited delayed 
tail withdrawal to moderately hot temperatures and a strong preference for warmer floor 
temperatures, whereas wild type mice did not discriminate between 30 and 34 °C (Lee et 
al., 2006). 
 This channel is also sensitive to changes in the pH. Reports have revealed the 
TRPV4 channel opening by low pH or citrate. Mechanical stress has also been described, 
both in vivo and in a cellular level, by extracellular osmotic pressure. Moreover, TRPV4 is 
capable of being gated in response to inflammation, since it increases interstitial fluid 
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volume and tonicity, which create abnormal mechanical pressure on the plasma 
membranes of the cells (Alenmyr et al., 2014). 
 Mechanistically speaking, the TRPV4 is a Ca2+ permeable non-selective cation 
channel that exhibits both inward and outward transition. Both spontaneous and agonist-
induced TRPV4 currents are substantially diminished without the presence of extracellular 
Ca2+. The rate and extent of channel activation is increased by Ca2+ entry during agonist-
induced TRPV4 activation. Ca2+ selectivity of TRPV4 pore was found to be influenced by 
two aspartate residues, Asp672 and Asp682. When both aspartates are neutralized, Ca2+ 
permeability decreases to a much higher extent than the reduction in channel rectification. 
While ,when either aspartate is neutralized to alanine, there is a small decrease both in the 
relative permeability for divalent cations and in the extent of outward rectification (Voets 
et al., 2002).  
 The modulation of the TRPV4 channel can occur by different mechanisms. For 
instance, studies suggest that the COOH terminus CaM-binding domain is a pre-requisite 
for Ca2+ induced potentiation of TRPV4 in certain systems. Nevertheless, NH2 terminal 
ARDs of TRPV4 possess CaM-binding site as well and it may function as Ca2+ induced 
modulator for TRPV4 in other systems (Strotmann et al., 2003; Strotmann et al., 2010). 
 Phosphatidylinositol 4,5-bisphosphate (PI(4,5)P2), a minor phospholipid 
component of cell membranes, is important for TRPV4 proper functioning. PI(4,5)P2 binds 
and rearranges the cytosolic tails of TRPV4 to enable hypotonic and heat stimuli to 
activate the channel (Garcia-Elias et al., 2013).  
 The ankyrin repeat domain found in TRPV1,TRPV3 and TRPV4 possesses a 
ligand binding site for ATP and calmodulin among other ligands. ATP and CaM function 
!53
through this multiligand site to mold the varying sensitivity and adaptation profiles of 
these several ion channels. Both function interactively to determine receptor sensitivity to 
Ca2+ concentration changes (Phelps et al., 2010). 
 High viscous loading and hypotonicity stimuli activates TRPV4 through 
phospholipase A2(PLA2) activation and the subsequent production of the arachidonic acid 
metabolites, epoxyeicosatrienoic acid (EET). Under conditions of low PLA2 activation, 
both activators also use extracellular ATP-mediated activation of phospholipase C (PLC)-
inositol trisphosphate (IP(3)) signaling to support TRPV4 gating (Fernandes et al., 2008). 
The IP3 receptor engages in a physical interaction with TRPV4 sensitizing this channel to 
stimulation by mechanical and osmotic stimuli although IP3 alone does not activate 
TRPV4. Threfore, binding of inositol 1,4,5-triphosphate receptor type 3 (IP3R3) to TRPV4 
is essential for IP3 effected sensitization of TRPV4 (Garcia-Elias et al., 2014). 
 TRPV4 can also become sensitized through both PKC and PKA pathways. 
Treatment with phorpol 12-myristate 13-acetate (PMA), TRPV4 is phosphorylated on 
Ser824 activating PKC. Ser824 is also phosphorylated after forskolin activates PKA 
pathway. phorphorylation in this site by the insertion of aspartic acid in lieu of Ser824 
increases Ca2+ influx in both resting and stimulated cells  (Peng et al., 2010).  
TRPV4 in the eye 
 TRPV4 expression is found in several ocular structures and cell types. Functional 
TRPV4 expression is found in neurons of the trigeminal ganglion nerve ending in the inner 
walls of the anterior chamber of the rat (Meng et al., 2015a) , as well as in retinal ganglion 
cells, in Muller glial cells, at the optic nerve head in the mouse (Ryskamp et al., 2011) and 
the retinal pigmented epithelium of human fetal cultured cells  (Zhao PY,2015). TRPV4 is 
!54
also found in human corneal endothelial cells and at the cell membrane surface and the 
cytosol of human epithelial corneal cells (Mergler et al., 2011a; Pan et al., 2008). 
Moreover, it is present in the trabecular meshwork and the epithelium of porcine lens (Luo 
et al., 2014; Shahidullah and Delamere, 2014).
Figure 1.13. Representative scheme of the distribution of TRPV4 in the eyeball and its 
importance in each structure.
 Studies have been made in the search for mechanosensitive channels in the 
trigeminal ganglion nerve ending in the inner walls of rat anterior chamber. The study took 
place in order to better understand the modulation of intraocular pressure (IOP). Given that 
IOP is regulated, in part,  through a neuronal feedback mechanism, the involvement of the 
trigeminal nerve as the primary afferent nerve in neural regulation of IOP seemed to be 
plausible (Lele and Grimes, 1960; Perkins, 1957; Zuazo et al., 1986). Using the whole cell 
patch-clamp technique, together with neuronal labelling, TRPV4 determined the activity 
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and localized its presence by immunofluorescence (Meng et al., 2015b). Investigation must 
continue for better understanding of the role of TRPV4 in the trigeminal ganglion nerve 
ending in regulating IOP. 
 Based on the idea of better understanding the regulation of IOP from different 
perspectives, anatomical, molecular and physiological evidences of TRPV4 participation 
in the transduction of hypotonic stimuli and its contribution to Ca2+ dependent intracellular 
signalling and membrane excitability have been shown in the mouse retina. Localization of 
TRPV4 was determined in retinal ganglion cells (RGC) somata and axons. Cell stretch 
induced by hypotonic swelling caused a marked increase in [Ca2+]i of RGCs. Because the 
remaining membrane potential of RGCs is within the operational range for inactivating 
and persistent Na+ conductances (∼ −60 mV) (Hayashida and Ishida, 2004; Kim and 
Rieke, 2003; Margolis et al., 2010), TRPV4 agonists, 4α-PDD and GSK1016790A 
elevated intracellular calcium concentration and cause a >100-fold increase in the 
frequency of spontaneous RGC spiking. Furthermore,  these agonists showed similar 
characteristics to those observed in hypotonicity conditions inducing [Ca2+]i increases in 
RGCs and initiating cell death pathways in RGCs. These results seem to suggest that 
retinal output neurones are capable of transducing mechanical, thermal, and/or osmotic 
stimuli (Ryskamp et al., 2016; Ryskamp et al., 2011). 
 TRPV4 has been described in endothelial and corneal epithelial cells (Fian et al., 
2007; Hartmannsgruber et al., 2007; Kohler and Hoyer, 2007; Pan et al., 2008; Yao and 
Garland, 2005). Thermo- and osmo-sensitive TRPV4 channel activity was characterized in 
the corneal endothelial cells. First by detection of mRNA expression of this channel, and 
then by several functional assays as planer patch-clamp recordings and fluorimetric 
measurements along with its response to described TRPV4 chemical agonists such as 
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GSK1016790A, which resulted in a significant increase of intracellular Ca2+ concentration, 
which diminished after the application of Ruthenium-red (TRPV antagonist). Also, the 
determination of the increment of Ca2+ influx via TRPV4 in endothelial cells was studied 
by using different hypotonic challenges, resulting in a significantly increased fluorescence 
ratio corresponding to intracellular Ca2+ inflow. These findings are of great relevance 
because corneal endothelial cells can suffer several processes in which TRPV4 can be 
activated in vivo, for example, membrane strech resulting for an elevation of IOP, 
cytokine-induced depletion of intracellular Ca2+ stores resulting in  the release of calcium 
influx mediators which activates TRPV4, or an increase of IOP sufficient enough to induce 
endothelial injury and anandamide release, which sensitizes activation of TRPV4 (Mergler 
et al., 2011b). 
 Corneal epithelial integrity is required to maintain tissue transparency and 
deturgescence (the mechanism in which the corneal stroma remains relatively dehydrated). 
This outermost layer, facing the tear film, provides a barrier function to protect the cornea 
from noxious insults. Fluctuations in tear film osmolarity can occur in daily living and 
challenge corneal epithelial barrier function by inducing acute epithelial cell volume 
changes. Nevertheless, under physiological conditions, corneal epithelial cells withstand 
such stresses by mounting regulatory volume (RV) responses (Capo-Aponte et al., 2005). 
During exposure to a hypertonic challenge, these cells initially shrink, which is rapidly 
compensated by activation of a RV increase (RVI) response. Ca2+ signaling is critical to 
induce regulatory volume decrease (RVD) during exposure to a hypotonic challenges in 
the cornea. TRPV4 expression was detected in human corneal epithelial cells as well as in 
intact human cornea, the expression proved to be functional since either TRPV4 agonist, 
4α-PDD, or exposure to a hypotonic medium mediated Ca2+ transients, suggesting the 
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importance of TRPV4 in maintaining corneal epithelial cells barrier integrity during the 
exposure to hypotonic challenges (Mergler et al., 2011b; Pan et al., 2008). 
 Another ocular tissue with an important role in maintaining the intraaocular 
pressure balance through the aqueous humor outflow is the trabecular meshwork (TM), 
which also, expresses TRPV4 channel. Studies indicated that elevated IOP mechanically 
strains the trabecular meshwork by stretching extracellular matrix (ECM) proteins, 
resulting in Ca2+ homeostasis perturbation and restructuring the architecture of the ECM/
cytoskeleton . In biomimetic TM scaffolds using human TM cells, TRPV4 agonists evoked 
TRPV4 dependent cation/Ca2+ influx producing thickening of F-actin stress fibers and 
reinforcing focal adhesion contacts. On the contrary, TRPV4 inhibition enhanced the 
outflow facility and lowered perfusate pressure. In vivo assays using a glaucomatous mice 
model, intraocular injection and topical application of TRPV4 antagonists lowered IOP, 
altogether indicating the critical role of TRPV4 channel as mechanosensitive and Ca2+ 
signalling machinery within the TM (Ryskamp et al., 2016).  
 TRPV4 is also expressed in the porcine lens epithelium and functions 
counteracting the negative actions of osmotic stress. Studies suggested that TRPV4 is 
activated when the lens goes through osmotic or damage-induced swelling, this permits 
Ca2+ entry and triggers a chain of events that open hemichannels (formed from connexin 
proteins) which allows ATP release and subsequently activates purinergic receptors in the 
lens epithelium and certain Src family tyrosine kinases (SFKs). This stimulates Na, K-
ATPase activity which allows the lens to improve its regulation of ion concentrations in the 
fiber mass, this effect being blocked by TRPV4 antagonists proving the involvement of 
this channel in ATP release (Mandal et al., 2015; Shahidullah et al., 2015). 
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 In view of all the studies and mentioned observations, TRPV4 can be legitimately 
considered a multi-micromachine, capable of sensing diverse stimulti and converting them 
to Ca2+ signals in the various tissues. 
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Melanopsin: A novel photopigment for ancient functions  
 Many years ago, a scientist, named Clyde Keeler, observed light response in mice 
with significant rod and cone dystrophy who were still able to generate a number of visual 
reflexes, including constriction of their pupils in response to light and photoentrainment 
(Keeler, 1928; Keeler et al., 1928) . These processes disappeared, however, when animals 
have their eyes removed, strongly supporting Keeler's prediction of a novel ocular 
photoreceptor (Klein and Weller, 1970). In 1998, Provencio and colleagues identified 
melanopsin in photosensitive dermal melanophores of Xenopus laevis, which was 
responsible for the redistribution of skin pigment in direct response to light. Finally, they 
identified human melanopsin exclusively present in the inner retina which was different 
from the classically known photoreceptors (rods and cones) (Provencio et al., 2000; Rollag 
et al., 2003). 
 In the mammalian eye, the image forming pathway uses spatial light dependent 
information to transmit information from rod and cone receptors through an intermediate 
retinal network of bipolar, amacrine, and horizontal cells which convey light responses 
through conventional retinal ganglion cells (RGCs) to the lateral geniculate nucleus (LGN) 
which contributes to conscious vision. The non image-forming pathway, is an ancestral 
pathway that enabled species to sense light levels as a key for organism response and 
survival, classically thought to inform unconscious vision that photoentrains the circadian 
cycle. Melanopsin was shown to be an active photopigment expressed in a small subclass 
of RGCs which are intrinsically photosensitive ganglion cells (ipRGC) projecting to the 
suprachiasmatic nucleus (SCN) of the brain (Czeisler, 1995). Nevertheless, melanopsin 
containing RGCs project directly onto the olivary pretectal nucleus (OPN) as well. This 
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may explain the persistence of pupillary light reflex in rodless and coneless mice (Lucas et 
al., 2003) since the OPN is a crucial node in the pupil reflex circuit linking the retina to the 
parasympathetic innervation of the iris. More recent studies proved that ipRGCs also 
project onto the visual centres of the lateral geniculate nucleus (LGN), therefore, the 
ability of rodless, coneless mice to perform pattern discrimination suggested that ipRGCs 
contribute to image-forming vision (Ecker et al., 2010; Hicks, 2011). The importance in 
contrast detection was also demonstrated when mice lacking melanopsin showed 
decreased contrast sensitivity (Schmidt et al., 2014).
Figure 1.14. Scheme of melanopsin pathway through retinal iRGCs to the suprachiasmatic 
nucleus for photoentrainment, reaching the paraventricular nucleus where it participate in 
pupillary light reflex. Finally signals reachs the pineal gland where melatonin synthesis is 
inhibited/activated by the intracellular pathway shown at the bottom of the photo.  
 The human melanopsin gene (OPN4) consists of 10 exons and is mapped to 
chromosome 10q22. The location and structure of the melanopsin gene is totally different 
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from the rest of human opsins, which typically have four to seven exons. Melanopsin is a 
534-amino acid membrane integral protein with 7 trans-membrane domains. The amino-
terminus end is found at the extracellular region, while the carboxy-terminus is in the 
cytoplasm. It has 3 extracellular loops, with the latter two loops containing cysteine 
residues (Cys-100 and Cys-178) which stabilize the tertiary structure by means of disulfur 
bonds. Melanopsin protein also has 3 loops in the cytoplasm where different amino acids 
are candidates as intracellular phosphorylation sites. Melanopsin has an insertion (Asn-225 
to Gly-233) in the third cytoplasmic loop. This third cytoplasmic loop determines the 
family of G protein that is activated by GPCRs. At the seventh trans-membrane domain, 
interaction occurs with the chromophore retinaldehyde. The most striking feature that 
distinguishes melanopsin from different human opsin is the greater homology to 
invertebrate opsins than those of vertebrates. The typical acidic Schiff´s base ,which is 
typical in vertebrates, is alternated by an aromatic residue (Tyr-103) that is typical in the 
invertebrate opsins. 
Melanopsin phototransduction  
 Visual phototransduction is the mechanism by means of which photons are 
absorbed by retinal photoreceptors to transduce them into a nerve impulse that the brain is 
able to interpret. Most animals have photoreceptors of one sort or another to detect food 
source, mate, predator, orientation, or simply the light/dark cycle dictated by the sun. 
Photoreceptors can be of two distinct morphologies: ciliary and rhabdomeric, both cell 
types enlarge the membraneous surface to storage photopigment. In particular rhabdomeric 
photoreceptors do so by folding the apical cell surface, while the ciliary cells fold the 
ciliary membrane (Eakin, 1982; Yau and Hardie, 2009). Physiologically, the ciliary rods 
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and cones hyperpolarize to light, whereas rhabdomeric photoreceptors depolarize to light. 
However, light response polarity is not an absolute distinguishing feature between both 
types of photoreceptors. Uniformly, these photoreceptors sense light using a visual 
pigment composed of vitamin A-based chromophore and a seven-transmembrane-helix 
apoprotein, opsin. These pigments are prototypical G protein-coupled receptors (GPCRs). 
Studies involving electrophysiological and pharmacological approaches with ipRGCs 
strongly suggest that the biochemical cascade of phototransduction pathway is similar to 
that of the invertebrate rhabdomeric photoreceptors acting through Gq protein coupled 
opsin (Contin et al., 2010; Qiu and Goz, 2010; Qiu et al., 2005). 
 Melanopsin shows a maximal absorbance at 460-480 nm, which corresponds to 
blue light. After light stimulation, the photopigment of ipRGC triggers signalling, 
presumably, through Gq/11-class G-superfamily, which in turn activates a phospholipase C 
(PLC), provoking the hydrolysis of phosphatidylinositol 4,5-bisphosphate (PI(4,5)P2) in 
the membrane generating inositol 1,4,5-triphosphate (IP3) and diacylglycerol (DAG) and 
the later increase in cytoplasmic Ca2+ and ultimately causing membrane depolarization. 
Furthermore, the participation of TRP and TRPL channels, the Ca2+-permeable light-
sensitive channels, made clear since treatments with a Ca2+ chelator or a TRP channel 
blocker were able to reduce the light effect. Treating chicken primary RGCs cultures with 
PLC inhibitors abolished the light-suppressive effect on 3H-melatonin synthesis. These 
findings demonstrated the chemical components of the phototransduction cascade 
operating in vertebrate embryonic RGCs is involving a Gq-protein (Contin et al., 2010; 
Graham and Wong, 1995; Graham et al., 2008; Isoldi et al., 2005; Koyanagi et al., 2005; 
Koyanagi et al., 2015; Valdez et al., 2009)  
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Melanopsin life cycle: a promising potential 
 From an evolutionary point of view, the melanopsin system is older than the rod 
and cone systems. Given its ancient origin, plus its key role in light dependent survival, it 
is worthwhile  mentioning that melanopsin is expressed pre-natally and that ipRGCs are 
the first developing photosensitive cells in the mammalian retina (Sekaran et al., 2005). 
Moreover, studies done in mice proved that they are capable of light detection 
embryonically (Rao et al., 2013). 
 At the same time ipRGCs are the first photoreceptors in development, they have a 
longer period of proliferation and may be some of the last retinal neurones to die in the 
course of an organism’s lifetime. They are considered atypical central nervous system 
neurons, acting both as photoreceptors responding directly to environmental stimuli, as 
well as standard neurons integrating synaptic input and generating action potentials 
(Pickard et al., 2009; Pickard and Sollars, 2012; Rollag et al., 2003). Many studies have 
raised awareness towards these cells being resistant or less vulnerable to damage and 
disease compared to conventional RGCs. For instance, one of the leading causes of vision 
loss is glaucoma, which is associated to elevated intraocular pressure, resulting in optic 
nerve damage and RGCs loss. Studies in some rodent glaucoma model examined the 
sparing of ipRGCs, suggesting that IOP threshold to damage these cells is much higher 
than it is in conventional RGCs (Zhang et al., 2013). Different studies indicate melanopsin 
resistance to damage in optic nerve damage in inherited optic neuropathy, as well as 
studies indicating that these cells may be resistant to glutamate-induced excitotoxicity 
(DeParis et al., 2012; Fujishiro et al., 2014; Moura et al., 2013; Muller et al., 2010). Little 
is known about the cellular and molecular mechanisms that provide neuroprotection to 
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these RGCs, and  more studies are needed for a better understanding of these mechanisms, 
which may lead to valuable insights for designing strategies to diminish vision loss 
following ocular diseases. 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Hypothesis and Objectives 
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Hypothesis: 
 Melatonin have been a molecule of interest in our group of investigation for the last 
decade, with a special attention towards this molecules’ potential to lower intraocular 
pressure. Such a molecule presence was already described in several ocular structures 
including the ciliary body, where the aqueous humor is formed. However, the composition 
of the aqueous humor is also due to its contact with other structures like the cornea and the 
crystalline lens. The focus has been over the effect of exogenous melatonin application on 
intraocular pressure, and results showed that melatonin administration have the ability to 
decrease IOP in heathy and glaucomatous models. Results are supported by different 
groups and with different experimental models, including humans. 
 Questions raised regarding the endogenous status of melatonin synthesis in the 
healthy and diseased subjects. The mechanisms regulating the changes in melatonin 
synthesis in the aqueous humor, independently of the circadian rhythm, is a matter of 
interest since it can be related to the changes in IOP this being a main risk factor for 
developing glaucoma disease. 
 Our hypothesis is that melatonin levels in the aqueous humor of normal and 
hypertensive patients are different. These possible variations will rely on the presence of a 
“sensor” that may connect intraocular pressure with the synthesis of melatonin, probably 
by modifying the activity of those enzymes that synthesize melatonin, such as the key 
enzyme AANAT. Moreover, we consider that those possible changes in the aqueous humor 
melatonin levels may influence melatonin receptors present in the ciliary body. In this 
sense and since it has been observed unusual pharmacological behaviors (i.e. melatonin 
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effect can be blocked by the adrenergic antagonist prazosin), it might be the case that 
receptor-receptor interactions between melatonin and adrenergic receptors may occur.  
 Finally, we believe that melatonin detected in the aqueous humor is not only 
produced by the ciliary body but also by the crystalline lens. Our hypothesis is that the 
crystalline lens contains a light sensor which regulates melatonin synthesis, and that 
melatonin coming from the crystalline is an important participant in the physiology of the 
aqueous humor. 
Objectives: 
1. To study the correlation between the increase in IOP and the increase in the levels 
of melatonin in the aqueous humor: Melatonin levels in the aqueous humor is of 
great importance because this molecule is known to lower IOP, however, a correlation 
between endogenous melatonin and IOP need to be addressed.  
2. To study the participation of the TRPV4 channel in regulating melatonin 
synthesis in the ciliary body: TRPV4 channel is known as an osmo- mechano- sensor. 
The present Thesis investigates its role in the ciliary body in regulating melatonin 
synthesis and the possible impact on intraocular pressure. 
3. To describe the cellular signalling mechanisms of AANAT regulation: The changes 
in the expression as well as the modulation by phosphorylation of the key enzyme in 
synthesizing melatonin (AANAT) will be studied in clear connection with the 
activation of a TRPV4, measuring the changes in the protein AANAT as well a the 
changes in melatonin synthesis. 
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4. To investigate the possible receptor heteromerization between melatonin receptors 
and different receptors: To study the interaction between melatonin receptors and 
mostly α1A-adrenergic receptor and to investigate wether such an interaction is 
functional, as well as to interpret the meaning of such a phenomena regulating IOP by 
means of  “in vivo” assays.  
5. To identify the presence of melanopsin in the crystalline lens and its role in 
regulating melatonin synthesis: To investigate the response of human crystalline lens 
epithelial cells to light and darkness, and to describe melanopsin presence in the 
studied cells as well as corroborating its presence in human crystalline tissue. In 
addition to study the mechanisms underlying melatonin synthesis controlled by 
melanospin. 
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Chapter II: Melatonin, Intraocular pressure, and 
TRPV4: Clear dots to connect. 
Nothing in life is to be feared, it is only to be understood. Now is the time to 
understand more, so that we may fear less.  
 Marie Curie 
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Introduction 
 Melatonin was classically considered to be exclusively produced by the pineal 
gland (Arendt, 2007). However, this indolamine is synthesized and present in many ocular 
structures, although its implications in ocular physiology is still under investigation 
(Adachi et al., 1998; Agorastos and Huber, 2011; Alarma-Estrany and Pintor, 2007) . For 
instance, discovering its presence in the aqueous humour (AH) and knowing the 
importance of the AH in regulating the intraocular pressure, attracted the attention of 
melatonin’s role in the aqueous humour dynamics and formation (Clarke and Osborne, 
1994). Melatonin levels are normally high during the night, while the intraocular pressure 
is decreased (Wurtman et al., 1963). Melatonin is, therefore,  considered to regulate 
intraocular pressure (IOP) (al-Qassab et al., 1988; Belforte et al., 2010; Chiou and 
McLaughlin, 1984; Pintor et al., 2001). This connection between IOP and melatonin was 
demonstrated on human patients who were treated orally with melatonin before 
undergoing cataract surgery to lower their IOP (Ismail and Mowafi, 2009). Moreover, 
Melatonin and its analogues were suggested as a treatment for elevated IOP and 
glaucoma(Lundmark et al., 2007; Mediero et al., 2009). Recent studies on animal models 
of elevated IOP showed a significant reduction of IOP after melatonin treatment 
(Martinez-Aguila et al., 2013), as well as more recent studies on human glaucoma patients, 
supporting and potentiating the results obtained on animal models (Pescosolido et al., 
2015). Melatonin mechanism of action to reduce IOP is mediated by its membrane 
receptors MT1, MT2 and MT3 which are present in the ciliary body among different ocular 
structures (Alarma-Estrany and Pintor, 2007). Melatonin activates MT3 receptor, which 
stimulates adenylate cyclase with concomitant activation of PKA. This activation produces 
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an inhibition of chloride efflux (Huete-Toral et al., 2015), the main factor responsible for 
the movement of water from the ciliary epithelium to the posterior chamber (Civan, 1998). 
Consequently, the reduction of chloride efflux causes a reduction in the formation of AH 
(Civan and Macknight, 2004). 
 Little is known either about the mechanism or the substances which may stimulate 
the endogenous melatonin’s presence in the aqueous humour. A channel which is sensitive 
to physical and chemical stimuli could be a possible candidate. The TRPV4 is a membrane 
protein that belongs to the transient receptors, a non-selective cation channel permeable to 
Ca2+ (Garcia-Elias et al., 2014).  
 The connection between IOP and melatonin seems logical. However, insufficient 
studies have been made to measure melatonin levels in the aqueous humour to establish a 
relationship between both areas of a great interest. Some groups have obtained non-
conclusive results, due to variability, indicating that melatonin concentrations can vary 
from pg/mL to the ng/mL range (Chiquet et al., 2006; Martin et al., 1992). In order to 
understand this natural phenomena, the present chapter is dedicated primarily to 
comparing melatonin levels in the aqueous humour of ocular normotensive patients and 
those of elevated IOP. This study is completed by measuring the same in a well established 
glaucoma animal model before and after developing an increment in IOP and a further 
comparison to normotensive mice. Finally, the TRPV4 channel activation emerges as a 
possible candidate, explaining the mechanism by which melatonin is produced from non-
pigmented ciliary body epithelium cells. Therefore, this chapter ends with the 
demonstration of the presence of this channel and its ability to stimulate melatonin 
synthesis. 
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Materials and methods 
“In vivo” Assays 
Subject recruitment and aqueous humour collection  
 Sample collection was made possible by the cooperation of Dr. Juan Sanchez 
Naves, an ophthalmologist practicing in the Instituto Balear de Oftalmología, Palma de 
Mallorca, Spain. Aqueous humour samples were brought to our lab for analysis (see 
below). The study protocol was approved by the clinical research ethics committee of 
Instituto Balear de Oftalmología, Palma de Mallorca, Spain. Signed informed consent to 
the aqueous humour contribution was obtained from all patients in accordance with the 
Declaration of Helsinki. 
 37 aqueous humour samples of patients who underwent cataract surgery were 
collected. Samples were divided according IOP measurements considering IOP > 21 mm 
Hg as hypertensive patients (Tavares et al., 2006) and IOP below 21 mmHg were 
considered normotensive. A random selection of hypertensive patients (n=14) and 
normotensive (n=23) took place (Table.1). 
  
 Patients with a history of primary acute angle-closure attack, chronic angle-closure 
glaucoma, any treatment for glaucoma or active inflammatory ocular disease were 
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Table 2.1. Demographic characteristic of patients participating in the study
Parameter Total < 21 mmHG  > 21 mmHG 
Patients 37 23 14
Mean age (years)± SD  63.41± 13.12 62.13 ± 13.97 66.36 ± 10.81
Age range (years) [24, 84] [35, 82] [35, 84]
Gender (male/female) [21,16] [15, 8] [6, 8]
IOP presurgery 
(mmHg) 17.70 ± 3.80 15.48 ± 0.48 22.25 ± 0.32
excluded from the experiment. Glaucoma was defined as high intraocular pressure 
associated with optic nerve glaucomatous characteristics, consistent with the visual field 
defect. The IOP measurements were taken before the surgery by means of a Perkins 
tonometer after the instillation of 1 drop of double anaesthetic Colircusí® which contains 
tetracaine 0.1% and oxybuprocaine 0.4% (Colircusí, Alcon Cusí SA, Barcelona). This 
value should be representative of at least three other previous visits with non-statistically 
different IOP values from those presented in the manuscript. Patients with variations 
among visits were also not considered in this study. 
 Samples were collected during the first step of the cataract surgery using 
anaesthetic drops (lidocaine 2%). Posterior to standard clear corneal microinsicion (mice 
2.2 mm), aqueous humour was aspirated using a 30-gauge Rycrof cannula on a tuberculin 
syringe (1ml). Aqueous humour volumes ranged between 0.1 to 0.2 ml, and immediately 
transferred to an eppendorf and stored at -20ºC protected from light until the 
chromatographic analysis were performed  (Castany et al., 2011). 
Glaucomatous mice model 
 Aqueous humours were collected from female C57BL/6J (control, n=6) and DBA/
2J (glaucomatous, n=6) mice obtained from the European distributor of Jackson 
Laboratories Mice (Charles Rivers Laboratories). All animal maintenance and 
experimental procedures followed Spanish and European guidelines for animal care in the 
laboratory and animal research (Guide for the Care and Use of Laboratory Animals) and 
the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research. Mice 
were housed (1-4 mice per cage) in temperature and light-controlled rooms maintained 
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according to a 12-hour light/dark cycle; all animals were fed ad libitum. DBA/2J and 
C57BL/6J mice were studied at 3 and 12 months of age.  
 Aqueous humour collection was performed after anesthetizing the mice with an 
intraperitoneal (i.p.) injection of a mixture of ketamine (95 mg/kg, Imalgene 1000, Merial, 
Barcelona, Spain) and xylazine (5 mg/kg, Rompún), Bayer, S.A., Barcelona, Spain). 
Aqueous humour was processed in the same way as with the human samples (for more 
details, see HPLC). Just before aqueous humor collection, IOP was measured by means of 
a TonoVet® contact tonometer supplied by Tiolat Oy (Finland). The application of this 
tonometer does not require the use of any anaesthetic. 
“In vitro” Assays 
Cells 
 Non-pigmented ciliary epithelial cells (59HCE), a human immortalized cell line 
was kindly supplied by Dr. Coca-Prados (Yale University, USA). Cells were grown in high 
glucose Dulbecco’s modified Eagle’s medium (Gibco/Invitrogen, Carlsbad, CA) 
containing 10% fetal bovine serum (Sigma-Aldrich, St. Louis, MO) and 0.05 mg/ml 
penicillin/streptomycin (Gibco/Invitrogen) at 37°C in humidified atmosphere 5% CO2–
95% air. After the culture reached the confluence, cells were detached with 0.25% trypsin 
and seeded into 6 well plates and/or to 4 well chamber slides respectively. All the 
experiments were performed using cells comprised numbers 10-15 passages to assure 
assays reproducibility.  
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Immunocytochemistry Studies 
 Staining was performed to evaluate location of the TRPV4 in the cells, cells were 
washed with PBS1X three times for 5 minutes each before permeabilization. Cell 
membranes were permeabilized with a solution of Triton X-1000- 0.05% - PBS for 30 
minutes, followed by blocking. In order to remove the joints, the sections were incubated 
in a PBS 1X-Triton X-100 0.1% solution, and normal serum from the animal from which 
the secondary antibody comes, in this case 10% normal donkey serum (NDS, Jackson 
Immunoresearch, West Grove, PA) was used and sections were incubated for 1 hour at 
room temperature. Sections were incubated in 0.1% Triton X-100 and 1% normal donkey 
serum together with the primary antibody TRPV4 primary antibody (Santa Cruz 
Biotechnology) with a dilution of 1:50 overnight at 4 ̊C. 
 The following day, in order to remove the excess of the primary antibody, three 
washes with PBS1X-Triton X-100-0.1% were performed for 5 minutes each. Followed by 
the secondary antibody; donkey anti-immunoglobulin IgG goat antibody conjugated with 
fluorescein isothiocyanate (FITC; green, Jackson ImmunoResearch, West Grove, PA, 
USA) at 1:100 dilution in PBS-0.1% Tx-100 for 1 hour in a dark chamber at a room 
temperature. Finally, sections were rinsed and mounted in Vectashield (Vector 
Laboratories, Palex Medical, Barcelona, Spain) and coverslipped. The samples were 
examined under a confocal microscope (Zeiss LSM 5, Jena, Germany). 
TRPV4 Experiments  
 Cells were plated in multiwells at a density of 1.2x106 cells and challenged with 
the TRPV4 agonist GSK1016790A (GSK) at the following concentrations: 1nM, 10nM, 
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100nM, 1µM, and 10µM. The cells were stimulated for 24 h and afterwards, the medium 
was collected and processed for melatonin analysis. 
 For antagonist analysis, the compounds ruthenium red (RR) and RN-1734 (RN) 
(Vincent et al., 2009), were assayed at concentrations of 1 nM and 10 nM respectively, 
either alone or 30 min before the application of the TRPV4 agonist GSK1016790A.  
High performance liquid chromatography (HPLC) analysis 
 High performance liquid chromatography is a technique that allows the separation 
of the components of a mixture of substances depending on the different chemical 
interactions of the same by a mobile phase subjected to high pressure and a stationary 
phase (chromatographic column). The high-performance liquid chromatography (HPLC) 
equipment used for the determination of melatonin levels consisted of an isocratic pump, a 
Rheodyne ® manual injection valve (with an external loop of 10-250 µl) and a detector 
UV / VIS. The column employed was a Kromaphase C18 ion-pair reverse phase column (5 
µm particle size, 25 cm in length, 4 mm internal diameter) (Scharlau, Madrid, Spain). a 
1515 Isocratic HPLC pump, a 2487 dual absorbance detector, and a Reodyne injector, all 
managed by the software Breeze from Waters (Milford, MA). The system was equilibrated 
overnight with 40% methanol, 60% H2O. Measurements were performed at a flow rate of 
0.8 ml/min fixing the detector at a wavelength of 244 nm. 
  After the experiments, the collected aqueous humour and mediums were 
maintained in ice for 5 min. The tubes were heated in a 98◦ C bath for 2 min and 
transferred to ice for 10 min for precipitation. To pellet the proteins, we centrifuged the 
tubes at 22,000g for 10 min at 4◦ C. For manual injection of the samples into the 
chromatographic system Hamilton, syringes were used. Quantification of melatonin was 
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performed by comparing the samples with external standards provided by Sigma (St Louis, 
MO. USA).  
Statistical analysis 
 The presented data were analyzed using the statistical software SPSS 22.0 (SPSS, 
Inc., Chicago, IL). Normal distribution of melatonin concentration was assessed by the 
Shapiro-Wilk normality test, resulting in no normality due to the heterogeneity of the 
patients. Then, its values were presented in the median and quartiles (first quartile; third 
quartile) of the experiments performed. The rest of variables are shown as means ± SD. 
Therefore, differences between before surgery and after surgery were estimated by the 
non-parametric test of Wilcoxon for paired samples. In the animal experiment, the 
differences were also evaluated by Wilcoxon for paired samples, comparing between ages 
of 3 and 12 months. For correlations, Pearson bivariate regression was used. P<0.05 was 
considered statistically significant. 
 GraphPad Prism (GraphPad Software Inc., San Diego, CA) was used to obtain the 
plots and to fit nonlinear regression curves in order to obtain the pD2 value (EC50). 
Statistical significance was calculated by ANOVA test, when needed. 
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Results
“In vivo” Assays
Melatonin levels in hypertensive patients’ aqueous humour
 All patients who were included; either not being diagnosed for, or treated for, 
glaucoma were divided in two groups. All patients with IOP values below 21 mm Hg were 
considered normotensive, and the hypertensive group was formed by those with IOP above 
21 mm Hg. Demgraphic details of recruited patients is shown in table 2.1. 
 After collecting and processing aqueous humour samples, chromatography analysis 
clearly showed that patients exhibiting elevated IOP presented concomitantly higher 
concentrations of melatonin (figure 2.1, left panel), while normotensive patients (IOP 
below 21 mm Hg) showed values of 14.62 (5.38; 37.99) ng/ml (n=23), hypertensive 
patients presented melatonin concentrations of 46.63 (10.28; 167.28) ng/ml (n=14) these 
values being statistically significant (p<0.002). Furthermore, a significant correlation was 
found between melatonin concentration and IOP pre-surgery (p= 0.03), the Pearson’s 
correlation coefficient being 0.441 (figure 2.2).
Figure 2.1. Presence of melatonin in the aqueous humour. On the left, representative 
HPLC elution profiles of human aqueous humour samples of patients with IOP above 21 
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mm Hg and below 21 mm Hg. On the right, bar plot showing the concentrations of 
melatonin in the two populations of patients. *p<0.039 (Wilcoxon for paired samples).
Figure 2.2. Correlation between melatonin concentration (ng/ml) in aqueous humour of 
patients who underwent cataract surgery and the IOP before the surgery. Pearson 
correlation was statistically significant (p= 0.025; r = 0.441).
Melatonin levels in control and glaucomatous mice’s aqueous humour
In parallel to the analysis of melatonin levels in the aqueous humour of human 
patients, melatonin concentration was determined in mice as well. The study took place 
using a glaucomatous mice model (DBA2/J) and a normal mice strain (C57BL/6J). The 
IOP values measured in the DBA2/J were 15.05 ± 0.87 mmHg at 3 months of age, and 
then raised to 30.41 ± 1.35 mmHg when they reached 12 months of age. IOP values 
obtained from the (C57BL/6J) mice were 11.86 ± 0.69 mmHg at 3 months and 11.13 ± 
1.21 mmHg at 12 months of age.  
 HPLC analysis to determine melatonin levels in the two animal groups at both ages 
showed statistically significant differences in the DBA2/J, before and after developing 
glaucoma. Melatonin values have changed from 0.37 (0.34; 0.59) ng/ml to 1.55 (0.94; 
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1.88) ng/ml at 3 and 12 months of age, respectively. Melatonin levels rose when the 
glaucoma model developed the pathology (n= 6, p<0.001) (Fig. 2.3). 
 However, the aqueous humour obtained from the control mice (C57BL/6J) at the 
same ages as the DBA2/J model did not show significant differences. Results showed 
melatonin levels of 0.47 (0.42; 0.53) ng/ml and 0.42 (0.32; 0.56) ng/ml at 3 and 12 
months, respectively (n= 6, p = 0.418).   
 Melatonin concentration in the aqueous humour and IOP revealed a strong 
correlation in mice the Pearson’s correlation coefficient being 0.851 (p < 0.001) for all the 
animals under study (Figure 2.3).
Figure 2.3. Melatonin concentrations in the aqueous humour of control (normotensive) 
and glaucomatous mice. One left panel, The DBA glaucomatous mice presented a marked 
increase in their aqueous humour melatonin concentrations when comparing 3 months of 
age, before the pathology starts and at 12 month of age, when the glaucomatous pathology 
has been fully established and the pressure in maximal. On the contrary, control mice, C57, 
did not change their melatonin concentrations with ageing. * p<0.001 (Wilcoxon for paired 
samples). Pearson correlation between melatonin concentration (ng/ml) in aqueous humour 
of glaucomatous (DBA2/J) and non-glaucomatous (C57) mice strains  and the IOP 
measured in all times of experiment was statistically significant (p< 0.001; r = 0.851) 
(right panel).
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“In vitro” Assays 
TRPV4 presence in non-pigmented ciliary epithelial cells  
 Immunofluorescence experiments took place to confirm the presence of TRPV4 
channel in the human non-pigmented ciliary epithelial cells. As can be observed in Fig. 
2.4., a positive labelling of TRPV4 can be seen mostly in the cytoplasm membrane of the 
cells. 
Figure.2.4. presence of TRPV4 in human non-pigmented ciliary epithelial cells (observed 
in green). The bar represents 20 µm  
Extracellular melatonin level changes depending on TRPV4 channel status 
 Melatonin concentration was measured from the supernatants of human non-
pigmented ciliary body epithelial cells by means of HPLC analysis. The concentration of 
melatonin obtained from a control culture (untreated cells) was 8.5 ± 1.6 nM/well of cells 
(n=12) (equivalent to 1.9 ng/ml). Whereas, activating the TRPV4 channel by using a 
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specific agonist GSK1016790A at a dose of 10 nM resulted in an increment of melatonin 
levels 23.3 ± 2.1 nM/well of cells (n=12) (equivalent to 5.4 ng/ml) (Fig. 2.5). 
 Antagonists were applied in different experiments to confirm that the effect shown 
is caused by TRPV4 channel, the selective antagonist RN1734 prevented the increase of 
melatonin release from the cells when applying GSK1016790A. A less selective 
antagonist, Ruthenium red was also able to suppress the agonist-induced effect over 
melatonin levels (Fig. 2.5.). 
Figure.2.5. Representative HPLC chromatograms and retention time for melatonin in the 
supernatant of human non-pigmented epithelial cells under normal conditions compared to 
the addition of TRPV4 agonist (GSK) and antagonists (RR, RN) as described in methods. 
C.- Quantification of the experiments described in A. The values represent the mean ± SD 
of 12 independent experiments (***p < 0.001 vs control).  
Dose-Response assays of GSK1016790A  
 TRPV4 agonist GSK1016790A was then evaluated at a wide range of 
concentrations in order to obtain the corresponding concentration-response curve. 
Concentrations of GSK ranging from 10-10 to 10-5 M, permitted to observe a sigmoid plot 
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from which a pD2 value of 8.5 ±  0.1 was obtained (EC50 of 3.0 nM). Melatonin content 
in the extracellular medium reached the maximum when cells were challenged with the 
TRPV4 agonist at 10nM concentration (n=7, figure 2.6.). 
Figure 2.6. Concentration-response analysis of GSK1016790A and possible role of the 
TRPV4 inducing the release of melatonin and how it may control the aqueous humour 
formation. Concentration-response curve for melatonin production by using the TRPV4 
agonist GSK in different concentrations (see methods). The values are the mean ± SD of 7 
independent experiments.  
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Discussion 
 The present work describes the changes of melatonin levels observed under 
elevated pressure. It shows the differences in melatonin concentration among patients with 
normal and elevated IOP and it correlates melatonin values with IOP measurements using 
a glaucomatous animal model (DBA/2J). Furthermore, studies took place using a human 
immortalized cell line of non-pigmented ciliary body epithelium in order to find a possible 
explanation for these differences in melatonin levels. 
 Findings pointed towards an increment of almost 3-fold of melatonin levels in 
patients with elevated IOP, compared to those patients who had normal IOP. Similar 
behaviour was observed in the glaucomatous mice model, when animals reached 12 
months of age when  they fully developed glaucoma pathology and their IOP were high. 
 On a cellular level, when the cells which produce the aqueous humour, the non-
pigmented ciliary body cells, were tested, results showed that they produce melatonin as 
well, and comparable findings were observed when TRPV4 channel was activated using 
an agonist. Melatonin levels increased.  
 The use of cellular model to mimic the natural finding in the human aqueous 
humour can be very useful to understand the mechanism of action. Nevertheless, using an 
animal model such as the DBA/2J, can be very useful to understand the changes in 
melatonin levels in the aqueous humour before and during the pathology after it is fully 
developed. This is very valuable, given the difficulties of collecting aqueous humour 
samples from patients in such a way. 
 The observations in the present work clearly showed the highest increment of 
melatonin levels in the aqueous humour in hypertensive patients, compared to healthy 
subjects, this increment being higher than the one observed in other fluids such as the 
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tears. Human tears contain melatonin and follow a circadian manner, but the changes of 
melatonin levels are about 1.6-fold higher during the night compared to the day (Carracedo 
et al., 2016). This clearly indicates that melatonin concentration in the hypertensive 
patients, as well as in mice, is not only governed by circadian aspects, but it may also be 
related to the fact of the abnormally elevated intraocular pressure. 
 The connection between melatonin and the intraocular pressure may be due to the 
existence of a pressure sensor, the TRPV4 channel, which, when activated, triggers the 
release of melatonin in the aqueous humour. The EC50 value obtained in non-pigmented 
ciliary body epithelium (3 nM) compared to different human cells was very similar to that 
obtained by Thorneloe and co-workers (Thorneloe et al., 2008) in the search of new 
agonists which induces urinary bladder contraction and hyperactivity, using TRPV4 knock 
out mice model together with TRPV4-expressing human embryonic kidney (HEK) cells. 
They showed a dose response behaviour of the agonist GSK1016790A, close to the one 
found in the current work. The values obtained from the cellular model used in this study 
were one order of magnitude lower than those obtained in the cerebrospinal fluid barrier 
protection carried out by TRPV4 (EC50 34 nM) (Narita et al., 2015), and also lower than 
the values found when measuring the human bronchus constriction (EC50 10 nM) 
(McAlexander et al., 2014). 
 TRPV4 channel activation produces changes in the extracellular levels of 
melatonin on a continuous stimulation basis. In this sense, glaucoma patients suffer the 
permanent rise in IOP before starting any treatment or those who are not using an effective 
treatment to lower IOP. Therefore, changes in the composition of the aqueous humour of 
patients presenting ocular hypertension could be a natural process to reduce IOP, given that 
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they showed higher levels of melatonin, and studies confirmed that melatonin has the 
ability to decrease IOP  (Crooke et al., 2012).  
 The fact that melatonin lowers IOP, together with the findings in the present work, 
causes challenging questions to arise, why do patients with elevated IOP have more 
melatonin? And why is melatonin not working as expected, in decreasing IOP in this case? 
To be able to fully understand and answer the role of melatonin in pathologies presenting 
high IOP, further studies are necessary. However, some hypothesis could be made. In order 
for melatonin to work properly, its receptors should be functional, and this could not be 
happening in glaucoma patients. The existence, of age-related and region-specific changes 
in the expression of the melatonin receptor subtypes has already been described in animal 
models (Guo et al., 2015). Different studies showed that mice lacking melatonin receptor 
type 1 presented elevated IOP, these new studies suggest that melatonin signalling 
dysfunction can be a possible risk factor in the pathogenesis of glaucoma (Alcantara-
Contreras et al., 2011; Tosini et al., 2013). This could be the case of some patients and 
therefore, increased melatonin levels are not enough to reduce IOP as one could expect.  
 Melatonin has many functions, besides regulating the circadian rhythm, it is a 
powerful free-radical scavenger and wide-spectrum antioxidant. This is a fundamental 
role, as glaucoma pathology presents an oxidative damage (Sacca and Izzotti, 2014). 
Therefore, melatonin increment could be also reflecting a mechanism of protection from 
the oxidative stress carried out in the eye to protect high efficient tissues as the ciliary 
body and the trabecular meshwork which are essential to control IOP (Sacca et al., 2016a, 
b). Moreover, if similar changes regarding melatonin levels were occurring in the retina, 
this molecule would help to ameliorate the glaucomatous pathology by acting on retinal 
glutamate clearance, GABA concentrations, NO synthesis, and retinal redox status 
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(Belforte et al., 2010). More experiments should be carried out to fully understand and 
confirm all possible explanations. 
 Future investigation may cover several aspects of the role of melatonin in 
glaucoma pathology. It would be worthwhile to study the effect of glaucoma current 
treatments on the aqueous humour melatonin levels. It is possible that it could modify the 
aqueous humour melatonin concentrations, as happens with other aqueous humour 
components in experimental animal models (Reyes et al., 1998). Furthermore, 
understanding the connection between melatonin levels and anti-glaucomtous treatments 
could be very useful to clarify the best moment of the day to apply medication, since 
melatonin follows a circadian rhythm as well as IOP (Bron, 2004; Santos et al., 2009). 
 Regarding the possible mechanism of TRPV4 activation when IOP is increased, 
although a response to hydrostatic pressure might be possible, it is worth taking into 
consideration that the mechanical distortion caused in some way by the elevation of IOP 
could be the main reason for TRPV4 activation, as previously suggested in other models 
(Garcia-Elias et al., 2014). Melatonin, acting in an autocrine way through its existent 
receptors in the ciliary body (Alarma-Estrany et al., 2008) could reduce chloride 
production as recently described (Huete-Toral et al., 2015).   
 To summarise then, TRPV4 channel stimulation is able to induce melatonin in 
human ciliary non-pigmented epithelium cells and this can explain the elevated melatonin 
concentration in the aqueous humour of patients with high IOP compared to normotensive 
patients. The lack of effect of melatonin in the aqueous humour to lower IOP could be due 
to an imbalance between melatonin release and the receptors that should reduce IOP. 
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Chapter III: TRPV4 activation effect on 
aralkylamine N-acetyltransferase (AANAT) and its 
phosphorylation in human ciliary body epithelial 
cells. 
  
“Don't confuse symmetry with balance.” 
Tom Robbins 
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Introduction 
 The ciliary body, together with the iris and choroid comprise the vascular coat or 
uvea of the eye. The ciliary body is composed of the ciliary muscle and ciliary processes, 
the latter being approximately 70 in number in the human eye. Ciliary processes consist of 
a central core of connective tissue stroma, covered by a double layered epithelium, the 
pigmented and non-pigmented epithelium which is in direct contact with the aqueous 
humor (Do and Civan, 2004). In fact, the non-pigmented epithelium of the ciliary 
processes is where the aqueous humor is secreted by a process of active transport, through 
diffusion and ultrafiltration (To et al., 2002). The aqueous humor bathes the avascular 
structures of the eye, such as the crystalline lens and the posterior surface of the cornea, 
and this constant flow supplies these structures with the necessary nutrients and carries out 
their metabolic waste. The dynamic of this is also very important to maintain the 
intraocular pressure of the eye balanced (Anshu et al., 2011; Mark, 2010). 
 The ciliary body is considered the third organ which secretes melatonin after the 
retina and the pineal gland (Martin et al., 1992). This discovery took place after observing 
that intraocular pressure follows a circadian variation, together with the fact that the ciliary 
epithelium shares an embryonic origin with the pineal gland and the retina (Martin et al., 
1992). These findings, opened a window of investigation to link melatonin and IOP. 
 Melatonin synthesis starts from 5 hydroxy-tryptamine (5-HT or serotonin), which 
is transformed into melatonin in two steps, being catalysed by the enzyme aralkylamine N-
acetyltransferase (AANAT) and acetylserotonin O-methyltransferase (HIOMT) (Blomeke 
et al., 2008; Coon et al., 1996; Klein et al., 1997; Roseboom et al., 1996). The rate limiting 
step in melatonin synthesis seems to depend on AANAT activity since it shows circadian 
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fluctuations throughout the day (Klein, 2007). However, AANAT could be regulated by 
other environmental factors rather than only the light/darkness changes, such as other 
hormones, food or alcohol intake (Garcia-Marin et al., 2015; Kashani et al., 2015; Peres et 
al., 2011). 
 AANAT has two known ways of regulation, first, a fast process of phosphorylation 
which depends on the binding of AANAT to 14-3-3 protein. This process of 
phosphorylation protects AANAT from proteosomal degradation and has been related to 
the activation of PKA after cAMP generation (Baler et al., 1997; Kleppe et al., 2014). 
However, cyclic AMP/protein kinase A pathway may also activate gene expression. In 
rodents, transcriptional activation of Aanat gene is the classical mechanism to induce 
melatonin biosynthesis. It involves PKA-dependent phosphorylation of the transcription 
factor cAMP response element binding protein (CREB) and binding of phosphorylated 
CREB in the promoter region of Aanat gene (Stefulj et al., 2001). 
 Melatonin synthesis in the ciliary epithelial cells is of great interest, since 
melatonin has many functions in the eye, besides working as a scavenger for free radicals, 
it also regulates intraocular pressure. These actions are mainly mediated by melatonin 
membrane receptors MT1 and MT2 (Zlotos et al., 2014) and the putative MT3  (Pintor et al., 
2003; Serle et al., 2004) which have been also identified in some tissues as the enzyme 
quinone reductase-2 (Nosjean et al., 2000). 
 Intraocular pressure is normally balanced by the aqueous humour production and 
its outflow. When this equilibrium is affected by any reason, this could lead to elevated 
IOP which is a significant risk factor leading to glaucoma pathology (Acott et al., 2014; 
Anshu et al., 2011; Paycha, 1992). Glaucoma is a multifactorial disease called “the silent 
thief of sight” (1995) because it shows no symptoms and, if not detected at an early stage, 
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could lead to permanent blindness (Abdull et al., 2016). All current treatments for 
glaucoma pathology aim to decrease and stabilize IOP levels, in such a way as to protect 
retinal damage and ganglion cells death. Melatonin and its analogues have been 
investigated in the search for new treatments for elevated IOP since commercial 
compounds present several side effects, which can sometimes be a reason to stop the 
medication. Melatonin taken orally has been proven to reduce IOP in human patients who 
underwent cataract surgery (Ismail and Mowafi, 2009) and it was tested on normotensive 
and hypertensive animal models as well (Martinez-Aguila et al., 2013; Martinez-Aguila et 
al., 2016). However, a previous study (refer to chapter 1) showed higher levels of 
melatonin in the aqueous humor of patients with elevated IOP. Here emerges the need to 
understand the mechanism in which melatonin levels rise under high pressure. A search 
was carried out to find a sensor in the non-pigmented ciliary epithelial cells which reacts to 
such stress.  
 The relatively recent discovery of the transient receptor potential (TRP) 
superfamily of cation channels allowed a further understanding  of  the  mechanisms  by 
which  cells  are  able  to  sense  various  stimuli  such  as  osmolarity,  mechanical 
loading,  heat  and  cold (Montell, 2005; Mutai and Heller, 2003; Peier et al., 2002a; Peier 
et al., 2002b). This discovery led to more studies, where the transient receptor potential 
vanilloid 4 (TRPV4), a non-selective cation channel that regulates osmo-, thermo-, 
mechanosensation (Loukin et al., 2010; Mutai and Heller, 2003) was seen to play an 
important role in the ciliary body epithelium cells after performing some experiments to 
confirm its presence and function (refer to chapter 1). This channel activation caused 
melatonin levels to increase in the extracellular medium, which raised the question about 
its mechanism of action and the reason behind its increment. 
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 The present work has been undertaken to answer the above questions, to conduct a 
more in-depth study to discover the role of TRPV4 in the non pigmented ciliary epithelium 
cells and its relation to melatonin in the case of mechanical stress when IOP is elevated.  
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Material and methods 
Cells 
 Non-pigmented ciliary epithelial cells (59HCEsv), a human immortalized cell line 
was kindly supplied by Dr. Coca-Prados (Yale University). Cells were grown in high 
glucose Dulbecco’s modified Eagle’s medium (Gibco/Invitrogen, Carlsbad, CA) 
containing 10% foetal bovine serum (Sigma-Aldrich, St. Louis, MO) and 0.05 penicillin/
streptomycin (Gibco/Invitrogen) at 37°C in humidified atmosphere 5% CO2–95% air. 
After the culture reached the confluence, cells were seeded in 6 well plates and/or to 4 well 
chamber slides respectively (for more details, see chapter 2). 
Human eye tissues 
 Donor human eyes were obtained from the Fundación Banco de Sangre y Tejidos 
de las Islas Baleares (Blood and tissue bank Foundation from Baleares Islands). Six donor 
eyes were used for this assay, two of a healthy normal subject and another four from 
glaucoma patients. Eyes were enucleated and collected without the cornea in sterile tubes 
and maintained in 4% paraformaldehyde in 0.1 M phosphate buffer (PB) (pH 7.2-7.4) at 
4ºC until posterior processing. Eyes were dissected under a stereo-microscope (Zeiss) and 
with 0.8 mm tip curved forceps and sterile dissecting scissors, the iris and ciliary processes 
were collected. Several washes in PBS1X were performed, each for 10 minutes under 
constant stirring, and then, the specimen were cryoprotected in a sucrose gradient. Initially, 
eye structures were submerged in a solution of 11% sucrose in PBS 1X for a minimum of 
12 hours at 4 °C; then transferred to 22% sucrose solution overnight, and finally sections 
were incubated with 33% of sucrose solution. In this way, we preserve the tissue from 
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deterioration caused by the formation of water crystals during the freezing process. Tissues 
were embedded in a tissue freezing medium (Tissue-Tek© OCT), maintaining the proper 
orientation taking into account the desired cutting plane. They were rapidly frozen with in 
liquid nitrogen. All included biological material was stored at -20 ° C.  
 The blocks were introduced into the cryostat chamber for about 1 hour to reach the 
optimum cutting temperature (about -27 ° C). Vertical sections of 10 µm thickness were 
obtained using a cryostat (Leica, Nussloch, Germany). Sections were adhered to slides 
(pre-treated with poly-L-lysine) and stored at -20 ° C until further use. 
Immunolabelling Asseys 
 Immunodetection was performed using histological sections of the ciliary body, as 
well as in immortalized non-pigmented epithelial cells.  
 Frozen sections were used for imumunodetection following the described 
procedure. First, sections were hydrated with PBS1X for 10 minutes each before 
permeabilization. Cell membranes were permeabilized with with a solution of Triton 
X-100- 0.05% - PBS for 30 minutes, followed by blocking. In order to remove inspecific 
labelling, the sections were incubated in a PBS 1X-0.1% Triton X-100 solution, and 10% 
normal donkey serum (NDS, Jackson Immunoresearch, West Grove, PA) was used and 
sections were incubated for 1 hour at room temperature. Sections were incubated in 0.1% 
Triton X-100 and 1% normal donkey serum together with the primary antibody rabbit anti-
serotonin N-acetyltrasnferase (AANAT, ab3505, Abcam, Cambrigde, UK) at a 1:500 
dilution at 4ºC overnight. 
 Next day, three washes with PBS1X-Triton X-100-0.1% were performed for 5 
minutes each. Followed by the secondary antibody; donkey anti-immunoglobulin IgG 
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rabbit antibody conjugated with fluorescein isothiocyanate (FITC; green, Jackson 
ImmunoResearch, West Grove, PA, USA) at 1:100 dilution in PBS1X-Triton X-100-0.1% 
for one hour in a dark chamber at room temperature. Several washes with PBS1X were 
done. The nuclei were stained with propidium iodide (red, Sigma-Aldrich, St. Louis, MO) 
diluted 1:500 in PBS for 10 min. Finally, sections were rinsed and mounted in Vectashield 
fluoromount (Vector Laboratories, Palex Medical, Barcelona, Spain) and coverslipped.  
 For ciliary epithelial cells immunostaining, cells were treated with a specific 
TRPV4 agonist GSK1016790A for 18 hours before performing the immunocytochemistry. 
Cells were washed with PBS1X three times for 5 minutes each, and they were incubated 
with 4% paraformaldehyde diluted in PBS1X during 15 minutes, followed by several 
washes and 15 minutes of incubation with a solution of Triton X-1000- 0.05%. 
Experiments were done afterwords in the same way as the above procedure with the tissue 
sections. Immunolabelling showing negative controls were performed by substitution of 
the primary antibodies with normal or isotype specific immunoglobulins serum of the 
same specie at a similar working concentration. 
 For the analysis, the images were acquiered using a laser scanning microscope, a 
confocal microscope (Zeiss LSM 5, Jena, Germany) at 40X magnification.  
TRPV4 experiments 
Long-term studies 
 Cells were seeded in 6-well multiwells and observed until they reached 100% 
confluence, a density of 1.2x106 cells. A TRPV4 agonist GSK1016790A (Tocris 
Bioscience, Bristol, United Kingdom) was applied at a concentration of 10nM and left for 
different durations of 1, 3, 6, 18, 24, 48 hours to establish the adequate time course. The 
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supernatants at each time were collected for melatonin and AANAT activity measurements 
by HPLC as described below. Posterior to collecting the medium, cells were homogenized 
for western-blot assays. 
 In different multiwells, after deciding the best time to see the desired effect, a dose-
response curve was obtained by incubating the cells for 18 hours with GSK1016790A at 
different concentrations: 1nM, 10nM, 100nM, 1µM, and 10µM. Cell lysis was done for 
AANAT quantification. 
 For antagonists studies, the compounds ruthenium red (RR) and RN-1734 (RN)
(Vincent et al., 2009), were assayed at concentrations of 1 nM and 10 nM respectively, 
either alone or 30 min before the application of the TRPV4 agonist GSK1016790A. Cell 
lysis was done afterwards.    
Short term assays 
 Experiments were designed equally as the above assays in terms of cell density and 
TRPV4 agonist and antagonists. A short-term assays were done to study AANAT 
phosphorylation effect. A time-course was done incubating cells with GSK1016790A for 
different durations starting from 1, 5, 10, 15, 30, and 60 minutes at 10 nM concentration. A 
dose-response curve assayed with the same concentration range but only incubating the 
cells with the agonist for 5 minutes. Finally, for antagonist studies, the same protocol was 
applied taking into account the agonist time of incubation (5 minutes). 
 Supernatants were collected and cells were homogenized for HPLC and western-
bolt analysis, respectively. 
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Silencing TRPV4 channel 
 Cells were grown in 6-well multiwells. Transfection took place using a transfection 
reagent (sc-29528, Santa Cruz, CA, USA) and a transfection medium (sc-36868). For 
some wells, TRPV4 siRNA (sc-61726, Santa Cruz, CA, USA) was incubated, and in others 
the scramble was incubated as a control (sc-36869, Santa Cruz, CA, USA). Incubation was 
for 5 hours for the transfection with either siRNA or scramble, followed by several washes 
and finally, cells were incubated with a fully supplemented medium with 10% foetal serum 
and 0.05% of antibiotics for 48 hours. Cells were homogenized after TRPV4 silencing. A 
western blot assay was done using rabbit polyclonal to TRPV4 primary antibody 
(ab94868), and the medium was collected for melatonin analysis by HPLC.   
 A different set of cell culture was prepared posteriorly, and transfected in the same 
way. Cells transfected with the TRPV4 siRNA were incubated with GSK1016790A for 5 
minutes, the same experiment in wells with no siRNA was done. Cell lysis was performed 
for p-AANAT quantification by western-blot. 
Second messengers inhibition 
 For second messenger studies, different agents were applied for 30 minutes to 
assure the inhibitory effect later. TRPV4 agonist GSK1016790A was applied for 5 minutes 
to study the effect of these inhibitors on p-AANAT expression by means of western-blot. 
An inhibitor of adenylyl cyclase (SQ 22536) was used at a concentration of 50µM, a 
protein kinase A inhibitor (KT 5720) at 600 nM, a calmodulin-dependent protein kinase II 
inhibitor (Autocamid-2-related inhibitory peptide) was used at a concentration of 500nM, 
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and calmodulin antagonist (Calp2) at 20µM. All the inhibitors were purchased from Tocris 
Bioscience, Bristol, United Kingdom. 
Western-blot studies  
 Cells were removed and homogenized in ice with radioimmunoprecipitation assay 
(RIPA) buffer (1:5 v/v) containing 50 mM HEPES, pH 8, 150 mM NaCl, 1% NP-40 (w/v), 
0.5% sodium deoxicolate, 0.1% SDS and Halt Protease and Phosphate Inhibitor Cocktail 
(Thermo Fisher Scientific). lysates were centrifuged at 15,000 g for 15 minutes at 4ºC. the 
supernatant were transferred to a chilled 1.5 ml eppendorf tubes and stored at -20ºC until 
use. 
 The evaluation of the protein concentration present in the cell extracts was 
performed by the commercial kit (Pierce BCA Protein Assay kit, Thermo Scientific), based 
on the copper ion reaction of bicinchoninic acid with the proteins of the biological sample, 
according to the manufacturers instructions. This kit allows us to evaluate amounts of 
protein between 20 µg / ml and 2000 µg / ml to construct the standard curve. In this assay 
the protein samples, whose concentration was intended to be titrated, were diluted (1:10) 
and applied in triplicate to a 96-well plate. To discover the protein concentration, a 
calibration line was generated from known concentrations of albumin. The WR compound, 
provided with the kit, was then added, containing copper ions which form coloured 
complexes with the proteins to be titrated. After 30 minutes of incubation at 37 ° C the 
absorbance of the colored compounds obtained in a plate reader (Power Wave XS2, 
Biotek) at a wavelength of 562 nm was measured. 
 In the case of AANAT detection, 60 µg proteins were used for western blotting, 
while 80µg proteins were used for p-AANAT. Gels for electrophoresis were always 
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prepared with a stacking gel of 15% and separator at 4% SDS-PAGE. Samples were 
diluted with Laemmli’s sample buffer, pre-stained ladders were loaded onto a well in the 
same gel (referencia patron). Electrophoresis took place at 150V for around 1 hour. 
 For electro-transfer, a transfer sandwich was prepared, still wet with the transfer 
buffer as follows, foam pad, 3 blot papers, gel SDS-PAGE, nitrocellulose membrane, 3 
blot papers, and a foam pad,on the black side on the cassette, ensuring there were no 
bubbles trapped between layers. Transference of the separated proteins was run at 150mA 
for 80 minutes at 4ºC, and covered by the transference buffer. A frozen cooling unit was 
then inserted in the rear of the cassettes to keep the transfering unit cool during the 
proccess.   
 After the electrotransfer, in the case of AANAT detection, membranes were 
blocked with 5% of non-fat milk (Bio-Rad) dissolved in TBS x 0.1% Tween20 for 1 hour 
using an orbital shaker, while in p-AANAT experiments, blots were blocked with 5% 
Albumin bovine serum (Sigma-Aldrich) for 1 h at room temperature. After discarting the 
washing solutions, blots were incubated with primary antibodies AANAT primary 
antibody (ab3505, 1:1000, Abcam) and p-AANAT primary antibody (ab3439, 1:1000, 
Abcam). Mouse monoclonal glyceraldehyde-3-phosphate dehydrogenase (anti-GAPDH, 
sc-166574, 1:500, Santa Cruz, CA, USA) served as a loading control diluted in the 
blocking solution and incubated at  4°C overnight on a shaker. 
 Blots were washed 3 times, each for 5 minutes with TBS x 0.1% Tween 20, and 
membranes were incubated with a goat anti rabbit IgG-HRP-conjugated or a goat mouse 
anti-IgG-HRP-conjugated with horseradish peroxidase secondary antibody (Jackson 
ImmunoResearch, West Grove, PA, USA) diluted in 0.25% of non-fat milk in TBS x 0.1% 
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Tween20  for 1 h at room temperature. All steps were performed with the membrane on a 
shaker. Several washes were done before visualization of the desired protein. 
 Proteins were revealed by chemiluminiscence, using enhanced chemiluminiscence 
(ECL) detection kit (Amersham Phamacia Biotech, Barcelona, Spain) in a dark room. 
Films were scanned with Gel Logic 200 Imaging System (Kodak, USA). The 
densitometric analysis was performed by using Kodak Molecular Imaging software 
(Kodak, Rochester, NY, USA). The densitometry values of each sample were normalized 
to respective densitometric GAPDH values. 
HPLC analysis 
 The chromatographic studies was performed to detect melatonin following the 
protocol previously described (for more details, see chapter 2). Briefly, supernatants of 
cells after the different experimental conditions were processed for injecting in the HPLC 
system. For melatonin detection, the system was equilibrated with 40% methanol and 60 
% water. Measurements were taken at a flow rate of 0.8 ml/min fixing the detector at a 
wavelength of 244 nm. 
 HPLC analysis to detect the product of AANAT, N-acetyl serotonin (NAS), was 
performed with a SunFire18 (5 µ, 25 cm in length, 0.4 cm inner diameter) from Waters 
(Milford, MA) equilibrated with a mobile phase consisting of 15 % acetonitrile, 0.1 % 
acetic acid and at a flow rate of 0.75 ml/min, detecting NAS at the wavelength of 244 nm.  
 Quantification of melatonin and NAS was examined by comparing the samples 
with external standard provided by Sigma (st. Louis, MO, USA). 
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Statistical analysis 
 The data represent the mean s.e.m. of 4-6 independent experiments (indicated in 
each case). Statistical significant was calculated by student t-test or ANOVA test when 
necessary. GraphPad Prism (GraphPad Software Inc., San Diego, CA) was used to obtain 
the plots and to fit nonlinear regression curves in order to obtain the pD2 value (EC50). 
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Results 
Presence and changes of AANAT in the human ciliary body
 Human ciliary body tissues were dissected from whole human eyes for 
immunofluorescent labelling. Six samples were compared, two of healthy donors and 4 
from patients who had glaucoma. Ciliary body epithelium showed a positive staining 
mostly in the cytoplasm. However, the ciliary body of the glaucomatous donor presented 
stronger fluorescent labelling (Fig. 3.1.).
Figure 3.1. Presence and changes of AANAT in human ciliary body tissue. A: 
Representative pictures of human ciliary processes of a non-glaucomatous individual. 
From left to right DIC image, nuclei (in red, propidium iodine), AANAT (in green) and 
merge image.B: Representative image of human ciliary processes of a glaucomatous 
individual. From left to right DIC image, nuclei (in red, propidium iodine), AANAT (in 
green) and merge image.
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 Experiments were performed in isolated non-pigmented epithelial cells of the 
ciliary body as well. Cells were grown in multiwells, and some were treated with TRPV4 
agonist GSK1016790A to mimic an elevated pressure since this channel is sensitive to 
pressure among other stimulus (Ramsey et al., 2006; Thorneloe et al., 2008). The results 
showed AANAT labelling in both control and TRPV4 stimulated cells. Interestingly, 
stronger fluorescent labelling was observed in cells treated with GSK1016790A (fig.3.2.). 
These results were consistent with the observed differences between healthy and 
glaucomatous donor eyes.  
Figure. 3.2. Presence and changes of AANAT in human ciliary body epithelial cells. A: 
Untreated human ciliary body epithelial cells showing the expression of AANAT (in green) 
and the nuclei (in red). B: Human ciliary epithelial cells after treatment with 10 nM 
GSK1016790A for 18 h. AANAT expression can be seen in green while nuclei appear in 
red. C: Positive and negative controls for AANAT performed with human lens epithelial 
cells (positive) and human chondrocytes (negative). 
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TRPV4 activation increases AANAT and its phosphorylation: time-dependent behavior 
 TRPV4 agonist GSK1016790A was applied to non-pigmented epithelial cells at 
different times. For the study of the long- term effect of TRPV4 stimulation on AANAT 
expression, assay durations took place from 1 hour up to 48 hours. Short term experiments 
were also performed to see the phosphorylation of AANAT. Short-term experiments started 
for 1 minute gradually increasing in time to 1 hour. All experiments were done at 10nM 
concentration of GSK1016790A. Both AANAT and p-AANAT expression can be observed 
in figure 3.3.
Figure 3.3. Time-course of the effect of GSK on AANAT protein synthesis. A) 
Representative western-blot showing the changes in AANAT during a maximal period of 
48 hours after cell treatment with 10 nM GSK1016790A. B) Column plot showing the 
relative quantification of the western-blots band intensities. Values represent the mean 
s.e.m of four independent experiments (*p < 0.05 and **p < 0.01 versus time 0). C) 
Representative western-blot showing the changes in p-AANAT during a maximal period of 
60 min after cell treatment with 10 nM GSK1016790A (GSK). D) Column plot showing 
the relative quantification of the western-blots band intensities. Values represent the mean 
s.e.m of six independent experiments (**p < 0.01 versus time 0).
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 Results showed a maximal peak of AANAT after 18 hours of incubation with 
TRPV4 agonist, AANAT increment reached 2.4 folds above the control values 
(**p<0.000, n=4). AANAT values decreased after 48 hours (Fig. 3.3 B). When the TRPV4 
channel was activated by GSK1016790A at short durations for the phosphorylation of 
AANAT, pAANAT increased after 5 minutes of the agonist application. The maximal 
increase corresponded to 60% above the control values (**p<0.01, n=6). Phosphorylation 
values of AANAT returned to control ones after one hour (Fig. 3.3 D). 
 Since AANAT is responsible for melatonin synthesis by producing the precursor N-
acetyl serotonin (NAS), HPLC studies were performed to investigate if there was a 
correlation between the expression levels of AANAT shown in figure 3 and the production 
of both, NAS and melatonin. As can be seen in figure 3.4, both the levels of NAS and 
melatonin presented maximal concentrations at 18h, presenting concentrations of 40.24 ± 
1.82 nM in the case of NAS and 21.36 ± 1.83 nM for melatonin (n=4, ###p<0.001 vs 
control for NAS and **p<0.005 vs control for melatonin). As happened in the case of 
AANAT expression, after 18h, both NAS and melatonin returned to their initial values. 
 The experiments performed to measure NAS and melatonin production showed an 
increase which was similar to that observed for AANAT phosphorylation (figure 2A). A 
maximal elevation in NAS concentration was observed at 5 min with a value of 39.4 ± 3.7 
nM which was different from the initial NAS concentration (19.2  2.0 nM, ***p<0.001, 
n=6, figure 3.4 A) 
The changes in melatonin concentration were observed between 5 and 10 min with values 
of 23.9 ± 3.0 and 21.9 ± 4.1 nM, which were statistically different from the initial 
melatonin concentration (8.8 ± 1.3 nM, ##p<0.01, n=6, figure 3.4 B). 
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Figure 3.4. Time-course on the effect of GSK on melatonin levels. A) Columns presenting 
the concentrations of NAS and melatonin calculated as described in material and methods. 
Values represent the mean  s.e.m. of six independent experiments (*p < 0.05 and **p < 
0.01 versus time 0). B) Line graphs presenting the concentrations of NAS (filled circles) 
and melatonin (open circles) calculated from the chromatographic studies. Values represent 
the mean  s.e.m. of six independent experiments (*p < 0.05, **p < 0.01, ***p<0.001 
versus time 0 for NAS and #p < 0.05, ##p < 0.01 versus time 0 for melatonin). 
Concentration-response effect of GSK1016790A over AANAT and its phosphorylation 
 After the observation of the time required to promote the maximal AANAT 
expression on a long term assay after activating TRPV4 channel for 18 hours, and the 
demonstration that 5 minutes is enough to maximize AANAT phosphorylation, a dose-
response analysis was performed both at the long term and short term activation by 
TRPV4 agonist. 
 Different graded concentrations were applied to ciliary non-pigmented epithelial 
cell cultures ranging from 1nM to 10 µM. After 18 hours incubation of GSK1016790A, 
AANAT expression was the highest at 10-8 M (10 nM) concentration of TRPV4 agonist 
(Fig. 3.5). Transformation of western-blots into a dose-response curve allowed the 
observation of a sigmoidal pattern which provided a pD2 value for GSK of 8.34 ± 0.302, 
which was equivalent to an EC50 value of 4.57 nM (n=3, figure 3.5 A). 
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 Figures 3.5C and D, shows the same behavior observed in the case of AANAT 
phosphorylation, it was possible to observe that the phosphorylation of AANAT reached a 
maximum at a concentration of GSK of 10-8 M (10 nM). And the transformation of 
western-blots into a concentration-response curve permitted us to observe a sigmoidal 
pattern which provided a pD2 value for GSK of 8.5 ± 0.3, which was equivalent to an EC50 
value of 2.87 nM (n=6, figure 3.5 D). 
Figure 3.5. A) Representative western-blot study showing the concentration dependency 
of AANAT when cells are challenged with GSK1016790A ranging from 1 nM to 10 M. B) 
Concentration-response curve plotted with the relative quantification of the western-blot 
band intensities. The values represent the mean s.e.m. of five independent experiments. C) 
Representative western-blot study showing the concentration dependency of AANAT 
phosphorylation when cells are challenged with GSK1016790A (GSK) ranging from 1 nM 
to 10 M. D) Concentration-response curve plotted with the relative quantification of the 
western-blot band intensities. The values represent the mean  s.e.m. of six independent 
experiments. 
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TRPV4 antagonist effect 
 The application of GSK1016790A showed an increase of both AANAT and 
pAANAT in a long and short period of time, 18 hours and 5 minutes for AANAT and 
pAANAT, respectively. This increment was blocked after applying a non-selective TRPV1/
TRPV4 antagonist RutheniumRed (RR) and by the selective antagonist of the TRPV4; 
RN-1734,  (P<0.01 for both compound vs. GSK alone; n=5, Fig. 3.6 B.
Figure. 3.6. Effect of TRPV4 antagonists on AANAT triggered by GSK1016790A. A) 
Representative western-blot study showing the activity of TRPV4 antagonist Ruthenium 
Red (RR) and RN-1734 (RN), both alone and together with GSK1016790A, following the 
protocol described in methods. B) Column plot showing the relative quantification of the 
western-blots band intensities. Values represent the mean  s.e.m. of five independent 
experiments  (***p < 0.001 versus GSK1016790A effect). C) Representative western-blot 
study showing the activity of TRPV4 antagonists. D) Column plot showing the relative 
quantification of the western-blots band intensities. Values represent the mean  s.e.m. of 
six independent experiments  (***p < 0.001 versus GSK1016790A effect).
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 As shown in figure 3.6, 10 nM GSK (5 min), produced a significant increase 
compared to non-treated cells. This rise in AANAT phosphorylation was blocked by 
Ruthenium Red (RR) and by the selective antagonist of the TRPV4 RN-1734 (***p<0.001 
for both compounds vs. GSK alone; n=6, figure 3.6 D). Interestingly, when applied alone, 
neither RR nor RN-1734 was able to change AANAT phosphorylation (n=6). 
Silencing TRPV4 
To fully confirm the involvement of a TRPV4 channel in the phosphorylation of AANAT, 
studies were performed with siRNA for this protein. As can be seen in figure 5A, the 
incubation of cells with the siRNA for TRPV4 produced a very significant reduction in the 
expression of this membrane protein with a decrease of 85.8 % (***p<0.001, n=4, figure 
3.7). 
Figure. 3.7. A) Representative western-blot showing the reduction in TRPV4 expression 
after the incubation with a siRNA against this protein. B) Relative quantification of the 
western-blots band intensities presented in A. Values represent the mean  s.e.m. of four 
independent experiments  (***p < 0.001 versus control). C) Western-blot showing AANAT 
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phosphorylation and how TRPV4 silencing abolishes this process. B) Relative 
quantification of the western-blots band intensities presented in A (***p<0.001, n=4).  
 When the silencing conditions previously demonstrated were obtained, cells were 
challenged with the TRPV4 agonist GSK. As observed in figure **, western-blots 
indicated that GSK was practically unable to induce AANAT phosphorylation when 
compared to GSK in untreated cells. Quantification of western-blots confirmed that 
TRPV4 siRNA blocked the effect of GSK on AANAT phosphorylation (***p<0.001, n=4, 
figure 6B), and that this silencing effect was also measurable in the melatonin levels 
(figure 3.8). The effect of the siRNA changed melatonin levels from 24.2 ± 3.2 nM (GSK 
in non-treated cells), to 10.4 ± 2.7 nM (***p<0.001, n=4, figure 3.8). 
Figure. 3.8. Effect of TRPV4 silencing on AANAT phosphorylation on NAS and 
melatonin concentrations. A) Representative chromatograms showing the variations in 
NAS. B) melatonin chromatograms with GSK, siRNA and GSK + siRNA. B) Bar plot 
presenting the concentrations of NAS and melatonin calculated from the chromatographic 
studies. Values represent the mean  s.e.m. of four independent experiments  (***p < 0.001 
versus control for NAS and ###p < 0.001 versus control for melatonin). 
Effect of the second messenger inhibitors on AANAT phosphorylation triggered by GSK 
 In order to see how the activation of the TRPV4 was able to induce AANAT 
phosphorylation, several inhibitors of the adenylate cyclase and calmodulin pathways were 
tested in their ability to reverse the effect produced by GSK. As presented in figure 3.9, 
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four different inhibitors were assayed: SQ 22536 (an adenylyl cyclase inhibitor), KT 5720 
(a protein kinase An inhibitor), Calp2 (an inhibitor of Ca-calmodulin) and Autocamid-2 
related inhibitory peptide (inhibitor calmodulin dependent protein kinase II, CMPKII). In 
figure 3.9 A, it was possible to observe that the increase of phosphorylation induced by 10 
nM GSK was not significantly affected by either, the adenylate cyclase inhibitor SQ 22536 
or the protein kinase inhibitor KT 5720 (n=4). When applied alone, both inhibitors were 
able to reduce slightly but significantly control phosphorylation levels of AANAT (results 
not shown). 
 On the contrary, the application of the inhibitor of calmodulin, Calp2 and the 
inhibitor of CMPKII, Autocamid-2, significantly abolished the effect triggered by GSK 
(figure 3.9A). The effect of both inhibitors returned GSK values to those close to the 
control (in the absence of GSK, figure 3.9 B) (***p<0.001 for both inhibitors vs. GSK; 
n=4). As happens with the inhibitors of adenylate cyclase and PKA, when applied alone, 
Calp2 and Autocamid-2, reduced slightly but significantly the level of phosphorylation of 
control AANAT (Results not shown). 
Figure. 3.9. Effect of cAMP-PKA and calmodulin-CAMPKII inhibitors on GSK1016790A 
induced AANAT phosphorylation.A) Representative western-blot showing the lack of 
inhibition of SQ 22536 (an adenylyl cyclase inhibitor), KT 5720 (a protein kinase A 
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inhibitor), on the phosphorylation effect of GSK1016790A (GSK) on AANAT, and the 
inhibition conducted by Calp2 (an inhibitor of Ca-calmodulin) and Autocamid-2 (Auto) 
related inhibitory peptide (an inhibitor calmodulin dependent protein kinase II, CMPKII) 
following the protocol described in methods. B) Column plot showing the relative 
quantification of the western-blots band intensities. Values represent the mean  s.e.m. of 
four independent experiments (***p < 0.001 versus GSK1016790A effect). 
 In a parallel way, the levels of NAS and melatonin were investigated when cells 
were treated with the indicated compounds. As can be seen in figure 9A, NAS and 
melatonin chromatographic peaks changed in a similar way to what occurred with AANAT 
phosphorylation. The quantification of such peaks indicated a strong inhibition of NAS 
and melatonin concentration by Calp-2 (**p<0.01 for NAS, ##p<0.01 for melatonin, n=4) 
and Autocamid-2 (***p<0.001 for NAS, ###p<0.001 for melatonin, n=4), while the other 
agents did not significantly change the effect triggered by GSK (n=4, figure 9B). 
Figure. 3.10. Effect of cAMP-PKA and calmodulin-CAMPKII inhibitors on 
GSK1016790A induced NAS and melatonin concentrations.  A) Representative HPLC 
profiles showing the changes in NAS (left set of chromatograms) and melatonin levels 
(right chromatograms) depending on the second messenger inhibitors tested. B) Bar plot 
presenting the concentrations of NAS and melatonin calculated from the chromatographic 
studies. Values represent the mean  s.e.m. of four independent experiments  (**p<0.01, 
***p < 0.001 versus GSK1016790A effect for NAS and ##p<0.01, ###p < 0.001 versus 
GSK1016790A effect for melatonin). 
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Discussion  
 In the present chapter, TRPV4 channel stimulation has been described in the 
human non-pigmented ciliary body epithelial cells. TRPV4 activation was able to increase 
the rate limiting enzyme of melatonin synthesis aralkylamine N-acetyltransferase 
(AANAT) after a long period of incubation by a specific agonist, as well as its ability to 
phosphorylate AANAT after 5 minutes of stimulation. Both AANAT and pAANAT 
maximal increment were discovered to be time and dosage dependent by the TRPV4 
specific agonist GSK1016790A (Vincent et al., 2009). This effect was blocked by TRPs 
antagonist Ruthenium Red and with a selective TRPV4 antagonist RN-1734 (Thorneloe et 
al., 2008). Abolishing TRPV4 by using siRNA specific for TRPV4 has been experimented 
to confirm the observed effect of TRPV4 channel on AANAT and its phosphorylation. It 
has also been possible to demonstrate that, after the activation with GSK1016790A for a 
short period of time, a cascade of intracellular events involves the participation of 
calmodulin and calcium-calmodulin dependent protein kinase II. Interestingly, when 
measuring the concentrations of melatonin, it was possible to observe that in all the cases 
where AANAT was phosphorylated a concomitant rise in melatonin levels was observed. 
 In a previous chapter (refer to chapter 1), the presence of the TRPV4 channel was 
demonstrated in human non-pigmented epithelium cells, and that TRPV4 stimulation 
increases melatonin levels. In order to understand the significance of this channel 
stimulation in the eye, measuring melatonin levels in the aqueous humor of healthy and 
elevated IOP subjects showed an increase of melatonin concentration in patients with high 
IOP. Hence, the existence of a TRPV4 able to detect the rise in pressure or variations in the 
aqueous humor osmolarity, may act as a sensor to reduce IOP by increasing the 
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extracellular concentrations of melatonin. This substance will act through melatonin 
receptors reducing aqueous humor formation (Huete-Toral et al., 2015). 
 TRPV4 channel was first discovered as an osmosensor; a strech-gated channel. 
Currently, it is recognized that the TRPV4 function extends remarkably beyond its role as 
an osmoregulator and that this ion channel is involved in mediating numerous arrays of 
physiological and pathological conditions ( Liedtke, 2007). In fact, the polymodal TRPV4 
channel is believed to be essential for osmoregulation and Ca2+ homeostasis in the 
mammalian ciliary body. A recent study hasidentified TRPV4 presence in mice non-
pigmented ciliary epithelial cells (pigmented C57BL/6J, non-pigmented B6.Cg-Tg(Thy1-
YFP)HJrs/J) and it has been discovered that calcium ions potentiate non-pigmented 
epithelium swelling, beside the observation of differential osmoregulation and Ca2+ 
homeostasis mechanisms in NPE vs. PE (Jo et al., 2016). Investigations have shown that 
TRPV4 channel is expressed in secretory and absorptive epithelia, regulating Ca2+ 
signaling, volume changes, cytoskeletal remodeling, and responses to shear flow and 
mechanical stress (Harteneck and Reiter, 2007; Krizaj et al., 2014; Mamenko et al., 2015; 
Sokabe et al., 2010).  
 The physiological importance of the tandem TRPV4-melatonin in the regulation of 
IOP has already been demonstrated (refer to first chapter). However, little is known about 
the mechanism connecting TRPV4 and melatonin. In the present chapter, TRPV4 
activation induced typical Ca2+ transient. However, Ca2+ regulation of TRP channels is 
complex, they often show Ca2+ dependent desensitization to many stimuli by multiple 
mechanisms including the action of Ca2+ calmodulin (Rosenbaum et al., 2004; Zhu, 2005). 
In the case of TRPV4, Ca2+ increases the channel response to hypotonicity (Loukin et al., 
2015). The presence of the cation in the cytosol may bind to calmodulin to further activate 
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calcium-calmodulin dependent protein kinase II, as can be seen in figures 3.9 and 3.10. 
This is an interesting mechanism by which AANAT is phosphorylated, and it is an 
alternative to the one  produced by cAMP and PKA already described (Ganguly et al., 
2001) or the one mediated to PKC (Choi et al., 2004). 
 The study of PKA phosphorylation of AANAT deserves special attention, since 
AANAT phosphorylation stimulates the formation of a complex with 14-3-3 proteins, this 
mechanism plays an important role in regulating melatonin diurnal synthesis. Indeed, it has 
been demonstrated that in darkness, when the complex is formed, the amount of the 
produced melatonin can rise 10 times in the pineal gland (Jones et al., 1995; Klein et al., 
2002). In the present work, melatonin concentrations could rise 2.5 times when AANAT is 
phosphorylated. This is clearly indicating that the mechanism triggered by the TRPV4 in 
the ciliary body is not so robust as the one present in the pineal gland, however it may 
produce melatonin in the aqueous humor in concentrations which are sufficient to reduce 
IOP, since melatonin receptors present in the ciliary are activated by nanomolar 
concentrations (Alarma-Estrany et al., 2008).  
 The regulation of AANAT by a phosphorylation dependent of CAMPKII is 
interesting and offers another pathway used by many receptors and channels to regulate the 
synthesis of melatonin, at least in the eye, and in this cellular model in particular. The 
analysis of the human AANAT sequence (GenBank: AAH92430.1), shows a sequence 
which fits in the consensus sequence for CAMPKII as previously indicated (Pearson and 
Kemp, 1991; Songyang et al., 1996), supporting the findings described in the present 
work. 
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Figure 3.11. Possible mechanism of acttion of GSK acting on the TRPV4 channel in the
ciliary body. After the activation of the TRPV4 the influx of Ca2+ will bind to calmodulin 
(CM) which from on side activates adenylate cyclase and later protein kinase A (PKA). 
This kinase will finally produce the phosphorylation of CREB (cAMP response element-
binding) then may stimulate the synthesis of the enzyme AANAT. From the other hand, 
CM binds to calcium-calmodulin dependant kinase II to phosphorylate AANAT. This 
protein together with HIOMT will finally augment the production of melatonin in ciliary 
body epithelial cells. TRPV4 channel can be stimulated by the abnormal elevation in the 
IOP that often occur in glaucoma pathology.
 Reducing IOP is a very important target for patients who present glaucoma, this 
being the main risk factor for developing glaucoma. This ocular neurophathy, 
progressively and irreversibly damages the retinal cells. The aqueous humor is essential 
for the regulation of intraocular pressure, if its formation increases in an abnormal manner, 
elevated intraocular pressure occurs. However, a different case is also possible, when 
aqueous humor drainage is decreased through the uveoscleral outflow pathway or the 
conventional way through the trabecular meshwork (Acott et al., 2014; Stamer and Acott, 
2012). Searching for new treatments to lower IOP is a serious challenge, because all 
current treatments present several adverse effect which can even result in patients
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eventually discarding the treatment (Lo et al., 2016). In previous studies, in the search for 
new treatments for glaucoma, TRPV4 was linked to trabecular meshwork cells. Authors 
have studied the role of TRPV4 mediating Ca2+ influx in the trabecular meshwork, the 
inhibition of TRPV4 by using an antagonist in glaucoma mice resulted in a decrease of the 
IOP (Ryskamp et al., 2016) suggesting that this could protect the retinal ganglion cells 
from mechanical stress by TRPV4 inhibition (Krizaj, 2016; Krizaj et al., 2014). However, 
different studies showed the opposite effect on IOP after TRPV4 activation. In lowe 
syndrome patients, TRPV4 activation actually lowered IOP by acting on the cilia present 
in the trabecular meshwork (Luo et al., 2014) These findings can be explained by 
understanding the mutations that this class of patients have. 
 From a pharmacological perspective, the fact of TRPV4 synthetic agonists being 
able to trigger a mechanism that produces a melatonin-induced reduction of IOP, opens the 
possibility to look for new agents to fight against those cases of glaucoma related with an 
abnormal increase of IOP. Indeed, it has been already demonstrated that the application of 
GSK1016790A in mice can reduce IOP by acting on TRPV4 located in the trabecular 
meshwork (Luo et al., 2014), one of the drainage site for the aqueous humor. The 
development of new selective compounds, to add to the already available (Vincent et al., 
2009), suitable to activate the TRPV4 present in these two ocular locations, may join the 
pharmaceutical compounds commercially available for the treatment of ocular 
hypertension and glaucoma. 
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Chapter IV: Melatonin and α1-adrenergic receptor-
receptor interaction: A new pharmacological 
approach for glaucoma treatment 
“What is now proved was once only imagined.” 
William Blake 
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Introduction 
 Glaucoma, a pathology characterized by visual field loss, is associated with the 
damage of the optic nerve (Casson et al., 2012b). The main risk factors are inter alia 
aging, genetic conditions, intraocular pressure (IOP) and myopia (Quigley, 2011). Without 
treatment glaucoma leads to blindness, being the second cause of blindness in the world. In 
this sense, it has been estimated that about 61 million people in the world suffer from 
glaucoma, and the afflicted individuals may increase to about 80 million in year 2020 
(Quigley and Broman, 2006). Nearly three quarters of all glaucoma occurs in individuals 
with irido-corneal open angles, and open angle glaucoma (OAG) is the most common form 
of glaucoma in nearly all countries. While some forms of OAG occur secondary to other 
phenomena, the vast majority is idiopathic and therefore is referred to as primary open 
angle glaucoma (POAG) (Quigley and Broman, 2006).  
 Since IOP is the only modifiable risk factor known to date, glaucoma treatment has 
focused on decreasing IOP, which is proven to slow the progression of the disease, 
decrease the rate of visual field loss, thus, protecting against visual function loss and 
blindness (2009; Boland et al., 2013). Although IOP measurments may fluctuate, IOP 
values in adult humans are established from 10 till 20 mm Hg (normotensive IOP). When 
the value exceeds 21 mm Hg ocular hypertension is diagnosed. A high and persistent 
ocular hypertension results in damage of the optic disc, causing the degeneration of the 
ganglion cells and subsequent blindness. The relationship between ocular hypertension and 
glaucomatous pathology has been well known for many years. Even today with the current 
and effective therapeutic arsenal to decrease IOP, ocular hypertension is still considered 
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the most important risk factor for the development of this disease (Rossetti et al., 2015; 
Tamm et al., 2015).  
 Many different agents have been used to reduce the ocular hypertension that 
presents glaucoma patients. These include parasympathomimetics, adrenergic receptor 
antagonists, carbonic anhydrase inhibitors or prostaglandins, the later the most popular 
nowadays (Hommer, 2010; Lee, 2005). These drugs are prescribed depending on the 
patients’ characteristics, mainly because all present notorious side effects. Looking for 
better and safer anti-hypertensive drugs, pharmaceutical companies have started to 
combine the aforementioned agents, providing combinations that may be more effective at 
reduced doses and with reduced side effects (Polo et al., 2001; Sakai et al., 2005). 
 On this regard, anti-glaucomatous compounds can act by reducing IOP in the 
ciliary body, which participate in aqueous humor formation by means of a strict control 
carried out, in the healthy eye, by a wide variety of neurotransmitters and messengers 
(Delamere, 2006). Adrenoreceptor ligands, in particular, α-adrenergic agonists and β-
adrenergic antagonists, decrease IOP due to the presence of both types of adrenergic 
receptors in the ciliary body (Kiuchi et al., 1992; Murray and Leopold, 1985; Naito et al., 
2001). Concerning α-adrenergic receptors, and in particular α1-adrenoceptors, studies in 
different animal models indicated that phenylephrine produce a reduction in IOP which 
can be blocked by a selective antagonist, prazosin. 
 Adrenergic-receptor family are members of GPCRs, which possesses an 
extracellular N-terminal domain and an intracellular C-terminal domain and different 
intracellular and extracellular loops. Intracellular loops allow adrenergic receptors to 
interact with cascade signaling proteins such as β-arrestin and dinamine (Cotecchia, 2010; 
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Small et al., 2006; Tan et al., 2009); while the extracellular loops form a structural 
“pocket” which allows ligand binding to the receptor. 
 The α1 adrenergic receptor is the first member of the α-receptor subfamily, and it 
consists of three subtypes receptors called α1A, α1B and α1D that differentiate among them 
by their pharmacological properties and localization in the organism. In general, α1 
adrenergic receptors are coupled to Gq protein, which activation induced by the exchange 
of GDP by GTP produces the activation of phospholipase C (PLC) and the consequent 
phosphorylation of protein kinase C (PKC). This phospholipase hydrolyzes 
phosphatidylinositol 4,5-bisphosphate (PIP2) to inositol triphosphate (IP3) and 
diacylglycerol (DAG). These secondary metabolites allow the opening of the calcium 
channels of the endoplasmic and sarcoplasmic reticulum thus increasing intracellular 
calcium levels, with the activation of a cascade of phosphorylation that leads to the 
induction of several transcription factors (Johnson and Liggett, 2011; Maronde and Stehle, 
2007; Schmitz et al., 1981). 
 A different approach in the treatment of glaucoma is by the use of melatonin and/or 
its  analogues which are proven to decrease IOP as well as working as a neuroprotectant 
(Belforte et al., 2010; Crooke et al., 2012; Ismail and Mowafi, 2009). Interestingly, α1 
adrenergic antagonist prazosin interacts with melatonin receptors by inhibiting melatonin’s 
action in normotensive  model (Dubocovich, 1995; Pintor et al., 2003). Such an 
observation opened the window of the possible interaction between melatonin receptors 
and α1 adrenergic in the ciliary body. The present section of this thesis describes a novel 
sight of melatonin-α1 adrenergic receptors heteromerization with a profound work using 
biochemical techniques together with the use of actual glaucomatous model and human 
samples of healthy and diseased subjects to confirm our hypothesis. 
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Material and methods 
Drugs and animals  
 Melatonin, IIK7 (a selective MT2 receptor agonist) (Sigma, St. Louis, USA), 
Prazosin (α1A-adrenergic receptor antagonist), (R)-(-)-Phenylephrine hydrochloride (α1A-
adrenergic receptor agonist), Luzindole (non-selective melatonin antagonist), 4-phenyl-2- 
propionamidotetralin (4PPDOT, MT2 selective antagonist) were purchased from Tocris 
Bioscience (Bristol, UK). All drugs were formulated in isotonic saline containing 1% 
DMSO (Sigma, St. Louis, USA) at a concentration of 100 µM. 
 Experiments were performed on female C57BL/6J (n=5) (control animals) and 
DBA/2J (n=5) (glaucomatous animals) mice obtained from the European distributor of 
Jackson Laboratories Mice (Charles Rivers Laboratories). All animal maintenance and 
experimental procedures followed Spanish and European guidelines for animal care in the 
laboratory and animal research (Guide for the Care and Use of Laboratory Animals) and 
the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research. Mice 
were housed (1-4 mice per cage) in temperature and light-controlled rooms maintained 
according to a 12-h light/dark cycle; all animals were fed ad libitum. DBA/2J and C57BL/
6J mice were studied at 3 and 12 months of age.  
Cells 
 A human non-pigmented ciliary epithelial (59HCE) immortalized cell line was 
kindly supplied by Dr. Coca-Prados (Yale University). Cells were grown in high glucose 
Dulbecco’s modified Eagle’s medium (Gibco/Invitrogen, Carlsbad, CA) containing 10% 
foetal bovine serum (Sigma-Aldrich, St. Louis, MO) and 0.05 mg/ml penicillin/
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streptomycin (Gibco/Invitrogen) at 37°C in humidified atmosphere 5% CO2–95% air. 
After the culture reached the confluence, cells were detached with 0.25% trypsin and 
seeded into 6 well plates and/or to 4 well chamber slides respectively. All the experiments 
were performed using cells comprised numbers 10-15 passages to assure assays 
reproducibility. 
 HEK-293T cells were grown in DMEM (Invitrogen) supplemented with 2mM L-
glutamine, 100 U/ml penicillin/streptomycin, and 5% (v/v) heat inactivated fetal bovine 
serum (all supplements were from Invitrogen). Cells were maintained at 37ºC in an 
atmosphere of 5% CO2 and were passaged when they were 80-90% confluent (i.e., 
approximately twice a week).  
Fusion proteins and expression vectors  
 The human cDNAs for the MT1, MT2 and α1A receptors was cloned in pcDNA3.1 
were amplified without their stop codons using sense and antisense primers harboring 
either unique HIND III and BamH1 sites (MT1, MT2) or EcoRI and BamHI (α1A). The 
fragments were then subcloned to be inframe with Renilla luciferase (Rluc) into the EcoRI 
and BamHI (α1A) restriction sites of an Rluc-expressing vector (pRluc-N1, PerkinElmer, 
Wellesley, MA), or into the BamH1 and HIND III (MT1, MT2) restriction sites of a yellow 
fluorescence protein YFP expressing vector, to give the plasmids that express MT1 ,MT2, 
and α1A receptors fused to Rluc or YFP on the C-terminal end of the receptor (α1A –Rluc, 
MT1–YFP or MT2–YFP).  
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Transient transfection and sample preparation for BRET and FRET experiments 
 HEK-293T cells growing in 6-well dishes were transiently transfected with the 
corresponding fusion protein cDNA by the PEI (PolyEthylenImine, Sigma, Steinheim, 
Germany) method. Cells were incubated (4h) with the corresponding cDNA together with 
PEI (5.47 mM in nitrogen residues) and 150 mM NaCl in a serum-starved medium. After 4 
hours, the medium was changed to a fresh complete culture medium. Forty-eight hours 
after transfection, cells were washed twice in quick succession in HBSS with 10 mM 
glucose, detached, and resuspended in the same buffer containing 1mM EDTA. To control 
the cell number, sample protein concentration was determined using a Bradford assay kit 
(Bio-Rad, Munich, Germany) using bovine serum albumin dilutions as standards. Cell 
suspension (20 µg of protein) was distributed into 96-well microplates; black plates with a 
transparent bottom were used for FRET and fluorescence determinations, while white 
plates with white bottom were used for BRET.  
BRET and FRET assays 
 HEK-293T cells were transiently co-transfected with a constant amount of the 
cDNA encoding for receptor fused to Rluc and with increasingly amounts of the cDNA 
corresponding to receptors fused to YFP. To quantify receptor-YFP expression, cells (20 
µg protein) were distributed in 96-well microplates (black plates with a transparent 
bottom), and fluorescence was read in a Fluo Star Optima Fluorimeter (BMG, Lab 
Technologies) equipped with a high-energy xenon flash lamp, using a 10 nm bandwidth 
excitation filter at 400nm reading. Receptor-fluorescence expression was determined as 
fluorescence of the sample minus the fluorescence of cells expressing the BRET donor 
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alone. The equivalent of 20 Šg of cell suspension was distributed in 96-well microplates 
(Corning 3600, white plates; Sigma), and 5 (Corning 3600, white plates; Sigma), and 5ŠM 
coelenterazine H (Invitrogen) was added. After 1 min of adding coelenterazine H, the 
readings were collected using a Mithras LB 940 that allows the integration of the signals 
detected in the short-wavelength filter at 485 nm (440-500nm) and the long-wavelength 
filter at 530nm (510.590nm). To quantify receptor-Rluc, luminescence readings were also 
performed after 10 min of adding 5 ŠM coelenterazine H. The net BRET is defined as 
[(long-wavelength emission)/(short-wavelength emission)] for the donor construct 
expressed alone in the same experiment. BRET is expressed as milli-BRET units (mBU = 
net BRET X 1000). The net BRET is defined as [(long-wavelength emission)/(short-
wavelength emission)]-Cf where Cf corresponds to [(long-wavelength emission)/(short-
wavelength emission)] for the Rluc construct expressed alone in the same experiment.
Figure 4.1. Illustration of BRET technique to study protein-protein interaction. For 
instance, two fusion proteins with Rluc and YFP must be coexpressed, and luminescent 
signals are measured at 480 nm (Rluc light emission) and 530 nm (YFP light emission) 
upon addition of the Rluc substrate coelenterazine. If one protein does not interact with the 
other and if Rluc and YFP are not at a BRET-permissive distance (>10nm) and orientation, 
non-radioactive light emission is mainly measured at 480 nm. On the contrary, if both 
proteins are in close proximity and interacting together, placing Rluc and YFP at a BRET-
permissive distance (<10nm) non-radioactive energy transfer can be measured at an 
increased light emission at 530 nm.
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Label-free dynamic mass redistribution (DMR) assay 
 The global cell signaling profile was measured using an EnSpire Multimode Plate 
Reader (Per- kinElmer, Waltham, Massachusetts, US). This label-free approach uses 
refractive waveguide grating optical biosensors, integrated into 384-well Epic® 
(Corning®, NY, USA) sensor microplates. Changes in local optical density are measured 
in a detection zone up to 150 nm above the surface of the sensor. Cellular mass movements 
induced upon receptor activation are detected by illuminating the underside of the 
biosensor with polychromatic light and measured as changes in the wavelength of the 
reflected monochromatic light. These changes are a function of the refraction index. The 
magnitude of this wavelength shift (in picometers) is directly proportional to the amount of 
DMR. Briefly, 24 h before the assay, cells were seeded at a density of 10,000 cells per well 
in 384-well sensor microplates with 30 µl growth medium and cultured for 24 h (37°C, 5% 
CO2) to obtain 70%–80% confluent monolayers. Previous to the assay, cells were washed 
twice with assay buffer (HBSS with 20 mM HEPES, pH 7.15) and incubated for 2 hours in 
30 µl per well of assay-buffer with 0.1% DMSO in the reader at 24°C. Hereafter, the 
sensor plate was scanned, and a baseline optical signature was recorded before adding 10 
µl of test compound dissolved in assay buffer containing 0.1% DMSO. Data were 
normalized and expressed as % of maximum activation induced by test compound. For 
analysis of DMR data, the AUC values of DMR signals between the 0 and 3600å s time 
points with mean and SEM were used to calculate agonist activity. AUC values were 
transformed into relative AUC units to give equivalent baseline optical recordings for all 
dose–response curves from any given assay plate. Data were then normalized and 
expressed as % of maximum (100%) activation induced by a saturating concentration of 
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LPI. Data were additionally analysed by determining the slopes of tangents to the origin of 
the real-time traces to capture the steepness of the initial ascending parts. Kinetic results 
were analyzed using EnSpire Workstation Software v 4.10.  
cAMP determination 
 Two hours before initiating the experiment, 59HCE cells or HEK-293T cell-culture 
medium was exchanged to serum-starved DMEM medium. Then, cells were detached and 
resuspended in growing medium containing 50 µM zardaverine were plated in 384-well 
microplates (2,500 cells/well), pretreated (15 min) with the corresponding antagonists -or 
vehicle- and stimulated with agonists (15 min) before adding 0.5 µM forskolin or vehicle. 
 Readings were performed after 15 min incubation at 25º. Homogeneous time-
resolved fluorescence energy transfer (HTRF) measures were performed using the Lance 
Ultra cAMP kit (PerkinElmer, Waltham, MA, USA). Fluorescence at 665 nm was analyzed 
on a PHERAstar Flagship microplate reader equipped with an HTRF optical module 
(BMG Lab technologies, Offenburg, Germany). 
Intracellular calcium release 
 Cells were co-transfected with the cDNA for the indicated receptors and 3 µg of 
GCaMP6 calcium sensor (Chen et al., 2013) using lipofectamine 2000 (Thermo Fisher 
Scientific). 48 hours after transfection, cells (150.000 HEK-293T cells/well in 96-well 
black, clear bottom microtiter plates) were incubated with Mg+2-free Locke’s buffer pH 7.4 
(154 mM NaCl, 5.6 mM KCl, 3.6 mM NaHCO3, 2.3 mM CaCl2, 5.6 mM glucose and 5 
mM HEPES) supplemented with 10 µM glycine and receptor ligands were added as 
indicated. Fluorescence emission intensity of GCaMP6 was recorded at 515 nm upon 
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excitation at 488 nm on the EnSpire® Multimode Plate Reader for 335 s every 15 s and 
100 flashes per well. 
Arrestin recruitment assays 
 Arrestin recruitment was determined using BRET experiments as described above 
in HEK-293T cells expressing the cDNA corresponding to β-arrestin-2-Rluc (1 µg 
transfected), MT1-YFP (1,5 µg transfected) or MT2-YFP (1,5 µg transfected) alone or with 
α1A (0.05 to 0,5 µg transfected) after the indicated treatment with ligands. 
 Intraocular pressure measurements 
 Mice were anesthetized by inhalation of isoflurane, by means of the Matrx VIP 
3000 Calibrated Vaporizer (Midmark, OH, USA). Oxygen is mixed with isoflurane and 
sent to two outflows at 500cc/ minute, delivering 2.5% of isoflurane in oxygen to the 
animal. One outflow enters a box where mice were placed into for initial sedation. After 
about 2 min, the sedated animal was positioned for IOP measurement and clinical 
examination with a nose cone delivering the isoflurane gas/oxygen mixture. The nose cone 
permitted access to the eyes.  
 The above-mentioned substances were applied in drops to the cornea at a fixed 
volume of 2 µl in both eyes. IOP was measured by means of a TonoLab® non-invasive 
rebound tonometer supplied by Tiolat Oy (Danias, Kontiola et al. 2003, Wang, Millar et al. 
2005). The tonometer is placed in a fixed position and the sensor aligns with the optical 
axis of the eye between 1-4 mm apart. Both eyes of each animal were measured 
immediately after the application of the anesthesia. Six consecutive measurements were 
taken for each reading, and three readings were obtained on each eye. To avoid the 
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putative effect of the circadian rhythm, the IOP was always tested at the same time of the 
day (Aihara, Lindsey et al. 2003). Finally, to study the effect of the different antagonists 
tested, they were instilled 2 µl 30 min before the agonist, at a concentration of 100 µM, 
measuring IOP in the same way as previously described.  
Human eye tissues 
 Donor Human eyes were obtained from the Fundación Banco de Sangre y Tejidos 
de las Islas Baleares (Blood and tissue bank Foundation from Baleares Islands). Three eyes 
of healthy normal subjects and two of glaucoma patients were used for these assays. Eyes 
were enucleated and collected without the cornea in sterile tubes and maintained in 4% 
paraformaldehyde in 0.1 M phosphate buffer (PB) (pH 7.2-7.4) at 4ºC until posterior 
processing. Eyes were dissected under stereo microscope (Zeiss) and with the 0.8 mm tip 
curved forceps and sterile dissecting scissors, the iris and ciliary processes was collected. 
Several washes in PBS were performed and then, the specimens were cryoprotected in a 
sucrose gradient (from 11% to 33%) and were embedded in tissue freezing medium 
(Tissue-Tek© OCT) until frozen with liquid N2. Vertical sections of control and 
glaucomatous human samples (10 µm thick) were collected using a cryostat (Leica, 
Nussloch, Germany) and mounted from the same region.  Samples were maintained in a 
-20 ºC until use. 
Immunofluorescent studies 
 Frozen sections of healthy and glaucomatous subjects were rinsed in phosphate 
buffer saline (PBS) 1X and permeabilized with PBS-0.05% Tx-100 solution for 30 min. 
Afterward, to avoid non-specific staining, sections were incubated in a blocking solution 
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with a 10% normal donkey serum (NDS, Jackson Immunoresearch, West Grove, PA) 
during 1 hour at room temperature. Then, primary antibodies were incubated in each 
section overnight at 4ºC. The antibody raised against MT1 receptor was used at (1:200) 
dilution (Santa Cruz, sc-13179), MT2 antibody at (1:1000, ABIN122307, antibodies-
online) and the -adrenergic antibody purchased from Abcam (1:500, ab3462). Sections 
were washed in PBS1X-0.1% Tx-100 and incubated with donkey anti-immunoglobulin 
IgG rabbit antibody conjugated with fluorescein isothiocyanate (FITC; green, Jackson 
ImmunoResearch, West Grove, PA, USA) at 1:100 dilution in the case of MT2 and -
adrenergic antibodies, and donkey anti-immunoglobulin IgG goat antibody conjugated 
with fluorescein isothiocyanate (FITC; green, Jackson ImmunoResearch, West Grove, PA, 
USA) at 1:100 dilution in the case of MT1 receptor, antibodies were diluted in PBS-0.1% 
Tx-100 for 1 hour in a dark chamber at a room temperature. The nuclei were stained with 
propidium iodide (red, Sigma-Aldrich, St. Louis, MO) diluted 1:500 in PBS for 10 min. 
Finally, sections were rinsed with PBS1X and mounted in Vectashield (Vector 
Laboratories, Palex Medical, Barcelona, Spain) and coverslipped. The samples were 
examined under a confocal microscope (Zeiss LSM 5, Jena, Germany) at 40X 
magnification. For ciliary epithelial cells immunostaining, similar protocol was done for 
immunostaining of ciliary epithelium cells after incubating them with TRPV4 agonist 
GSK1016790A at 10µM for 18 hours. 
In situ and In vitro proximity ligation assay (PLA)  
 The proximity ligation assay (PLA) allows the detection of molecular interactions 
between two endogenous proteins ex vivo. PLA requires both receptors to be sufficiently 
close to allow the two antibodies DNA probes to form double stranded segments (<16 nm), 
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a signal that is further amplified in the presence of fluorescent nucleotides. By PLA, the 
heteromerization of MT1 ƒ1A-adrenergic and MT2 ƒ1A-adrenergic was detected in non-
pigmented epithelial ciliary body cells and, in situ, in human ciliary body sections of 
healthy and glacomatous donors. 
 59HCE cells were treated with a selective TRPV4 agonist GSK1016790A at 
different concentrations graded from 10nM, 100nM, 1ŠM, to 10ŠM during 18 hours for 
the performance of proximity ligation assay.
Figure 4.2. Schematic representation of the PLA assay. The direct method uses antibody 
pairs with primary conjugation. Following incubation with primary antibodies linked to 
PLA PLUS and MINUS probes (1), Hybridize connector oligos and use ligase to complete 
the DNA circle (2). Roling circle amplification (3). Hybridize fluorescence-labeled 
oligonucleotides for signal detection (4).
 The PLA technique was carried out in paraformaldehyde-fixed human ciliary body 
sections and non-pigmented epithelial ciliary body cells. The presence/absence of receptor-
receptor molecular interactions in the samples was detected using the Duolink II in situ 
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PLA detection kit (developed by Olink Bioscience, Uppsala, Sweden; and now distributed 
by Sigma-Aldrich as Duolink® using PLA® Technology). To create our PLA probes we 
linked the primary MT1 and MT2 antibodies to PLUS oligonucleotide (DUO92009, 
Sigma, St. Louis, USA) and the α1A-adrenergic antibody to MINUS oligonucleotide 
(DUO92010, Sigma, St. Louis, USA). Sections were washed in PBS 1X pH 7.4 buffer, 
permeabilized with PBS containing 0.05% Triton X- 100 for 30 min and finally washed 
with PBS. After permeabilization, sections were washed at room temperature, incubated in 
a preheated humidity chamber for 1 hour at 37°C with the blocking solution provided with 
the PLA kit and then incubated overnight with the PLA probe-linked antibodies (1:100 
dilution for all antibodies) at 4°C. After washing with buffer A (Wash buffer A, 
DUO82047, Sigma-Aldrich, St. Louis, MO, USA) at room temperature, sections were 
incubated with the ligation solution for 1 hour at 37°C in a humidity chamber. Following 
washes with buffer A, sections were incubated with the amplification solution for 100 min 
at 37°C in a humidity chamber and then washed in buffer B (Wash buffer B, DUO82048, 
Sigma-Aldrich, St. Louis, MO, USA), followed by another wash with buffer B x0.01. 
Finally, samples were incubated with 1:1000 dilution of SYTOX green stain (S7020, 
Thermo fisher scientific) and then washed with buffer B x0.01 and mounted using 
amounting medium vectashield (Vector Laboratories, Palex Medical, Barcelona, Spain). 
Appropriate negative control assays were carried out by incubating only one antibody to 
ensure lack of nonspecific labeling and amplification. Finally, sections were rinsed and 
mounted in Vectashield (Vector Laboratories, Palex Medical, Barcelona, Spain) and 
coverslipped. The samples were examined under a confocal microscope (Zeiss LSM 5, 
Jena, Germany) at 40X magnification.  
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 For each field of view, a stack of two channels (one per staining) and 13 to 22 Z 
stacks with a step size of 0.7 µm were acquired. A quantification of cells containing one or 
more red spots versus total cells (green nucleus) was determined considering a total 2200- 
2500 cells from 18 different fields. Nuclei and red spots were counted on the maximum 
projections of each image stack. After getting the projection each channel was processed 
individually. The nuclei were segmented by filtering with a median filter, subtracting the 
background, enhancing the contrast and finally applying a threshold to obtain the binary 
image and the regions of interest (ROI) around each nucleus. Red spots images were also 
filtered and thresholded to obtain the binary images. Red spots were counted in each of the 
ROIs obtained in the nuclei images. 
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Results 
Identification of an Interaction between both MT1, MT2 and !1A adrenergic receptor 
 To identify potential direct interactions between receptors, a FRET biophysical 
approach was used using HEK-293T cells. Cells were transfected with a constant amount 
of cDNA for ƒ1A -Rluc and increasing amounts of cDNA for MT1-YFP. In co-transfected 
cells, a saturable FRET curve was obtained (BRETmax 48.9 BRET50 43.5) (Fig. 4.4A), 
indicating the existence of for !1A-MT1 heteroreceptor complexes. Similar experiments 
using increasing amounts of cDNA of MT2-YFP also provided a saturable BRET curve 
with BRETmax 168.5 and BRET50 values of 128.2 ,thus demonstrating that both melatonin 
receptors may form heteromers with !1A-adrenergic receptors (Fig. 4.4B).
Figure 4.4. BRET saturation experiments showing !1A –MT1 and !1A –MT2 
heteromerization were performed using cells transfected with 0.5 µg of cDNA 
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corresponding to !1A-Rluc and increasing amounts of cDNA (0–3 µg cDNA) 
corresponding to either MT1-YFP or MT2-YFP. As negative control, cells were also 
transfected with cDNA corresponding to !1A (0.5 µg) and serotonin 5HT-YFP (0 to 4 µg 
cDNA). Both fluorescence and luminescence for each sample were measured before each 
experiment to confirm similar donor expressions (approximately 150 000 bioluminescence 
units) while monitoring the increase in acceptor expression (100 to 80 000 net 
fluorescence units). The relative amount of BRET is given as the ratio between the 
fluorescence of the acceptor minus the fluorescence detected in cells expressing only the 
donor and the luciferase activity of the donor. BRET data are expressed as the mean ± 
SEM of 4–8 different experiments; data are grouped according to the signal provided by 
the BRET acceptor. mBU, mili BRET units. 
Co-expression of MTs and !1A causes cell signaling via Gs
 Signaling was investigated in both, single transfected and co-transfected cells. First 
of all, one of the main findings was the Gi-protein-coupling when melatonin or ƒ1A-
adrenergic receptors were individually expressed (Fig 4.5A-C). In fact, the application of 
either melatonin agonists or ƒ1A-agonist reduced cAMP levels induced by forskolin. 
Activation of receptors in single transfected cells also provided significant DMR read-outs 
(Fig 4.5 D-F). Finally, BRET assays using -arrestin-2-Rluc and receptors fused to YFP, 
showed „-arrestin recruitment only induced by the selective agonists of either ƒ1A, MT1 or 
MT2 receptors (Fig 4.6 A-C).
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Figure 4.5 !1A and MTs alone are associated to Gi and Gq signaling respectively when 
expressed alone. HEK-293T cells expressing !1A ,MT1 or MT2 receptors were used. In 
A,B, and C cAMP production was determined in cells stimulated with 5 µM  forskolin. 
Cells were stimulated with 10 µM melatonin or 10 µM IIK7 or 10 µM  phyneliphrine. 
Values (cAMP produced in each condition minus basal stimulation in the absence of 
forskolin or agonists) represent mean ± SEM of n = 3–4 and are expressed as the 
percentage of the forskolin-treated cells in each conditions (120–150 pmols cAMP/106 
cells). One-way ANOVA followed by a Dunnett’s multiple comparison test showed a 
significant effect over the forskolin-alone effect in each condition (* p < 0.05, ** p < 
0.01). In (D,E,F) label free real time DMR analysis of each receptor expressed alone in 
HEK-293T cell, in D cells were challenged with phyneliphrine, E, with melatonin and F 
with IIK7, and wavelength shift was monitored over time as a measure of receptor 
activation. . Each curve is the mean of a representative optical trace experiment carried out 
in triplicates
 As it has been reported that !1A-adrenoceptor is generally coupled to Gq/11, 
experiments on Ca2+ mobilization were performed using a calmodulin-based biosensor 
(GCaMP6 sensor). The results in cells individually expressing the !1A-adrenergic receptor 
showed Gq/11 coupling, with a robust increase in the Ca2+ biosensor (Fig.4.6 D). The effect 
of phenylephrine in these cells was antagonized by prazosin, but not by the melatonin 
antagonists luzindole or 4-PPDOT. Neither MT1 nor MT2 receptors were coupled to Gq/11
in HEK-293T cells (Fig. 4.6E and 4.6F).
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Figure 4.6. A, B and C: BRET-based „-arrestin recruitment assay in HEK293T cells 
transiently expressing with either 2 µg of MT1, MT2, or ƒ1A –YFP cDNA, 0.2 µg of „-
arrestin II-Rluc cDNA. Each agonist showed a positive reaction which was diminished by 
its corresponding agonist. Values represent mean ± SEM of n = 4–6. One-way ANOVA. D: 
robust increase in the Ca2+ biosensor in cells expressing ƒ1A receptor, and the effect was 
antagonized by prazosin. F and K confirmed that melatonin receptors MT1 nor MT2
receptors were negatively coupled to Gq/11 in HEK-293T cells  
 Qualitatively different results were obtained in the signaling experiments 
performed in co-transfected cells (Fig. 4.7, 4.8 and 4.9). Actually, the cAMP determination 
data in co-transfected cells were very similar to the results obtained in HCE cells. In this 
sense, the activation of receptors in HEK-293T cells expressing !1A-MT1 heteromers or 
!1A-MT2 heteromers produced an increase in forskolin-induced cAMP levels, in clear 
contrast to what happened in single-transfected cells (Fig. 4.7 A and 4.7 B). Also, cross-
antagonism reappeared in co-transfected cells.
Figure 4.7 cAMP experiments in HEK-293T expressing either !1A-MT1 heteromers 
or !1A-MT2 heteromers (A and B). Stimulation with melatonin and phyneliphrine caused 
an increment in forskolin-induced cAMP levels, same results obtained with !1A-MT2  with 
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the activation by IIK7 and phyneliphrine. As shown in C and D cross-talk of melatonin and 
!1A-agonists was blocked by cholera but not by pertussis toxin.
 Analogies between HCE and co-transfected KEK-293T cells were further found in 
experiments with toxins; in KEK-293T cells expressing melatonin-adrenergic receptors, 
the cross-talk of melatonin and !1A-agonists was blocked by cholera but not by pertussis 
toxin (Fig. 4.7C and 4.7D). Also, matching the results obtained in HCE cells, a 
potentiation of the label-free DMR signal upon co-activation, cholera toxin sensitivity and 
a cross-antagonism were detected (Fig 4.8A-4.8D).
Figure 4.8 label free real time DMR analysis of receptors coexpressed in HEK-293T cell 
confirms response of a cross talk between phyneliphrine and melatonin (A) and 
phyneliphrine and IIK7 (B). in C and D this effect was blocked by cholera but not by 
pertussis toxin.Each curve is the mean of a representative optical trace experiment carried 
out in triplicates. 
 Remarkably, phenylephrine did not produce any Ca2+ response in cells expressing 
either !1A-MT1 or !1A-MT2 heteroreceptor complexes (Fig. A 4.9A and 4.9B). These results 
indicate a lack of productive coupling of receptor heteromers with Gq/11 or Gi, and a 
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dependence on GS-proteins. Cross-modulation was also detected in G-protein independent 
signaling investigated in co-transfected cells. Indeed, „-arrestin recruitment occurred. Not 
only !1A-receptor activation but the activation of MT1 melatonin receptor recruited „-
arrestin to the !1A-receptor, co-activation resulting in a stronger signal (Fig. 4.9C and 
4.9D). The recruitment was abolished by the !1A-receptor antagonist as well as by the MT1
melatonin receptor antagonist. Fully similar results were obtained in cells co-expressing 
!1A-MT2 heteromers using the selective MT2 agonist and antagonist (Fig. 4.9C and 4.9D). 
Figure 4.9. Ca2+ response after stimulation with !1A and MTs agonist was deleted when 
cells were cotransfected with both receptors (A and B). BRET-based „-arrestin recruitment 
assays showed a stronger signal when cells were challenged with both receptors aginsts, 
this effect was abolished by antagonists of both receptors. Values represent mean ± SEM 
of n = 4–6. One-way ANOVA.
 Altogether, these results indicate the formation of heteromeric complexes in the 
heterologous expression system, and that the receptor-receptor interactions condition 
intracellular signaling. Since the results obtained in HEK-293T cells in terms of signaling 
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are identical to those obtained in HCE cells, we presume that human HCE cells present 
heteromers that are functionally coupled to Gs but not to Gi or Gq/11 proteins. 
Important role of C-terminal tail of the α1A adrenergic receptor 
 Looking at the primary structure and membrane topological domains of the GPCR 
receptors here studied, we hypothesized that some of the intracellular domains might be 
responsible of the differential G coupling to heteromers versus to individual receptors. On 
the one hand, the area projected by a G protein on the membrane plane almost doubles that 
of a GPCR molecule.  On the other hand, the “clam-shell like” opening of the small 
globular domain in Gα subunits (also known as the α-helical domain), which occurs in 
every GTP/GDP exchange, has been structurally elucidated (Chung et al., 2011, Westfield 
et al., 2011). With all this information and with the restricted transmembrane interface 
possibilities for heteromer formation we noticed that the long C-terminal domain of the 
α1A adrenergic receptor could lead to steric hindrance in the heteromer-G protein 
macromolecular complex (Cordomi et al., 2015). It is predicted that the human α1A 
adrenergic receptor has 137 amino acids in the cytoplasmic C-terminal domain 
(www.uniprot.org/uniprot/P35348), and that human MT1 and MT2 receptors have C-
terminal ends of, respectively, 55 (www.uniprot.org/uniprot/P48039) and 54 
(www.uniprot.org/uniprot/P49286) amino acids. For the three receptors, we prepared 
mutants lacking most of the C terminal domain; some amino acids after the las 
transmembrane helical domain are needed to link the FRET/BRET donor/acceptor proteins 
(see Methods for details).  
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Figure 4.10 BRET assays in cells transfected with !1, MT1 and MT2 mutant receptors 
resulting from C-terminal deletion. However, BRET showed a positive interaction between 
receptors. E: cAMP experiments in cells transfected with only one of the mutant receptors 
confirmed that truncated receptors are functional and all coupled to Gi. 
 Biophysical energy transfer assays showed that truncated melatonin receptors were 
able to interact with !1-adrenergic receptors and that truncated !1-adrenergic receptors 
were able to interact with melatonin receptors (Fig. 4.10A-D). BRET parameters in the 
case of !1-MT1mut  resulted in BRETmax 77.1 and BRET50 84.8  and for !1-MT2  BRETmax 
85.4 and BRET50 137.7. For the !1 mutant BRET curve was saturated when cells were 
cotransfected with !1mut-MT1, BRETmax 43.2 BRET50 24.7  and finally !1mut-MT2 resulted 
in BRETmax 99.7 BRET50 70.4. This indicate that efficiency was variable thus reflecting 
either less dimer formation or a different conformation that in turn leads to changes in the 
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donor-acceptor distance. Truncated receptors, when expressed individually, were 
functional and, as the full length version, were all coupled to Gi (Fig. 10E). Functional 
assays of Ca2+ mobilization in cells co-expressing truncated melatonin and full length !1A
adrenergic receptors, or full length melatonin and truncated ƒ1A adrenergic receptors, 
showed that truncation of melatonin receptors did not lead to any significant effect (Fig. 
4.11A and 4.11B). In sharp contrast, removal of the C-terminal domain of !1-adrenergic 
receptors results in adrenergic-receptor mediated Ca2+ mobilization (Fig. 4.11C and 
4.11D). Thus, the truncated !1-adrenergic receptor even in an heteromeric context, is able 
to mobilize Ca2+, as it occurred when the full length receptors was individually expressed.
Figure 4.11. A and B: Both melatonin receptors mutations had no effect on Ca2+ 
mobilization. C and D: Truncated !1-adrenergic was able to mobilize Ca2+ even when it is 
coexprssed with either MT1 or MT2.
 Relevant results were also obtained in cAMP determination assays. Truncated 
melatonin receptors interacting with full-length !1A adrenergic receptors are still coupled 
to Gs protein (Fig 4.12A and 4.12B), whereas truncated !1A adrenergic receptors 
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interacting with melatonin receptors, behaved as the full length receptor when individually 
expressed, i.e. they coupled to Gi (Fig. 4.12C-F). In summary, the C-terminal tail of the !1A
adrenergic receptor is important for the change of coupling, from Gi to Gs, when it forms 
heteromers with MT1 or MT2 receptors. 
Figure 4.12. A and B: cAMP assays done in cells co-transfected with !1A adrenergic 
receptor and either truncated MT1 or MT2 receptors showed similar response when 
agonists applied; cAMP levels increased indicating a Gs protein coupling. whereas 
truncated !1A adrenergic receptors interacting with melatonin receptors,  showed a clear 
reduction in cAMP levels confirming that they are coupled to Gi (C-F). 
Pharmacology of receptors expressed in HCE cells 
 The pharmacological characterization of melatonin and ƒ1A-adrenergic receptors 
was performed in HCE cells paying particular attention to variations within the canonical 
signalling pathways reported for these receptors. In fact, the reported cognate G proteins 
are Gi for both melatonin receptors and Gq/11 for ƒ1A-adrenergic receptors 
(www.guidetopharmacology.org). We measured cAMP intracellular levels and dynamic 
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mass redistribution (DMR) upon receptor activation. The effect of 100 µM melatonin 
produced a further increase in the forskolin-induced intracellular cAMP levels, effect 
which was reversed by the melatonin MT1 receptor antagonist, luzindole (Fig. 4.13A). 
When the MT2 melatonin receptor selective agonist, IIK7, was applied, a rise in forskolin-
induced cAMP levels was also observed (Fig. 4.13B) that was reversed by the receptor 
MT2 selective antagonist, 4-PPDOT (Fig. 4.13B). When cells were challenged with the α1-
adrenergic agonist phenylephrine (1 µM) a remarkable elevation of cytosolic forskolin-
induced cAMP was achieved. The antagonist prazosin abolished the cAMP elevation 
produced by phenylephrine. These results demonstrate that human ciliary epithelial cells 
express functional MT1 and MT2 melatonin, and α1A-adrenergic receptors, none of which 
was coupled to the reported cognate G protein.   
 To further confirm such finding, similar assays were performed in the presence of 
cholera toxin, which disrupts Gs-mediated signaling or pertussis toxin which disrupts Gi-
mediated signaling. The results show that cholera but no pertussis toxin is inhibiting the 
action of all the agonists indicating that a Gs protein is involved in signal transduction 
afforded by activation of any of the assayed receptors (Fig. 4.13C, 4.13D). Interestingly, 
when melatonin or IIK7 action on cAMP levels were studied in the presence of prazosin, 
this α1-adrenergic antagonist was able to abolish the effect of each melatonergic agent. 
Remarkably, when phenylephrine was assayed in the presence of either luzindole or 4-
PPDOT, the α1-adrenergic agonist was unable to rise cAMP levels in the way it did when 
applied alone.  
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Figure 4.13 cAMP experiments in 59HCEsv cells. Stimulation with melatonin and 
phyneliphrine caused an increment in forskolin-induced cAMP levels, same results 
obtained with the activation by IIK7 and phyneliphrine. As shown in C and D cross-talk of 
melatonin and !1A-agonists was blocked by cholera but not by pertussis toxin.
The label-free DMR induced by adrenergic or melatonergic compounds was relatively
high. The combination of melatonin and phenylephrine (Fig 4.14A), or IIK7 and 
phenylephrine (Fig 4.14B), provided a more robust DMR response than single 
treatments.When the experiments were carried out in the presence of cholera and pertussis 
toxins, we again found that only cholera toxin was able to abolish the DMR responses 
triggered by all the agonists (Fig 4.14C and 4.14D).
  In the same way as we found in cAMP determination assays, it was possible to 
observe cross-antagonism between melatonin and ƒ1-adrenergic receptors. Taken together 
these results suggest the possible crosstalk between melatonergic and ƒ1-adrenergic 
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signalling. Also, and importantly finding was the cross-antagonism, which up to date is a 
feature only displayed by GPCR heteromers.
Figure 4.14 label free real time DMR analysis of receptors natively expressed in 59HCEsv 
cells confirms response of a cross talk between phyneliphrine and melatonin (A) and 
phyneliphrine and IIK7 (B). in C and D this effect was blocked by cholera but not by 
pertussis toxin.Each curve is the mean of a representative optical trace experiment carried 
out in triplicates. 
 Identification of !1A-MT1  and !1A-MT2 heteromer complexes in healthy and 
glaucomatous conditions
 Proximity ligand assay (PLA) is being instrumental as a complementary technique 
to detect receptor-receptor interaction in a native system. PLA assays using specific 
antibodies against the receptors of interest, proved the occurrence of both !1A-MT1  and 
!1A-MT2 heteromer complexes in HCE cells. Red dots, which reflect the existence of 
heteromers were clearly visible for both receptor pairs. The analysis of the PLA labeling 
provided values of 65±10 dots/nucleus in the case of the MT1/ƒ1 heteromer (negative 
control value: 5±1 dots/nucleus), and 73±8 dots/nucleus in the case of the MT2/ƒ1
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heteromer (negative control value: 2±2 dots/nucleus (n=5, P<0.005). The percentage of 
cells that presented positive PLA in the case of the MT1/ƒ1 receptor heteromer was 56±4, 
while in the case of MT2/ƒ1 receptor heteromer the percentage was 57±5 (n=150). 
Figure 4.15. PLA ƒ1A-MT1 heteromers or ƒ1A-MT2 in human non-pigmented ciliary 
body epithelial cells (59HCE). A dose –response effect was observed when activating 
TRPV4 channel by using a selective agonist GSK1016790A. From left to right, increased 
dosis of the agonist was used after observing a positive PLA with no treatment (first at 
left). ƒ1A-MT1 heteromers or ƒ1A-MT2  close proximity are detectable as a punctate red 
fluorescent signal by confocal microscopy. Cell nuclei were stained with SYTOX green 
stain. C: Quantitavie analysis revealed a decrease in PLA with higher concentrations of 
GSK1016790A (n=5, P<0.005).
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 In order to check whether a glaucomatous condition modifies the amount of 
heteromeric complexes, cells were subjected to stimulation of the transient receptor 
potential vanilloid 4 (TRPV4) channel. As previously reported (for more details, see 
chapter 2), activation of the channel mimics the changes in the hydrostatic and osmotic 
pressure that occur in the glaucomatous eye. The application of the TRPV4 agonist, 
GSK1016790A, to HCE cells modified the PLA signal in a dose-dependent manner. As 
shown in Fig. 4.15, the higher the concentration of GSK1016790A, the lower the PLA 
signal. Therefore, when a glaucomatous condition is reproduced in HCE cells, a reduction 
in the expression of MT1/α1 or MT2/α1 receptor heteromers occurred.  
 Studies to check the expression of heteromers in samples from human eyes were 
also performed. The analysis carried out in ciliary body samples of glaucomatous 
individuals and age-matched healthy controls, presented relevant findings. In the healthy 
eye, the presence of melatonin receptors, MT1 and MT2, as well as 1A-adrenergic receptors 
were confirmed by immunohistochemical assays using validated antibodies, showing a 
clear immunoreactivity across the human ciliary body (Fig. 4.16.A,4.16B,4.16C). 
 A strong labeling for the MT1 melatonin receptor was present in the non-pigmented 
epithelial cells, while the labeling for the MT2 melatonin receptor was observed in the 
basal membrane of the non-pigmented epithelium (Fig. 4.16D and 5F). No 
immunoreactivity for any of the two melatonin receptors was observed in the stromal part 
of the ciliary body. Concerning the 1A-adrenergic receptor, a positive labeling was 
observed in the pigmented and non-pigmented epithelial cells as well as in the stromal part 
of the ciliary body (Fig 4.16B).  
 When a similar immunohistochemical study was carried out in samples obtained 
from patients with glaucoma, we observed that the expressions of MT1 and MT2 melatonin 
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receptors were markedly reduced compared to healthy individuals, with decreases of 81.2 
15.6 % and 54.1  13.2  % for MT1 and MT2 respectively (normalized values to non-
glaucomatous patients, n=4, **P<0.005, ***P<0.001). On the contrary, the ƒ1-adrenergic 
receptor showed a trend (to increase) that was not statistically significant (Fig. 4.16.D-F).
Figure 4.16. Immunohistochemistry analysis of human ciliary body tissue. A and D: 
Comparison of MT1 labelling in healthy and glaucomatus donor showing a clear decrease 
in recptor presence (D: glaucomatous subject). B and E: Similar results were obtained 
regarding MT2 receptor, clear labelling was observed in healthy donors (B). C and F: ƒ1A 
immunolabelling showing no statistically segnificant differences between healthy and 
diseased subjects. G: normalized values to non-glaucomatous patients, n=4, **P<0.005, 
***P<0.001.
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We then reasoned that the marked reduction in melatonin receptor expression would also 
lead to a decrease in the expression of melatonin-adrenergic receptor heteromers. 
Accordingly, we investigated by PLA in the ciliary body from the healthy and the 
glaucomatous eye, the ability of MT1 and MT2 receptors to form heteroreceptor complexes 
with the ƒ1-adrenergic receptor. For both MT1/ƒ1 and MT2/ƒ1 receptor pairs, a marked PLA 
positive labeling was observed in samples from healthy individuals (Fig. 4.17A and 
4.17C), Remarkably, when PLA was performed in samples from glaucoma patients, PLA 
labeling for the two pair of receptors was strongly reduced as observed in Fig. 4.17B, 
4.17D and 4.17E .
Figure 4.17. A and C showing PLA of !1A-MT1 heteromers and !1A-MT2 , respectivly, in 
human ciliary body tissue of healthy subjects. B and C: Same PLA experiments done in 
glaucomatous tissue sample, indicating a decline in PLA labelling. E: Quantitavie of PLA 
dots (***P<0.001).
 Once more, these results match with the results obtained in HCE cells treated with 
a TRPV4 activator to mimic a glaucomatous condition. Taken together, these results 
indicate that the number of heteromers are reduced in glaucoma, mainly because a 
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reduction in the presence of melatonin receptors in a context of robust expression of the 
ƒ1-adrenergic receptor. Considering these results, one would expect that the use of a ƒ1-
adrenergic receptor antagonist in the presence of melatonin may help to recover the lack of 
effect of the indoleamine in a glaucoma condition. We next moved to a well-established 
murine model of glaucoma. 
MTs and !1A Heteromers are involved in glaucoma pathology: in vivo evidences 
 The glaucoma DBA/2J mouse model presents most of the features of the human 
pathology. IOP andmelatonin levels normal and undistinguishable from the control mouse 
C57BL/6 at 3 months of age, while these physiological parameters change when the 
pathology is established at 9 months of age (see chapter 2).  
 We predicted in 3-month-old DBA/2J and control animals, the existence of 
heteromers and, consequently, a marked cross-antagonism. Indeed, the results, measuring 
the IOP in the eye, proved the assumption. In this sense, the effect of melatonin or IIK7 
were blocked by, respectively, luzindole and 4-PPDOT, but also by the !1-adrenergic 
receptor antagonist, prazosin (Fig. 4.18A and 4.18D).
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Figure 4.18. Effect of of α1A,MT1 and MT2  activation over IOP in both  C57BL/6J and 
DBA/2J mice models. A: Both melatonin and phyneliphrine reduced IOP, Interestingly, 
melatonin effect was antagonized by prazosin (α1A antagonist). D: Same effect was 
observed when IIK7 was instilled. B and E demonstrate the effect of same compound 
onDBA/2J mice models at 12 months old. Prazosin allowed melatonin and IIK7 to act 
more effectively instead of antagonizing melatonins effect. IOP was lower in mice treated 
with prazosin and afterwards, with melatonin or IIK7. C and F represent a time course 
effect of melatonin+prazosin and IIK7+prazosin respectivly. **P<0.005, 
***P<0.001versus control (two-way ANOVA with Tukey post-test, n = 4). 
 The prediction in 12-month-old animals was the opposite, i.e. that cross-
antagonism was markedly reduced due to the negligible level of melatonin-α1-adrenergic 
receptor heteromers. Indeed, when IOP was measured in 12-month-old glaucomatous 
animals, all the agonists tested reduced IOP, and when assaying the antagonists for the 
three receptors, no cross-antagonism was detected, i.e. the antagonists worked only in 
blocking the effect mediated by their respective receptors (Fig. 4.18B and 4.18E). 
Remarkably, the hypotensive effect of melatonin receptor activation was further enhanced 
by the application of prazosin. Moreover, the effect of prazosin lasted more than 6 hours, 
this indicating a very appropriate therapeutic time window for therapy (Fig. 4.18C and 
4.18F). 
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Discussion 
 The present work introduce the concept of heterodimerization between both 
melatonin receptors and α1A-adrenirgic receptor. A growing body of biochemical and 
biophysical evidences indicates that some GPCRs are able to form both homodimers and 
heterodimers with their existence at this time widely accepted (Angers et al., 2002; Jordan 
and Devi, 1999). 
 The concept that GPCR heterodimerization could have a role in pharmacological 
diversity was first indicated by studies on the δ- and κ-opioid receptors when co-
expression of both receptors led to the formation of a stable heterodimer with a very low 
affinity for either the δ- or the κ-selective ligand alone. However, high affinity was 
restored following the combination of the two ligands, suggesting the occurrence of 
positive cooperativity (Jordan and Devi, 1999). Such an observation led to more 
discoveries although the the direct link between heterodimerization itself and the changes 
in pharmacological properties has not been formally established, positive or negative 
ligand-binding cooperativity that occurs after receptor co-expression has been interpreted 
as resulting from receptor heterodimerization for many other GPCRs. These include the 
metabotropic GbR GbR1/GbR2 (Galvez et al., 2001), opioid δ/µ (Gomes et al., 2000), and 
adenosine A2A /dopamine D1 (Franco et al., 2000) receptors. If this is a general 
phenomenon, such heterodimerization between pharmacologically distinct receptors could 
underlie a level of pharmacological diversity that would have far-reaching implications for 
drug development. In particular, it could provide new opportunities for the development of 
more selective compounds that would target specific heterodimers without affecting the 
individual protomers (George et al., 2002). 
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 An interesting molecule that modulates aqueous humor production by acting in the 
ciliary body is melatonin. This indoleamine has emerged as a good candidate for the 
treatment of ocular hypertension, mainly because it is a natural substance already present 
in the aqueous humor and because melatonin MT1 and MT2 receptors are expressed in the 
ciliary body (Alarma-Estrany and Pintor, 2007). It is well known the existing inverse 
correlation between melatonin presence in blood and intraocular pressure (IOP). In the 
same way, when melatonin is administered to patients during the daytime their IOP get 
clearly reduced1. Paradoxically, when melatonin is measured in the aqueous humor of 
glaucoma patients its concentration is higher than in normotensive individuals. In fact, the 
mean concentration in the aqueous humor of healthy subjects was 14.62 ng/ml (range: 
5.4-38.0; n=23) whereas in glaucoma patients it was 46.63 ng/ml (range: 10.3-167.3; n = 
14). It appears as if the system is unbalanced in such a way that the 3.2-fold increase in the 
concentration of melatonin is totally insufficient to achieve normotension (for more detail, 
see chapter 2). Accordingly, melatonin-receptor mediated signalling is impaired in 
glaucoma.   
 Melatonin performs its hypotensive action on the ciliary body and in particular on 
its epitheliums, which express MT1 and MT2 melatonin receptors. Its action on IOP is 
mediated by regulation of Cl- efflux from ciliary body epithelial cells (Huete-Toral et al., 
2015). Interestingly, one of the molecules that block the effect of melatonin on reducing 
IOP is prazosin, the α1-adrenoceptor antagonist. Melatonin should reduce IOP in glaucoma 
patients since its levels are abnormally high, nevertheless, patients with this pathology 
exhibit elevated IOPs. It could be the case that melatonin receptors may interact with α1A-
adrenergic receptors according to prazosin actions on melatonin effects. This evidence 
points to some sort of interaction between melatonin and α1-adrenergic receptors. Ciliary 
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body non-pigmented epithelial cells (HCE) present MT1 and MT2 melatonin receptors as 
well as α1A-adrenergic receptors. Interestingly, we have been repeatedly trying to find the 
canonical coupling of α1A-adrenergic receptor to increases in the concentration of cytosolic 
Ca2+ with no success whatsoever. In fact, as shown in Fig. 1 α1A-adrenergic receptor 
activation using phenylephrine did not trigger any intracellular Ca2+ mobilization in HCE 
cells. The relation between melatonin receptors and α1A-adrenergic receptors may exist not 
only because they are present in the same cells but because some of melatonin actions can 
be blocked by the α1A-adrenergic receptors antagonist prazosin as observed in fig 1.  
 Since Neufeld et al. first reported that adrenergic agents, including epinephrine and 
phenylephrine have the ability to increase cAMP concentration in the aqueous humor 
(Neufeld et al., 1972), the attention on the adrenergic control of IOP and the therapeutic 
potencial of the cAMP signalling pathway in glaucoma treatment has been taken into 
consideration. Since that moment, several studies have identified an adrenergic receptor-
AC complex in the ciliary processes (Caprioli and Sears, 1984) supporting the functional 
role of cAMP in aqueous humor formation. The activation of ACs-linked receptors by 
several endogenous or exogenous factors not only increases intracellular cAMP level, but 
also decreases net aqueous humor flow and lowers IOP (Eakins and Eakins, 1964; Lee, 
1958; Neufeld et al., 1972; Neufeld and Sears, 1974). Furthermore, an increase of the 
cAMP level by a topical suspension of 1% forskolin lowered IOP in rabbits and monkeys, 
as well as in normal human volunteers (Caprioli and Sears, 1983) suggesting that 
increasing cAMP may decrease the net rate of aqueous humor inflow (Caprioli and Sears, 
1984). Our findings in this regards suggest a reduction in cAMP in the case of cells 
transfected with melatonin receptors or α1A-adrenergic receptor (Fig 2F-H). However, 
cAMP ditermination in co-transfected cells with α1A-MT1 or α1A-MT2 heteromers showed 
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an increase in forskolin-induced cAMP levels, such results were very similar to the 
experiments done in HCE cells supporting the results obtained from native ciliary body 
tissue; we were able to visualize heteromer labelling through PLA technique and it was 
clearly reduced in the case of glaucomatous subjects. These results suggest a change of 
intracellular signalling when melatonin receptors form heteromers with α1A-adrenergic 
receptor, nevertheless, when heteromerization is reduced due to glaucoma pathology, and 
receptors are separated, the cross-antagonism is missed as it can be shown in IOP 
measurements of 12-month-old glaucomatous DBA/2J mice. Remarkably, the hypotensive 
effect of melatonin receptor activation was further enhanced by the application of prazosin 
(Fig. 6E and 6H). 
 Here we propose the important role of melatonin receptors interaction with α1A-
adrenergic receptor in the physiology of the ciliary body and the role it has in reducing 
IOP. It can be a great possibility to suggest a potential pharmacological approach by using 
prazosin in combination with melatonin for the treatment of glaucoma. 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Chapter V: Presence of melanopsin in human 
crystalline lens epithelial cells and its role in 
melatonin synthesis 
Sensing the light through the crystalline lens 
 Light brings us the news of the Universe. 
 Sir William Bragg 
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Introduction 
 One of the most ancient phenomena of nature is light. It provides all living 
creatures with the information about the time of day in order for them to be able to adapt 
their physiology to their internal clock (Do and Yau 2010). In this sense, the ability to 
receive light is essential to regulate the circadian system. In mammals, including humans, 
the ocular system is responsible for light detection, beside its visual function, such as 
object recognition (vision), it is responsible for other non-image forming tasks like 
photoentrainment. In this sense, melanopsin emerges as a photoreceptor protein which has 
different functions from the classically known photoreceptors, rods and cones (Fu et al., 
2005; Schmidt and Kofuji, 2011; Zele et al., 2011). 
 Melanopsin, expressing photosensitive retinal ganglion cells, represents a third 
class of photoreceptors, called intrinsically photosensitive retinal ganglion cells (ipRGCs), 
and it mediates several non-image forming responses to light, but can also contribute to 
visual pathways (Brown et al., 2012). Melanopsin is blue light sensitive photopigment 
which regulates pupil constriction, circadian entrainment and melatonin production 
(Foster and Bellingham, 2002).  
 Melanopsin is a member of the G-protein-coupled receptor family, a vitamin A-
based opsin in the vertebrate retina  (Zhao et al., 2014). It is specifically sensitive to blue 
light (Hattar et al., 2002; Provencio et al., 2000), in the way in which they capture this 
specific wavelength and send signals through several areas of the brain, such as the 
suprachiasmatic nucleus until reaching the pineal gland to suppress melatonin synthesis 
during the day  (Vimal et al., 2009; Viola et al., 2008). 
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 Since the discovery of this new opsin, it has been known to exclusively exist in the 
ipRGCs. However, with the development of new techniques, recent studies showed that 
melanopsin is present in several cerebral regions in the human brain (Nissila et al., 2016). 
 Melatonin is a molecule which is involved in the regulation of the circadian 
rhythm, it was classically known to be synthesized in the pineal gland. However, in recent 
decades, it has been possible to investigate this substance and come to numerous 
conclusions. Melatonin presence, its synthesis, as well as melatonin receptors have been 
found in several organs, besides the pineal gland. These findings allow us to see that 
melatonin has many different functions, apart from regulating the circadian rhythm (for 
more details, see general introduction) It is present and synthesized by several ocular 
structures, such as in the ocular surface, ciliary body, crystalline lens, aqueous humour and 
the retina (Alarma-Estrany and Pintor, 2007; Alkozi et al., 2016; Itoh et al., 2007). 
 Melatonin is synthesized from serotonin through two steps. First, serotonin is 
catalysed by an enzyme called aralkymine N-acetyltransferase (AANAT) and transformed 
to N-acetylserotonin. Melatonin is then synthesized by the final enzyme Hydroxindole O-
methyltransferase (HIOMT) (Klein et al., 1997; Menendez-Pelaez et al., 1987). Both 
enzymes are necessary for melatonin synthesis; nevertheless, AANAT seems to be the rate 
limiting step of melatonin synthesis (Blomeke et al., 2008; Coon et al., 1996; Izawa et al., 
2009; Klein, 2007).  
  In the eye, and specifically, in the anterior segment of the eye, melatonin has been 
measured in the aqueous humour , which is in contact with the crystalline lens and is 
responsible for several functions, such as maintaining the intraocular pressure, as well as 
nourishing the crystalline lens, because it is a transparent structure with no access to 
nutrients from the blood (Alkozi et al., 2016; Chiquet et al., 2006). Melatonin in the 
!168
aqueous humour can have an autocrine/paracrine effect on the trabecular meshwork, 
ciliary body and the lens, since all mentioned structures are in contact with the aqueous 
humour and present melatonin receptors (Alarma-Estrany and Pintor, 2007; Osborne and 
Chidlow, 1994). 
 Little is known about melatonin function and regulation in the crystalline lens, 
despite the importance it could have related to homeostatic processes controlling the lens 
transparency and its possible role as an antioxidative (Bai et al., 2013; Tok et al., 2014). In 
this sense, this work has been performed to study the possiblity of melanopsin being 
present in the lens and the possible regulation of melatonin synthesis in the lens through 
melanopsin receptor by studying melatonin levels under light, darkness and different light 
wavelengths.  
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Material and methods 
Cells 
 Crystalline epithelial cells (HCL), a human immortalized cell line was kindly 
supplied by Dr. Coca-Prados (Yale University). Cells were grown in high glucose 
Dulbecco’s modified Eagle’s medium (Gibco/Invitrogen, Carlsbad, CA) containing 10% 
foetal bovine serum (Sigma-Aldrich, St. Louis, MO) and 0.05 penicillin/streptomycin 
(Gibco/Invitrogen) at 37°C in humidified atmosphere 5% CO2–95% air. After the culture 
reached the confluence, cells were detached with 0.25% trypsin and seeded into 6 well 
plates and/or to 4 well chamber slides respectively. All the experiments were performed 
using cells comprised numbers 10-15 passages to assure assays reproducibility.  
Human eye tissue 
 Donor Human eyes were obtained from the Fundación Banco de Sangre y Tejidos 
de las Islas Baleares (Blood and tissue bank Foundation from Baleares Islands). Eyes were 
enucleated and collected without the cornea in sterile tubes and maintained in 4% 
paraformaldehyde in 0.1 M phosphate buffer (PB) (pH 7.2-7.4) at 4ºC until posterior 
processing. Eyes were dissected under a stereo microscope (Zeiss) and with the 0.8 mm tip 
curved forceps and sterile dissecting scissors, the crystalline lens was collected. Several 
washes in PBS were performed and then, the specimen were cryoprotected in a sucrose 
gradient (from 11% to 33%) and were embedded in tissue freezing medium (Tissue-Tek© 
OCT) until frozen with liquid N2. Vertical sections of control and glaucomatous human 
samples (10 µm thick) were collected using a cryostat (Microm, Walldorf, Germany) and 
mounted from the same region.  Samples were maintained in a -20 ºC until use. 
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Immunofluorescent studies 
 In the case of the cells, when cells reached 60% confluence, they were washed with 
PBS1X and then fixed in 4% parafprmaldehyde in PBS 0.1 M for 15 minutes. Several 
washes with PBS 1X were done before permeabilization using PBS 1X triton 0.05% 
during 15 minutes. Afterwards, one hour incubation  was done with a blocking solution 
which contains 10% normal donkey serum (NDS), followed by incubation of CRYAB 
antibody (1:200, MA5-15383, Thermo Fisher Scientific) in the case of studying alpha 
crystalline presence and melanopsin antibody (1:100, sc-26957, Santa Cruz 
Biotechnology).  
 In a different slide chamber, cells were incubated either in darkness or in light 
condition for a duration of 8 hours before the immunocytochemistry, then, the same 
protocol was applied and cells were incubated with AANAT primary antibody (ab3505, 
1:500, Abcam). All incubations took place overnight at 4 ̊C. Thereafter, an incubation of 
one hour with secondary antibody labelled with FITC (Jackson ImmunoResearch 
Laboratories) at a dilution of (1:100) was performed. Samples were examined under a 
confocal microscope (Axiovert 200M. Carl Zeiss Meditec GmbH, Germany). Similar 
protocol was applied to the human lens tissue, except the permeabilization duration which 
was for 30 minutes. 
Light/darkness experiments  
 In order to perform these experiments, cells were seeded in multiwells at a density 
of 75x104  cells/well and then incubated in the presence of a LED system. Cells were 
treated with white (WL), blue (BL, 465-480 nm, 2.66 -2.58 eV, 400 Luz, 3.2 W), green 
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(GL, 520-550 nm, 2.38-2.25 eV, 400 Lux, 3.2 Lux) red (RL, 625-640 nm, 1.98-1.93 eV, 
400 Lux, 3.2 W) in total darkness. All experiments were performed at different durations, 
starting from 2, 4, 8, 12 hours. Afterwards, the medium was collected for HPLC analysis 
of melatonin levels, whereas the cells were homogenized for western blot assays.   
HPLC experiments  
 HPLC was used to measure both N-acetylserotonin and to measure melatonin, in 
both cases the supernatant was processed as previously explained (chapter 2). 
 For N-acetylserotonin measurments, HPLC was performed following the protocol 
described by (Semak et al., 2008). NAS detection was carried out with SunFire18 (5 µ, 25 
cm in length, 0.4 cm inner diameter) from Waters (milford, MA) equilibrated with a 
mobile phase consisting of 15% acetonitrile, 0.1% acetic acid and at a flow rate of 0.75 ml/
min, detecting NAS at the wavelength of 244 nm.  
 Melatonin detection was performed as described previously (refer to the second 
chapter). In brief, the column was a kromaphase C18 column 5.0 mm (25 cm in length, 0.4 
cm inner diameter) (Scharlau, Madrid, Spain). The system was equilibrated overnight with 
40% methanol, 60% H2O. Measurements were performed at a flow rate of 0.8 ml/min 
fixing the detector at a wavelength of 244 nm. Quantification of NAS and melatonin was 
performed by comparing the samples with the corresponding external standard provided 
by Sigma. 
Western-blot studies 
 Experiments took place to quantify AANAT protein level in each condition and to 
visualize melanopsin protein by means of western-blot. In the case of AANAT detection, 
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cells were removed and homogenized with radioimmunoprecipitation assay (RIPA) buffer 
(1:5 v/v) containing  50 mM HEPES, pH 8, 150 mM NaCl, 1% NP-40 (w/v), 0.5% sodium 
deoxicolate, 0.1% SDS and Halt Protease and Phosphate Inhibitor Cocktail (Thermo 
Fisher Scientific). The lysates were centrifuged at 15,000 × g for 15 min at 4 °C. The 
supernatant was stored at −20 °C until use. 
 Protein concentration was determined by Pierce BCA Protein Assay Kit (Thermo 
Scientific). Cell samples (30 µg proteins) were diluted in Laemmli's sample buffer, loaded 
on a 15% SDS-PAGE gels and transferred to nitrocellulose membrane. Blots were blocked 
with 5% non-fatty milk (Bio-Rad) for 1 h at room temperature and then they were 
incubated overnight at 4 °C in TB- S1X 0.1% Tween 20 containing 5% of blocking buffer 
and AANAT primary antibody (ab3505, 1:1000, Abcam). 
 For melanopsin detection by western blot, a lysate of lens epithelial cells was used 
together with 4 homogenized retinas taken from mice (C57BL/6J, 6 months of age) 
isolated as described previously (Perez de Lara et al., 2015). Briefly, C57BL/6J mice were 
euthanized through decapitation on a sterile gauze pad. Both eyes were enucleated by a 
sterile curved scissors to cut the optic nerve. Eyecups were placed in PBS 1X solution and 
dissected under a stereomicroscope (SteREO Discovery.V8, Zeiss, Madrid, Spain). With 
0.8 mm tip curved forceps and sterile fine-angled dissecting scissors, the cornea was 
severed. The forceps were then gently moved at a slight backward angle to pull up the 
cornea. Then the lens was removed with slight pressure on the eyecup. Gently, the retina 
was separated from the sclera, and the retina was cleaned of choroid pigment and vitreous. 
The mice lung was also dissected to use as a negative control and was homogenized 
similarly to retinas. Samples were removed and homogenized in ice with 
radioimmunoprecipitation assay (RIPA) buffer (1:5 v/v) containing 50 mM HEPES, pH 8, 
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150 mM NaCl, 1% NP-40 (w/v), 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate 
(SDS), and inhibitor proteases (1 mM phenyl methanesulfonyl fluoride (PMSF), 10 µg/ml 
leupeptin, 5 µg/ml pepstatin, 10 µg/ml aprotinin, 1 mM sodium fluoride, and 2 mM 
sodium orthovanadate). The lysates were centrifuged at 15,000 ×g for 15 min at 4 °C. The 
supernatant was stored at −20 °C until use. 
 Melanopsin was detected by submitting all samples to electrophoresis and western-
blot as previously described, nitrocellulose membrane were incubated with a specific 
melanopsin antibody (1:50) (sc-26957, Santa Cruz Biotechnology, CA, USA) overnight. 
Mouse monoclonal glyceraldehyde-3-phosphate dehydrogenase (anti-GAPDH 1:500) 
(Santa Cruz, CA, USA) served as a loading control.  
 All the membranes were incubated with a goat anti IgG rabbit or a goat anti IgG 
mouse conjugated with horseradish peroxidase secondary antibody (Jackson 
ImmunoResearch, West Grove, PA, USA) for 1h at room temperature. Then, proteins were 
revealed by chemiluminescence using ECL detection (Amersham Pharmacia Biotech). 
Films were scanned with Gel Logic 200 Imaging System (Kodak, U.S.). The densitometric 
analysis was performed by using Kodak Molecular Imaging software (Kodak, Rochester, 
NY, USA). The densitometry values of each sample were normalized to respective 
densitometric GAPDH values.   
Blocking Melanopsin function  
 Cells were treated with a selective melanopsin inhibitor AA92593 (prepared in 
PEG-400, DMSO, SML0865, Sigma, St. Louis, Mo, USA) at a final concentration of 1.5 
µM and then were incubated under light for 8 h. For second messenger inhibition, cells 
were incubated with a phospholipase C inhibitor (also prepared in PEG-400, DMSO, 
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U73122, Tocris, Bristol, UK) at 3 µM. In different wells, a negative control was incubated 
at same concentrations with the inactive compound U73343 (prepared in PEG-400, 
DMSO, Tocris, Bristol, UK), the experiments being performed under 8 h illumination with 
white light. Thereafter, supernatant was collected and cells were homogenised for HPLC 
analysis and western blot studies respectively. 
Statistical analysis 
 All the data are the mean ± S.D. of 6 independent experiments. Statistical analysis 
was performed with ANOVA or Student's t-test when necessary. Statistical analysis and 
plots were carried out by means of the program Prism Graph Pad (GraphPad Software Inc., 
San Diego, CA). 
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Results
Melanopsin presence in human crystalline lens epithelial cells 
 The characterization of the human lens epithelial cells was done by means of the B 
chain of alpha crystalline (CRYAB), a representative protein of the lens (Augusteyn, 2004; 
Maddala and Rao, 2005; Yang et al., 2016). There was an intense labelling of the 
cytoplasmic area in the cells, indicating the abundance of this protein which is typical in 
the lens cells as commented (Fig. 5.1A).
Figure. 5.1. Presence of melanopsin in human lens epithelial cells. A) Expression of the B 
chain of the alpha crystalline (CRYAB, in green) in human lens epithelial cells (nucleus 
labelled with propidium iodine in red). B) Localization of melanopsin in human lens 
epithelial cells (green), nucleus appear in red labelled with proidium iodine. C) Negative 
control for the presence of melanopsin in human chondrocytes. D) Presence of melanopsin 
in the epithelial cells of a human lens section (green), nuclei labelled with DAPI in blue. 
E) Western-blot showing melanopsin band obtained from mice retinas (positive control), 
human lens epithelial cells and lung negative control.
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 For melanopsin detection in the lens epithelium, an immunocytochemistry and 
western-blot experiments were conducted. With regard to immunocytochemical assays, a 
positive labelling of melanopsin was observed mostly on the cytoplasmic membrane of the 
lens epithelial cells, as well as in the human epithelial cells obtained from healthy donors 
(Fig.1B and 1D). As a negative control for melanopsin, human chondrocytes were used as 
observed in Fig.1C. 
 Western-blot experiments using the lens epithelial cells homogenate showed a band 
with a molecular weight of 65 kDa, which is similar to that described in literature (Carr et 
al., 2011). A lysate of mice retinas was used for a positive control and lung tissue as a 
negative control   as well (n = 3) (Fig. 1E). 
NAS and melatonin levels changes under different light conditions  
 Melatonin synthesis follows a circadian rhythm in the pineal gland and this is 
regulated by light. Melanopsin is the protein responsible for such task transmitting light 
information to the pineal gland through a certain pathway starting from the retina. 
However, in other organs which synthesize melatonin, such as the crystalline lens in this 
case, it was interesting to see the effect on melatonin after stimulating the lens epithelial 
cells with light or darkness, together with NAS determination, the precursor of the first 
enzyme of melatonin synthesis (AANAT). An increasing temporal assay was done in both 
conditions starting from 0, 2, 4, 8, 12 hours of incubation. 
 Results of HPLC analysis showed no significant changes neither in NAS nor 
melatonin levels at all times under light condition (Fig. 2A and C). Nonetheless, when 
cells were submitted to total darkness for the same period of time, the melatonin level, as 
well as NAS, increased with a maximal effect occurring after 8 hours (Fig. 2B and D). In 
the case of NAS it was clear that the peak increased between 4 to 8 hours. Melatonin peaks 
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increased up to 8 hours and then stabilized up to 12 hours of darkness. Melatonin levels 
quantification after 2 hours incubation in darkness was 10.32 ± 2.40 pmol/106 cells, while 
NAS levels were 15.06 ± 2.52 pmol/106 cells. These values changed in the case of NAS 
from 120.59 ± 11.21 pmol/106 cells at 8 h to 104.29 ± 11.80 pmol/106 at 12 h (***p < 
0.001, n = 6). Melatonin values increased from 59.45 ± 15.71 pmol/106 cells to 66.01 ± 
22.14 pmol/106 cells after 8 h and 12 h incubation respectively (***p < 0.001, n = 6).
Figure. 5.2. Effect of light and darkness on NAS and melatonin production in human lens 
epithelial cells. A) Representative HPLC elution profiles showing the changes in NAS 
levels after cell treatment with light (left panel) and darkness (right panel). B) Line graph 
presenting the concentrations of NAS calculated from the chromatographic studies under 
light and darkness conditions shown in A. C) HPLC profiles showing the changes in 
melatonin levels after cell treatment with light (left panel) and darkness (right panel). D) 
Line graph presenting the concentrations of melatonin calculated from the 
chromatographic studies under light and darkness conditions shown in C. Values are the 
mean ± SD of 6 independent experiments (***p < 0.001).  
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Light/darkness effect on AANAT 
 Aralkylamine N-acetyltransferase (AANAT) is considered the key enzyme which 
regulates melatonin synthesis. After observing that NAS levels were modified under 
darkness conditions as well as melatonin concentration, the presence of AANAT was 
verified by western-blotting. A study took place to evaluate and quantify the differences 
between light and dark conditions after incubating the cells for 8 hours in the 
corresponding condition.
Figure. 5.3. Changes in AANAT expression under light and darkness conditions in human 
lens epithelial cells. A) Representative western-blot showing the changes in AANAT 
expression after 8 h of light or darkness. B) Column plot showing the relative 
quantification of the western-blots band intensities shown in A. Immunohystochemical 
study performed in human lens epithelial cells showing the changes in cytosolic AANAT 
(green label) before and after 8 h of darkness (the nuclei appear in red). A negative control 
was obtained using human chondrocytes. The values represent the mean ± SD of six 
independent experiments (**p < 0.01).  
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 A decrease in AANAT band (23 kDa) could be appreciated when cells were 
incubated with light (Fig. 5.3A). A clear difference was shown between AANAT levels 
under light and dark condition. Western-blot showed that AANAT expression increased 
approximately 2.5 times in darkness compared to light (Fig. 3B, **p < 0.01, n = 6). 
 The presence of AANAT in the crystalline epithelial cells was also proven by 
immunocytochemical analysis as shown in Fig. 3C (n=4). There was an increase in the 
cytosolic presence of the enzyme when the cells were submitted to darkness during 8 h. On 
the other hand, human chondrocytes served as a negative control since they did not 
apparently show the presence of AANAT in their cytoplasm (Fig. 5.3C).   
NAS and melatonin sensitivity to wavelength 
 Melanopsin is a photosensitive protein with a specific sensitivity to 460-480nm, 
which corresponds to blue light in the visible spectrum. To verify melanopsin functionality 
and its characteristics regarding its absorbance properties, lens cells were incubated with 
blue (465–480 nm), green (520–550 nm) and red light (625–640 nm) during 0, 2, 4, 8, and 
12 hours. Later, extracellular medium was analyzed to determine NAS and melatonin 
levels.  
 Results revealed that blue light did not modify either NAS or melatonin (Fig. 5.4 
A, B). On the contrary, red and green lights were able to change NAS and melatonin 
levels. Analysis of NAS levels showed values of 129.45 ± 9.14 pmol/106 cells at 8 hours 
and 124.66 ± 26.16 pmol/106 cells after 12 hours incubation with red light. Values 
obtained from experiments with incubation of 2 hours were 14.58 ± 2.99 pmol/106 cells, 
significant differences were observed after 8 hours of incubation (***p < 0.001, n = 6). 
Green light also stimulated NAS presence at 8 and 12 h, providing values of 113.89 ± 
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15.44 pmol/ 106 cells and 95.99 ± 14.59 pmol/106 cells respectively (*p < 0.05, ***p < 
0.001, n = 6) (Fig. 4A).   
 Effect of wavelength on melatonin production in human lens epithelial cells. A) 
Line graphs showing the changes in NAS after cell treatment with blue (465–480 nm), 
green (520–550 nm) and red light (625–640 nm) during 0, 2, 4, 8, and 12 h. B) Line graph 
presenting the concentrations of melatonin under the light conditions and time exposure 
shown in A. The values are the mean ± SD of 6 independent experiments cells (*p < 0.05, 
**p < 0.01, ***p < 0.001 vs. Blue light).  
 Melatonin analysis showed an increase after 8 - 12 hours incubation with red light 
of 51.99 ± 6.51 pmol/106 cells (Fig. 4B, n = 6). However, under blue and green light 
melatonin levels were 37.61 ± 6.64 pmol/106 cells and 42.31 ± 7.72 pmol/106 cells 
respectively (n = 6). Differences between 8 h and 12 h were statistically significant in the 
case of red and green illumination when compared to blue treated cells (**p < 0.01, ***p 
< 0.001, n = 6). 
Figure 5.4. Effect of wavelength on melatonin production in human lens epithelial cells. 
A) Line graphs showing the changes in NAS after cell treatment with blue (465-480 nm), 
green (520-550 nm) and red light (625-640 nm) during 0, 2, 4, 8, and 12 h. B) Line graph 
presenting the concentrations of melatonin under the light conditions and time exposure 
shown in A. The values are the mean ± SD of 6 independent experiments cells (*p < 0.05, 
**p < 0.01, ***p < 0.001 vs. Blue light). 
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Lens AANAT levels varies under different light conditions  
 A study of the expression of AANAT took place at the same time as the 
identification of melatonin levels by HPLC. After the incubation of the cells under blue, 
green, and red light during 8 h, as can be observed in Fig. 5.5A, intensities of AANAT 
expression were different under each mentioned condition. A clear reduction of the 
expression can be seen in blue light treated cells, while an increment could be observed in 
the cells submitted to green or red light (Fig. 5.5A).  
 AANAT expression was found to be 2.5 times more robust under green light in 
comparison to blue light, and it rose up 3.2 times under red light compared to blue light 
(Fig. 5.5B, **p < 0.01, n = 6).
Figure 5.5. Effect of wavelength on AANAT expression in human lens epithelial cells. A) 
Representative western-blot showing the changes in AANAT expression after 8 h of blue 
(465e480 nm), green (520e550 nm) and red light (625e640 nm). B) Column plot showing 
the relative quantification of the western-blots band intensities shown in A. Values 
represent the mean ± SD of six independent experiments (**p < 0.01). (For interpretation 
of the references to colour in this figure legend, the reader is referred to the web version of 
this article.)  
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NAS, melatonin and AANAT levels after blocking melanopsins’ effect 
 There are only a few melanopsin antagonists commercially available, such as 
AA92593. Melanopsin antagonist AA92593 was assayed under light condition to verify if 
NAS and melatonin can be synthesized under light and in the antagonist presence. Also, as 
melanopsin is coupled via phospholipase C (PLC), the inhibitor U73122 and the inactive 
analogue of the former, the compound U73343, were also used.
Figure 5.6. Effect of melanopsin agents on melatonin production in human lens epithelial 
cells. A) HPLC elution profiles showing NAS peaks under 8 h light conditions in the 
presence of the melanopsin antagonist AA92593 and the PLC inhibitor U73122 and the 
inactive compound U73343. B) Column plot presenting the concentrations of NAS 
calculated from the chromatographic studies shown in A. C) HPLC chromatograms 
showing the changes of melatonin with the agents described in A. D) Column plot 
presenting the quantification calculated from the chromatograms showed in C. Values are 
the mean ± SD of four independent experiments (***p < 0.001).  
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 As presented in figure Fig. 5.6, cells stimulated with light for 8 h in the presence of 
melanopsin antagonist AA92593, both NAS and melatonin levels increased. NAS level 
was 116.94 ± 9.34 pmol/106 cells in the presence of AA92593 and 120.75 ± 9.82 pmol/ 106
cells with the PLC inhibitor U73122 (n = 4, ***p < 0.001, Fig. 6A and B). The change in 
melatonin level with AA92593 was 58.16 ± 4.26 pmol/106 cells, which is very close to the 
one obtained in darkness conditions during 8 h, this being 66.01 ± 12.14 pmol/106 cells (n 
= 4, Fig. 5.6C). When the experiments were performed with the PLC inhibitors U73122 
melatonin levels were 62.13 ± 7.80 pmol/106 cells, while in the case of the inactive 
compound melatonin presence was 18.66 ± 3.52 pmol/106 cells (n = 4, ***p < 0.001, Fig. 
5.6D).
Figure 5.7. Effect of melanopsin agents on AANAT expression in human lens epithelial 
cells. A) Representative western-blot showing the expression of AANAT under 8 h light 
conditions in the presence of the melanopsin antagonist AA92593 and the PLC in- hibitor 
U73122 and the inactive compound U73343. B) Column plot showing the relative 
184
23 kDa 
37 kDa 
AANAT 
GAPDH 
Li
gh
t 
Da
rk
ne
ss
 
Li
gh
t +
 
AA
92
59
3 
Li
gh
t +
 
U7
31
22
 
Li
gh
t +
 
U7
34
33
 !"
#"
Lig
ht
Da
rkn
es
s
Lig
ht 
+ A
A9
25
93
Lig
ht 
+ U
73
12
2
Lig
ht 
+ U
73
14
33
0.0
0.2
0.4
0.6
A
A
N
A
T/
G
A
PD
H
***
***
quantification of the western-blots band intensities shown in A. Values are the mean ± SD 
of four independent experiments (***p < 0.001).  
 Studies of AANAT expression using western-blot of the mentioned assay resulted 
consistent with the results previously commented (Fig. 7A). Quantification of western-
blots showed no significant differences between darkness and light in the presence of 
melanopsin antagonist or the PLC inhibitor (n = 4, ***p < 0.001, Fig. 7B).  
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Discussion 
 Melanopsin presence was discovered for the first time in the human lens epithelial 
cells and it has been related to the local synthesis of melatonin. Changes in the 
extracellular melatonin levels were able to be induced by changing light/darkness 
conditions, due to the variation of the expression of melatonin synthesizing enzyme 
AANAT. Light reduced the expression of AANAT, therefore, a concomitant decrease in 
melatonin production was observed. On the other hand, darkness increased both AANAT 
and melatonin levels.   
 Melanopsin presence in the intrinsically photosensitive retinal ganglion cells 
(ipRGC) shares some features with the one described in this study, for instance, 
melanopsin sensitivity to blue light was found in the literature, and melanopsin present in 
the epithelial cells of the lens were mainly stimulated by the blue component of white 
light, about 480 nm wavelength, as what happens with ipRGC showing similar spectral 
sensitivity (Bailes and Lucas, 2013; Graham and Wong, 1995; Kumbalasiri and Provencio, 
2005). Inhibition of melanopsin action by using a specific antagonist AA92593 was able to 
abolish the effect of melanopsin and AANAT and melatonin levels followed a very similar 
pattern to the darkness, an increment in AANAT expression as well as melatonin levels 
was observed, confirming that the effect observed is due to melanopsin (Bertolesi et al., 
2016; Jones et al., 2013). Moreover, melanopsin in the ipRGCs has been shown to be 
linked to phospholipase C (PLC) membrane protein(Angueyra et al., 2012; Panda et al., 
2005; Xue et al., 2011). It was worthwhile investigating this feature of melanopsin 
pathway in the studied cell model, blocking PLC by an inhibitor U73122 demonstrating 
that, in the presence of light, there was no inhibition in AANAT expression or in melatonin 
production. 
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 Light profoundly influences circadian, neuroendocrine, and neurobehavioral 
regulation in all mammals, it is essential to life on our planet. Daily rhythmic melatonin 
signals provides temporal coordination of physiological functions, such as chronobiologic 
rhythms of locomotor activity, sleep-wake cycle, dietary and water intake, hormone 
secretion and metabolism (Slater, 1983). Melanopsin containing photoreceptors, is very 
important in many aspects and studies have shown that, although light suppresses 
melatonin production, which can appear as a negative effect, however, daytime exposure 
to blue-enriched light resulted very positively on the night-time melatonin amplitude and 
the circadian regulation  (Dauchy et al., 2015; Dauchy et al., 2016). 
 Light effect on melatonin production has been investigated in the past (Burgess et 
al., 2015). However, classically, melatonin synthesized in the pineal gland was studied, and 
regulation was driven through the suprachiasmatic nucleus (Berson et al., 2002). In the 
current study, the control of AANAT expression by the light was shown to have similar 
behaviour to the one studied in the pineal gland (Bergstrom et al., 2003), but with no 
connection to the neural component. Since the crystalline lens is neither innervated nor 
vascularized, this makes it difficult to receive neuronal messages or vascular melatonin 
release at night. Therefore, it may synthesize melatonin locally to allow it to follow the 
same rhythmicity of the pineal melatonin.  
 Melatonin synthesis in the lens has been discovered in experimental animals, and 
its preventive role in cataract pathology has been suggested (Abe et al., 1999; Abe et al., 
1994). The current research using human epithelial lens cells and human lens tissue added 
a relevant importance to the role of melatonin and its synthesis and regulation by 
melanopsin in the human crystalline lens, together with the ciliary body, melatonin is 
released by both ocular structures to the aqueous humour (Aydin and Sahin, 2016; Chiquet 
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et al., 2006). Melatonin presence in the aqueous humour plays numerous functions in the 
anterior segment level of the eye, such as an antioxidant and protectant agent (Khorsand et 
al., 2016; Sande et al., 2016). 
 Recent studies have shown a negative effect of crystalline lens removal due to 
cataract on the circadian rhythm and melatonin levels, all studies are focused on the 
harmful effect of blue light on the retina and the fact that the lens absorbs UV light and 
protect the retina from photo-toxicity (Alexander et al., 2014; Brondsted et al., 2015; 
Erichsen et al., 2015). Besides the afore-mentioned facts occurring due to the lens 
removal, it could be important to remember that, by removing the lens, a melatonin 
synthesizing structure is also removed. More studies are definitely needed to assess the 
importance of melatonin presence in the lens. Moreover, further speculations could also 
rise by the discovery of melanopsin in the lens.  
 It would be possible to modify the levels of melatonin in the lens by changing the 
illumination condition, especially because melatonin has the ability to reduce free radicals 
(Ianas et al., 1991), and all those damaging products would be diminished, thereby 
preventing cataract formation, as suggested by other authors (Siu et al., 2006). This may 
suggest that the use of some filters preventing the light in the range 460-480 nm 
wavelength may facilitate the production of melatonin and would protect the lens of free 
radical damage, bearing in mind, of course that the time of usage of such filters since 
exposing to short wavelength light could be time-dependant beneficial at some moments of 
the day (An et al., 2009). This technology has been applied in some intraocular lenses used 
in cataract surgery or also in spectacles to treat some neurological disorders such as 
migraines (Hoggan et al., 2016; Mainster, 2006). It would be very interesting to test 
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melatonin levels in the eye for variation regarding what happens in the pineal gland and 
bloodstream (Casper and Rahman, 2014; Csernus et al., 1999; Sasseville et al., 2006). 
 On the other hand, melatonin synthesized by the lens would contribute to 
melatonin levels observed in the aqueous humour as previously studied (for more details, 
see chapter 2). Since melatonin synthesis can be induced by darkness, it can activate MT2 
and MT3 receptors located in the ciliary body (Alarma-Estrany and Pintor, 2007). This 
activation leads to a reduction in the chloride efflux which produces a concomitant 
decrease in aqueous humour formation and a reduction in IOP (Huete-Toral et al., 2015). 
This is clearly suggesting a possible role of melatonin and analogues in the treatment of 
glaucoma. Indeed, recent studies have demonstrated that the applications of melatonin or 
its analogue 5-MCA-NAT were able to reduce IOP in an animal model of glaucoma 
(Martinez-Aguila et al., 2013; Martinez-Aguila et al., 2016). Filtering the blue component 
of light could be useful to trigger the synthesis of melatonin in the lens increasing the 
concentration of this substance in the aqueous humour with the related reduction in IOP. 
Experiments are necessary to confirm this possibility. 
 In conclusion, melanopsin is present in human lens epithelial cells. Its stimulation 
by light reduces the expression of melatonin synthesis enzyme AANAT, reducing the 
presence of melatonin in the extracellular milieu. Since melatonin presents interesting 
features such as a scavenger agent towards free radicals and it has hypotensive properties 
on IOP, it would be of interest to explore its therapeutic use by naturally stimulating it in 
the lens using filters or other optical devices. 
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Chapter VI: General discussion 
It's not what you look at that matters, it's what you see 
Henry David Thoreau 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Discussion 
 In the present work, several aspects of melatonin in some ocular structures were 
investigated, mainly in the search for a better understanding of its role on intraocular 
pressure. First of all, human aqueous humor of patients with ocular hypertension were 
analyzed and they showed higher levels (around 46.63 ng/ml) of melatonin compared to 
normotensive patients (14.62 ng/ml). Currently, it is possible to assume that melatonin 
found in the aqueous humor does not only come from the ciliary body, where the aqueous 
humor is produced. Also, the crystalline lens, which stand in contact with the aqueous 
humor, contributes to the aqueous humor melatonin levels as previously described (see 
chapter 5).  
 In order to study in depth the phenomena of finding higher melatonin 
concentrations in patients with elevated intraocular pressure, a cellular model was used. In 
vitro studies mimicking a glaucomatous condition were carried out by activating a channel 
sensitive to pressure (TRPV4).  Several assays were done to investigate melatonin 
synthesis and signalling pathways in non-pigmented ciliary body epithelial cells, where the 
formation of aqueous humor is held. TRPV4 channel is a member of the transient receptor 
potential channels which are expressed in a range of species from yeast to humans and are 
widely expressed throughout many different tissues (Clapham, 2003; Shibasaki, 2016). In 
the current work, the presence of the channel TRPV4 was confirmed in human non-
pigmented ciliary epithelial cells, and its role in activating the mechanism of melatonin 
synthesis was studied. Many TRPV channels are activated by multiple stimuli (Benham et 
al., 2003; Hardie, 2003), implying a diversity in ion selectivity and the polymodal 
mechanisms of activation, which necessarily result in equally diverse cell functions 
(Montell, 2005; Mutai and Heller, 2003; Nilius and Voets, 2004). For instance, TRPV4 
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channel was first cloned as an osmosensor (Strotmann et al., 2000), however, it can also 
act as shear stress or fluid flow sensor as well as a temperature sensor (Chung et al., 2003). 
The presence of TRPV4 in the ciliary body epithelial cells was recently described in the 
mouse experimental model and it was suggested to play an important role in regulating cell 
volume, lipid, and calcium signals and therefore it represented a novel and potencial target 
for antiglaucoma medications (Jo et al., 2016).   
 Interestingly, our experiments revealed a relevant relationship between TRPV4 and 
AANAT phosphorylation, a process known to protect AANAT enzyme from proteosomal 
degradation (Pozdeyev et al., 2006). Not only that TRPV4 activation permits melatonin 
release into the aqueous humor, but also at a short period stimulation by a selective 
agonist, a series of intracellular actions occurred with the final goal of permitting the 
melatonin enzyme  (AANAT) to rise and to be phosphorylated. 
 Our results indicated that activating TRPV4 resulting in AANAT phosphorylation 
is mediated by calmodulin and calcium-calmodulin dependent protein kinase II. Previous 
studies using heterologous cellular models expressing TRPV4 channel, showed that 
intracellular Ca2+ potentiates this channels’ currents and it accelerate and amplifies the 
current response to hypotonic solutions and phorpol ester agonists. Moreover, This effect 
of Ca2+ occurs through an action at an intracellular site in the C terminus of the TRPV4 
channel protein and is mediated by CaM binding (Strotmann et al., 2003).  
 Activation or potentiation of Ca2+ permeable channels by Ca2+ is uncommon, 
particularly for channels in the plasma membrane, because of the positive feedback effect 
and the potential damage due to the cellular Ca2+ overload. Other Ca2+-permeable channels 
that are potentiated by Ca2+ are those involved in Ca2+ release from intracellular stores and 
include ryanodine receptors and inositol 1,4,5-trisphosphate receptors. As for TRPV4, the 
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activity of these channels is tightly controlled by Ca2+-dependent negative feedback 
mechanisms that involve CaM (Rebas et al., 2012). It is likely that Ca2+-CaM, by binding 
to the C-terminal domain, induces a conformational change in the TRPV4 channel protein 
resulting in increased channel activity. Similar mechanisms have been proposed for the 
activation of a number of channel types, including Ca2+-activated K+ channels and cyclic 
nucleotide-gated channels, whose activity is controlled by intracellular mediator (Ca2+, 
Ca2+-CaM, or cAMP/cGMP) binding in the C terminus (Strotmann et al., 2003).  
 TRPV4 channel has been extensively investigated in several areas and its presence 
was confirmed in numerous cell types. Concerning the eye, recent studies indicated a 
special importance of this channel in regulating IOP as a result of its presence in the 
trabecular meshwork. Results confirmed that TRPV4 in the trabecular meshwork 
represents a crucial link between membrane stretch, Ca2+ signals and cytoskeletal 
reorganization, moreover, TRPV4 activation is required for persistent IOP elevation in an 
animal model of glaucoma (Ryskamp et al., 2016). Our results suggests an added value in 
the search to understand glaucoma for several reasons, TRPV4 presence in both important 
ocular structures corroborate its role in the regulation of IOP. From the one hand, non-
pigmented ciliary body epithelial cells are secretory cells where aqueous humor is formed, 
and elevated IOP could be due to an excessive formation of aqueous humor, or a decrease 
of its drainage through the trabecular meshwork. A pressure sensor in essential for both 
functions to work properly avoiding IOP to raise and TRPV4 could be a good target for the 
treatment of elevated IOP.  
 Both in the case of glaucoma patients and in the cellular model, the rise in pressure 
produces an increase in extracellular melatonin levels. So, the unanswered question is: 
Why if melatonin levels are high in the aqueous humor IOP is not reduced? 
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 One possibility is that melatonin receptors are not working as they normally do 
when glaucoma appears. This led us to study melatonin receptors considering the 
possibility of forming receptor-receptor heteromers with different types of receptors.  
 In recent years, new strategies have been proposed to consider the complex 
functioning of GPCRs. Thus, the complexity of the receptors at different molecular levels 
is considered, so specific drugs are sought for a subtype of GPCR, drugs that recognize an 
allosteric binding center, drugs that consider the oligomerization of GPCR, drugs that 
neutralize constitutive activity and drugs targeting other molecular elements that regulate 
different signalling pathways (Liebmann, 2004). In this sense, a study was conducted to 
investigate the possibility of melatonin receptors to heteromerize with other receptors 
present in the ciliary body.  
 Receptor homomerization is defined as the physical association between identical 
receptors, whereas heteromerization is the association between distinct receptors. Because 
to date, the available techniques did not allow the distinction between higher order dimers 
or oligomers, the term dimer is often used in the sense that it is the simplest form of an 
oligomeric functional unit; In spite of this, at the moment the techniques to distinguish 
between dimers, trimers and tetramers are being developed (Carriba et al., 2008; Vidi and 
Watts, 2009). 
 The dimers/oligomers have different functional characteristics than the receptors 
that constitute them, so oligomerization confers new properties to GPCRs, which 
establishes a possible mechanism to generate new functions in these receptors. This 
phenomenon has given rise to a new level of complexity that governs the signaling and 
regulation of these proteins (Ferre et al., 2009). 
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 Concerning melatonin and some of its analogues, it has been possible to suggest an 
interaction between melatonin and its analog 5-methoxycarbonylamino-N-
acetyltryptamine, 5-MCA-NAT and other adrenergic receptors like ß2 and α2a on a 
pharmacological level. Results showed that pre-treatment with melatonin or its analog 5-
MCA-NAT, followed by the application of commercial eye drops of ß2 antagonist or α2 
adrenergic agonist, potentiate ocular hypotensive effect of melatonin or its analogue 
(Crooke et al., 2013). These results support the possibility of melatonin receptor forming 
heteromers with different receptors. In addition, studies confirmed that MT1 and MT2 
receptors form heteromers in transfected HEK293T cells, as well as its presence and 
functionality in mice photoreceptor cells (Baba et al., 2013). Another interesting 
pharmacological finding was the use of agomelatine, a commercial antidepressant agent 
which was proven to restore disrupted circadian rhythm and reduces depression-like 
behavior. Agomelatine is an agonist for MT1 and MT2 receptors as well as an antagonist of 
serotonergic 5-HT2C receptors. Interestingly, treatment with 5-HT2C antagonists or 
melatonin alone failed to reproduce these effects (Cardinali et al., 2012; Carney and 
Shelton, 2011; Racagni et al., 2011). Supporting these findings, melatonin was found to 
inhibit the ability of 5-HT to phase shift the suprachiasmatic circadian clock (Prosser, 
1999). More recently, with the technological advances in the area of GPCRs 
heteromerization, consistent results have shown that melatonin receptor MT2 physically 
interact with serotonin 5-HT2C (Kamal et al., 2015).  
 A fascinating discovery regarding receptor-receptor interaction, is the fact that in 
some cases, signalling pathways can change the canonical pathway. In fact, reports are 
starting to appear that link heteromers to a distinct signalling machinery recruitment. An 
example of such a phenomena is dopamine receptors D1 and D2, these two receptors are 
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coupled to Gs and Gi respectively (George and O'Dowd, 2007; Rashid et al., 2007a). 
These receptors were investigated and showed to form heteromers with a selective Gq-
protein coupling (Rashid et al., 2007b). Earlier, dopamine receptor-mediated calcium 
signalling in the central nervous system was assumed to be due to an interaction between 
Dopamine receptor D1 and calcyon (Lezcano et al., 2000). Up to date, the only evidence 
correlating dopamine neurotransmission and calcium signalling is through the D1-D2 
receptor heteromer (Casado et al., 2009). 
 Our findings suggests that melatonin receptors MT1 and MT2 when forming 
heteromer with  an α1A adrenergic receptor, shifts its signalling to be coupled to Gs-protein 
(while MT receptors are coupled canonically to Gi). Such a behavior in shifting the 
signalling pathway was found also in the previous example of MT1-MT2 heteromer in 
photoreceptors, were experiments showed that the effect of melatonin on the 
photoreceptors is independent of the Gi/cAMP pathway and it involves instead an 
activation of PLC/PKC pathway (Baba et al., 2013). Actually, there is consensus in 
considering that a receptor heteromer is an entity with a different pharmacology and a 
different functionality (Ferre et al., 2009). Therefore, distinctive pharmacological and 
functional characteristics (a kind of “heteromer fingerprint”) are indeed helpful to detect 
receptor heteromers in native tissues and it would be predicted to be invaluable for drug 
development (Casado et al., 2009). 
 Our findings showed a decrease in melatonin receptors in glaucomatous cases, 
together with a drop of receptor heteromerization with alpha adrenegic α1A receptor (for 
more details, see chapter 4). However, antagonizing the effect of alpha adrenergic receptor 
by applying prazosin seems to permit melatonin action to work. Such a behavior is 
demonstrated in different heteromer formed cases mentioned above. 
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 Melatonin appears to be helpful together with its effect in decreasing intraocular 
pressure among other functions, it could be beneficial since it works as an antioxidant 
among numerous functions (Anderson and Rodriguez, 2015; Tchekalarova et al., 2015). 
 Another ocular structure bathed with the aqueous humour is the crystalline lens. It 
is known that the lens synthesize melatonin as well. Accordingly, melatonin synthesis and 
regulation by the crystalline lens was studied and a search for a light sensor to regulate 
melatonin synthesis took  place and resulted in the discovery of melanopsin receptors in 
the lens epithelial cells. These findings are of extreme importance from several aspects. In 
the present work, light is spotted towards the aqueous humor melatonin content and its 
possible contribution of the crystalline lens in producing enough melatonin to lower IOP. 
Nevertheless, melanopsin presence in an ocular anterior segment part demand a deeper 
investigation since it indicates numerous hidden functions which needs to be addressed in 
the future.  
  (Kamel et al., 2017).(Aydin and Sahin, 2016; Marseglia et al., 2017). 
(Chrysostomou et al., 2013; McElnea et al., 2011). (Gurer-Orhan and Suzen, 2015).   
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Conclusions 
“People think of education as something they can finish.” 
Isaac Asimov 
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Conclusions: 
1. Melatonin levels are increased in the aqueous humor of patients with 
elevated intraocular pressure. A correlation between melatonin and IOP is 
proved. 
2. The TRPV4 channel acts as a pressure sensor in non-pigmented ciliary 
body epithelial cells. TRPV4 activation triggers melatonin release in a time and 
dose dependent manner, this effect beingabolished by silencing TRPV4 as well 
as by the use of antagonists. 
3. TRPV4 activation in a short period of time was able to phosphorylate 
AANAT enzyme, phosphorylation was mediated by calcium-calmodulin 
dependent protein kinase II, the effect being an activation of this enzyme. 
4. Melatonin receptors MT1 and MT2 form heteromers with α1A adrenergic 
receptors in the ciliary body epithelial cells. Also, cross-antagonism was 
confirmed between both receptors. 
5. Melatonin receptors MT1 and MT2 when forming heteromers with  an α1A 
adrenergic receptors, shifts its signalling to be coupled to Gs-protein. 
Stimulation with either receptor agonist produced an increment in cAMP, this 
effect was blocked by cholera toxin. 
6. Glaucomatous model DBA/2J showed a different behaviour depending 
on the disease development when treated with melatonin or IIK7 together with 
phenylephrine. Healthy mice showed that both agonists revealed a potential 
hypontensive effect, however, in glaucomatous mice, blocking α1A by prazosin 
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prior to melatonin instillation resulted in more potent effect of melatonin in 
lowering IOP.  
7. The discovery of melanopsin in the crystalline lens is an indication of 
various roles and mechanisms of melatonin regulation in the anterior segment 
of the eye. 
8. Light can regulate melatonin levels in the crystalline lens epithelial cells, 
this effect is mediated by PLC in the same manner described in the retina. 
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Annex I : Reagents and Buffers 
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Table 1. Phosphate-Buffered Saline (PBS) 10X
Compounds Concentration
NaCl 1.37 mM
Na2HPO4 81 mM
KCl 26.8 mM
KH2PO4 14.7 mM
Table 2. Radioimmunoprecipitation assay buffer (RIPA)
Compounds Concentration
Tris-HCl pH=8 50 mM
SDS 0,1%
NaCl 150 mM
NP-40 1%
Na deoxicolate 0,5%
Protease inhibitors cocktail 1%
Table 3. Electrophoresis Buffer 5X
Compounds Concentration
Tris 125mM
Glycine 0.96 M
SDS 0,5%
Table 7. SDS-Page stacking gel-1
Compounds Concentration
Tris-HCl pH=6.8 0.125 mM
SDS 4%
Glycerol 29%
ß-mercaptoethanol 10%
EDTA 15mM
Bromophenol blue 0.006g
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Table 5. Reprobing solution
Compounds Concentration
ß-mercaptoethanol 1%
SDS 10%
Tris pH=6.8 6,25%
Table 6. TBS 10x (concentrated Tris-buffered saline)
Compounds Concentration
Tris 10mM
NaCl 100mM
Table 7. SDS-Page stacking gel
Compounds Concentration
Tris-HCl pH=6.8 0.125 mM
SDS 0,1%
Ammonium persulfate 0.25 mg/ml
TEMED 0%
Acrylamide/Bis-acrylamide 4%
Table 8. SDS-Page separating gel
Compounds Concentration
Tris-HCl pH=6.8 375$mM
SDS 0,1%
Ammonium persulfate 0.25 mg/ml
TEMED 0,05%
Acrylamide/Bis-acrylamide Specifically determined for each 
protein%
Table 9. HPLC mobile phase for melatonin detection
Compounds Concentration
Methanol 40%
H2O 60%
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Table 10. HPLC mobile phase for NAS detection
Compounds Concentration
Acetonitrile 15%
acetic acid 0,1%
Table 11. 33% Sucrose solution in PBS 1X
Compounds Concentration
Sucrose 330 g/l
PBS 10X 10% (v/v)
Table 11. 4% Paraformaldehyde Fixative (PFA) in PB 0.1M (pH: 7.4)
Compounds Concentration
PFA 4% (m/v)
Na2HPO4  0.2M 36%$(v/v)
NaH2PO4$$0.2$M 14%$(v/v)
Table 13. Hank’s Buffered Salt Solution (HBSS)
Compounds Concentration
NaCl 0.137 M
KCl 5.4 mM
Na2HPO4  0.25 mM
Glucose 0.1 g
CaCl2 1.3 mM
MgSO4 1.0 mM
NaHCO3 4.2 mM
KH2PO4 0.44 mM
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Annex II: Scientific Contributions 
“Tell me and I forget, teach me and I may remember, involve me and I learn.” 
Benjamin Franklin  
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Abstract
Neurohormones melatonin and its analogues are pres-
ent with an important physiological and pharmacologi-
cal ability to reduce intraocular pressure (IOP); thus, 
they are suitable for the treatment of ocular hyper-
tension often associated with glaucoma. It is demon-
strated that two of its analogues, 5-MCA-NAT and IIK7, 
are more effective than melatonin to reduce IOP for a 
longer period of time. The research for the discovery of 
better compounds resulted in the development of new-
er and improved analogues compared to 5-MCA-NAT 
and IIK7. Furthermore, already commercially available 
drugs currently used as treatment for other patholo-
gies, presenting a resemblance to the melatonin struc-
ture, are being tested as potential glaucoma drugs. In 
this sense, agomelatine, which is already used as an 
anti-depressant medicine, is recognized as a worthy 
candidate since it reduces IOP, even under hyperten-
sive conditions. To sum up, the use of melatonin and its 
analogues as promising anti-glaucomatous substances 
is of great importance and should be given serious con-
sideration.
© 2013 Baishideng Publishing Group Co., Limited. All rights 
reserved.
Key words: 5-MCA-NAT; IIK7; Glaucoma; Ocular hyperten-
sion; Melatonin
Core tip: This mini review depicts the main features of 
melatonin and derivatives as interesting agents for the 
treatment of the ocular hypertension associated with 
glaucoma.
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There is a general interest in searching for novel com-
pounds capable of  reducing intraocular pressure (IOP) as 
an improved alternative to the existing drugs. IOP can be 
lowered through the reduction of  aqueous humor pro-
duction or by increasing its outflow through the trabecu-
lar meshwork or uveoscleral pathways. The interest for 
searching for new compounds relies on the fact that most 
of  the existing drugs produce important side effects, 
hampering the treatment of  certain patients. Side effects 
are a common issue in glaucoma medications. β-blockers 
such as timolol can cause bradycardia and hypotension 
and they are unsuitable for patients suffering from car-
dio vascular problems[1], asthma, obstructive pulmonary 
disease or corneal dystrophy[2]. Cholinergic agonists such 
as pilocarpine produce fixed pupils and induce myopia 
and cataracts[1], whereas prostaglandins (e.g., latanoprost) 
cause eyelash growth, iris pigmentation[3], muscle and 
joint pain[2]. Frequently, ocular redness and ocular surface 
discomfort obligates patients to abandon the treatment.
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Several new compounds and approaches are under 
development in companies’ pipelines or in academic 
institutions. Among the plethora of  substances, the natu-
rally occurring are more attractive as its administration is 
expected to result in fewer side effects[4]. Among these, 
the neurohormone melatonin emerges as a promising 
substance with interesting hypotensive properties[5]. The 
use of  5-MCA-NAT (a melatonin analogue, see below) 
when applied to the eye does not produce severe side ef-
fects. It does not affect corneal and lens transparency nor 
cause redness or corneal edema. No negative effects were 
noticed in general ocular examinations[5]. It is important 
to bear in mind that most of  melatonin intake is not by 
prescription as it is considered a dietetic supplement. In 
this case, high dosages and an elevated number of  intakes 
could produce some minor side effects. The Mayo Clinic 
indicates that the most common side effects are drowsi-
ness, headache and dizziness. Moreover, large doses of  
melatonin can interfere with some medications, such as 
anticoagulants, immunosuppressants, diabetes medica-
tions and birth control pills.
There are two interesting works describing the mela-
tonin effect and its analogues on reducing IOP. Serle et 
al[6] demonstrated that a melatonin analogue was able to 
reduce IOP in glaucomatous monkeys, suggesting these 
molecules as a possible treatment of  ocular hypertension 
related to glaucoma. Additionally, a group of  ophthal-
mologists started to use melatonin during cataract surgery 
because it reduces IOP substantially, which is recom-
mendable during phacoemulsification
[7]. 
From these two relevant works, the question arises as 
why these groups decided to use melatonin and its ana-
logues for clinical purposes and mainly for reducing IOP. 
The present mini review introduces the reader to the ba-
sis of  why melatonin is an attractive molecule to reduce 
IOP and why it should be considered in the future as a 
respectable alternative to the current ocular hypertension 
and glaucoma therapies.
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Melatonin is a molecule known by its chemical name 
N-acetyl-5-methoxytryptamine (Figure 1). It has been 
traditionally related to a particular area of  brain, termed 
the pineal gland, where it is synthesized in low illumina-
tion conditions like during the night[8] and it regulates 
many day-night processes, called circadian rhythms[9]. It 
is necessary to emphasize that this substance is also syn-
thesized in other tissues and ocular structures such as the 
retina, the ciliary body or the lens. This clearly suggests 
that melatonin can exert some local actions on the tissues 
where it is synthesized or in surrounding areas. Keeping 
in mind that melatonin is released by the lens or the cili-
ary body, its presence in the aqueous humor, modifying 
the physiology of  these structures being bathed in the 
fluid, can be speculated about. Interestingly, one of  the 
possible physiological processes to be modified is IOP. 
It is documented that in many animal models there are 
changes in IOP during the day (high IOP) and night (low 
IOP). It is possible that both processes are associated 
considering the circadian pattern of  melatonin produc-
tion. Consequently, we should study what happens if  we 
topically apply melatonin during the day when IOP is 
high.
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When melatonin is topically applied at a single dose of  
100 µmol/L in a volume of  10 µL, there is a transient re-
duction in IOP and values return quickly to initial figures 
in about 2 h[10]. This effect is similar to that of  endog-
enous melatonin at night which reduces IOP. Despite the 
acquired hypotensive effect, the rapid return to normal 
pressure values suggests that either it is necessary to regu-
late the doses or to look for an alternative compound to 
produce a more sustained effect[11].
There are several commercially available melatonin 
analogues depicting similar behavior to melatonin. Two 
compounds present sharper and long lasting effects on 
reducing the IOP compared to melatonin. In particular, 
the compound N-butanoyl-2-2-methoxy-6H-isoindolo 
([2,1-a]indol-11-yl) ethanamine (abbreviated as IIK7) 
has a hypotensive effect that lasts up to 7 hours and the 
compound 5-methylcarboxyamino-N-acetyltryptamine 
(also known as 5-MCA-NAT), which can reduce IOP 
for up to 9 h (Figure 1)[12]. Consequently, 5-MCA-NAT 
is more interesting since it presents a longer term effect 
with a significant reduction of  IOP for up to 96 h. This 
remarkable effect has been taken into consideration as we 
indicate below[11] (Table 1).
5-MCA-NAT was tested in normotensive models as 
well as under hypertensive conditions, including glauco-
matous monkeys (Table 1). Interestingly, the effects on 
the monkeys, a model closer to the human glaucomatous 
pathology, were extremely interesting. Compared to vehi-
cle treatment, twice daily administration of  5-MCA-NAT 
for 5 d reduced IOP from 1 to 5 h after the first dose and 
the IOP-lowering effects were shown to last at least 18 h 
following administration, based on IOP measurements 
made after the fourth and eighth doses[6]. 
One interesting characteristic to take into account 
was that the ocular hypotensive effect of  5-MCA-NAT 
was enhanced by repeated dosing. The maximum reduc-
tion of  IOP was acquired 3 h after each morning dose 
and was 10% on day 1, 15% on day 3, and 19% on day 5 
(control = 100%). No adverse ocular or systemic side ef-
fects were observed during the 5 treatment days, suggest-
ing that this compound could be used perfectly as ocular 
hypertension treatment [6] (Table 1).
IIK7 reduced intraocular pressure by acting through 
MT2 melatonin receptors, presumably decreasing aqueous 
humor formation. Its effect is concentration dependent 
and it can reduce IOP 38.5% ± 3.2% when compared 
to controls (Table 1). It is important to notice that these 
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experiments have not been performed in glaucomatous 
monkeys yet but only in rabbits[12].
In summary, it seems that some compounds, such as 
melatonin, 5-MCA-NAT and IIK7, clearly reduce IOP. 
But what is the mechanism for this IOP reduction? What 
receptors activate these substances in order to produce 
the observed effects?
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Melatonin exerts its effect via membrane and nuclear 
receptors. The protein membrane receptors are bet-
ter understood and until recently three proteins have 
been cloned. Two of  these membrane receptors, termed 
MT1 and MT2, are melatonin receptors belonging to the 
7-transmembrane G protein-coupled receptor family 
(GPCR). There have been claims that a third receptor ex-
ists, the MT3 melatonin receptor, although it has not been 
cloned yet. Some authors have identified it as quinone re-
ductase 2 (QR2), demonstrating features of  a melatonin 
receptor in some animal models (for a review see[9]). 
MT1, MT2 and the probable MT3 melatonin receptors are 
present in several ocular structures, according to pharma-
cological, biochemical and immunological studies[13,14]. This 
evidence suggests that melatonin plays a role in physio-
logical processes in ocular tissues, such as the modulation 
of  IOP, and it has been documented that MT2 and MT3 
are responsible for IOP reduction.
When melatonin, 5-MCA-NAT and IIK7 are applied 
to normotensive or hypertensive eyes, they produce a 
dissimilar IOP reduction, depending on the compound 
under study. The use of  selective antagonists for melato-
nin receptors has allowed identification of  the presence 
of  MT2 melatonin receptors in the ciliary body of  experi-
mental animals, such as New Zealand white rabbits. This 
has been confirmed through immunohistochemical stud-
ies. In these studies it has been possible to verify the pres-
ence of  MT2 melatonin receptors on pigmented and non-
pigmented ciliary epithelia. Accordingly, the application 
of  melatonin or IIK7, which is a selective MT2 agonist, 
results in a reduction in the production of  the aqueous 
humor[12] (Figure 2).
5-MCA-NAT has been suggested as an MT3 melato-
nin receptor agonist that reduces IOP. To date, the loca-
tion of  the receptor is unknown. As there is a contro-
versy with the possible identification of  the MT3 receptor 
which is tentatively identified in some animal models as 
QR2, some sophisticated experiments were performed to 
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Melatonin
   Human   32.0%± 3.2% Unknown [7]
   Rabbit  22.0% ± 1.6% MT2, MT3 [10,11]
   Mouse (glaucomatous)  33.4% ± 2.5% MT2 UD
5-MCA-NAT
   Monkey (hypertensive)  19.2% ± 2.1% MT3 [6]
   Rabbit  42.5% ± 1.6% MT3 [10,11]
IIK7
   Rabbit  38.5% ± 3.2% MT2 [12]
INS48848
   Rabbit  36.0% ± 2.0% MT3 [22]
INS48852
   Rabbit  33.1% ± 1.4% MT2 [22]
INS48862
   Rabbit  26.0 V ± 1.3 V MT2 [22]
Agomelatine
Rabbit
   Normotensive  20.8% ± 1.4% MT2 [25]
   Hypertensive  68.8% ± 5.7% MT2 [25]
The values represent the mean ± SEM for the indicated compounds in the 
respective animal model. IOP: Intraocular pressure; UD: Unpublished 
data.
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Figure 1  Chemical structure of melatonin and analogues. Melato-
nin (N-acetyl-5-methoxytryptamine), IIK7 (N-butanoyl-2-(2-methoxy-6H-
isoindolo[2,1-a]indol-11-yl)ethanamine) and 5-MCA-NAT (5-methylcarboxyami-
no-N-acetyltryptamine).
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Several aspects need to be studied, taking into account 
that melatonin and analogues can significantly reduce 
IOP. 
It is clear that it is necessary to research and design 
new melatonin analogues with more profound and long 
lasting effects[5]. Inspire Pharmaceuticals Inc. (now ab-
sorbed by Merck) has designed several melatonin ana-
logues with interesting hypotensive properties to reduce 
IOP. In recent studies, melatonin analogues, termed 
INS48848, INS48852 and INS48862, demonstrated 
similar behavior to melatonin, 5-MCA-NAT and IIK7[22]. 
Indeed, these three compounds decreased IOP in a 
dose-dependent manner similar to melatonin, 5-MCA-
NAT and IIK7, confirming their efficiency in decreasing 
IOP (Table 1). Concerning their selectivity on melatonin 
receptors, the effects of  INS48848 were completely 
blocked by prazosin, an antagonist of  MT3 melatonin re-
ceptors, and were potently inhibited by luzindole, a non-
selective antagonist of  melatonin receptors. However, 
DH97, a selective MT2 receptor antagonist, had a limited 
effect against INS48848 and the results obtained from 
INS48862 and INS48852 were contradictory. Luzindole 
and prazosin had no significant effects against those two 
compounds, whereas DH97 blocked them completely. 
These results strongly suggest that INS48848 could be 
acting through the MT3 melatonin receptors and that 
INS48862 and INS48852 could be acting preferentially 
through MT2 melatonin receptors. In any case, all these 
compounds are worthy candidates to reduce IOP, espe-
cially when it is abnormally elevated[22].
Another alternative to the development of  newly 
synthesized compounds is to search for melatoninergic 
compounds already used for other medical purposes. 
Compounds such as ramelteon ((S)-N-[2-(1,6,7,8-tetrahyd-
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clarify the issue[15-17]. In New Zealand rabbits, the use of  a 
siRNA silencing QR2 (therefore avoiding the expression 
of  this enzyme) did not abolish the hypotensive effect 
of  5-MCA-NAT, clearly indicating that, in this animal 
model, MT3 ≠ QR2, opening the possibility of  speculating 
about the existence of  a receptor that needs to be cloned 
to fully understand its functioning and location[18].
Apart from melatonin and its derivatives, some other 
compounds, like 5-MCA-NAT, can keep IOP below 
normal values for up to 5 d. This long-term effect is 
mediated by the action of  melatonin receptors on the ex-
pression of  genes expressing proteins important for the 
homeostasis of  the aqueous humor.
To date, it has been possible to demonstrate that the 
5-MCA-NAT long-term effect is in part the result of  the 
expression inhibition of  carbonic anhydrases. This down-
regulation means that 24 h after 5-MCA-NAT applica-
tion there is a reduction in IOP because the amounts of  
carbonic anhydrases are severely reduced. In particular, 
when 5-MCA-NAT is applied, carbonic anhydrase 2 is re-
duced 32% (protein levels), while carbonic anhydrase 12 
is reduced 39% (protein levels). This reduction in protein 
expression mimics the carbonic anhydrase inhibitor ac-
tion, such as dorzolamide or acetazolamide[19].
Likewise, the expression of  adrenergic receptors is 
modified by the application of  5-MCA-NAT. Interest-
ingly, this melatonin analogue is able to produce a se-
quential process consisting of  an initial reduction in the 
β2-adrenoreceptors expression, followed by an increase 
in α2A-adrenoreceptors[20]. Altogether, these consecutive 
effects produce a sustained reduction in IOP lasting for 
at least 96 h[21].
In summary, 5-MCA-NAT, apart from a sharp hypo-
tensive effect, exerts a long term effect, maintaining low 
IOP for 4 d.
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Figure 2  Expression of mRNA levels in ciliary body cells. The amounts of mRNA and concomitant adrenoceptors were changed after the application of 5-MCA-NAT. 
While there was an increase of α2A-adrenoreceptors (in red), there was a decrease in the levels of β2-adrenoreceptors (in blue).
30% reduction in IOP during cataract surgery compared 
to the initial patient’s pressures. This is quite interesting 
because the IOP reduction has been obtained in normo-
tensive patients and it could be even more substantial 
in hypertensive (glaucomatous) patients. Several experi-
ments in animal models demonstrated that melatonin and 
analogues are able to reduce IOP equally in normotensive 
and hypertensive animals, being more effective in hyper-
tensive than in normotensive animals (Table 1). Also, ex-
periments performed with 5-MCA-NAT on hypertensive 
monkeys, a step before human clinical trials, have proved 
that this melatonin analogue reduced IOP.
In conclusion, agomelatine is the compound that we 
strongly believe should be tested in glaucomatous pa-
tients for its ability to reduce IOP. Agomelatine is already 
used as a depression treatment drug under the commer-
cial name Valdoxan[24]. Since many of  the pre-clinical tests 
have already been completed, we should not be surprised 
if  agomelatine clinical trials start and it becomes the first 
melatoninergic compound to join the group of  glaucoma 
treatment substances.
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used for the treatment of  depression, could be candidates 
to reduce IOP since their structure is similar to melatonin.
There is a lack of  information regarding the use 
of  ramelteon in IOP studies. Agomelatine significantly 
reduces IOP when topically applied on rabbit eyes. 
Agomelatine (10 µL, 100 µmol/L) reduced IOP by 
20.8% ± 1.4% and its maximal IOP reduction was 180 
minutes after the compound application. Interestingly, 
this compound exhibited an ability to reduce IOP in 
hypertensive conditions. It is noteworthy to stress that 
under high IOP the ability of  this melatonin analogue to 
reduce IOP was 68.8% ± 5.7% (Figure 3, Table 1)[25]. 
There is a clear advantage in using compounds al-
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It is necessary to perform an exhaustive study on the role 
of  melatonin and its analogues in the different ocular 
structures since it is very probable that this knowledge 
will contribute to the discovery of  more effective treat-
ments for pathologies  like glaucoma, corneal wound 
healing, cataracts or retinal pathology[26].
Taking into account the importance of  the role of  
melatonin and its analogues in hypertension, often asso-
ciated with glaucoma, it is quite evident that these com-
pounds should be used as treatment to reduce IOP. Mela-
tonin or agomelatine can simply and rapidly reduce IOP, 
although further research is required to prove that they 
can be safely used as treatment for ocular hypertension.
Most of  the presented data resulted from experiments 
assaying melatonin or its analogues on animal models. 
We still have a long way to go to test these compounds 
on human beings. Nevertheless, there are a lot of  posi-
tive points regarding the efficacy of  certain melatonin-
ergic compounds. For instance, melatonin itself  is able 
to reduce IOP in normotensive humans, as previously 
described[7]. These authors reported an approximate 
100
  90
  80
  70
  60
  50
  40
  30
  20
  10
    0
IO
P 
(%
 o
f 
co
nt
ro
l)
Control  Melatonin 5-MCA-NAT   IIK7   Agomelatine
Figure 3  Comparative effects of melatonin and analogues in an animal 
model. Equal doses of melatonin or the corresponding analogues (100 µmol/L, 
10 µL), reduced intraocular pressure in New Zealand white rabbits. Differences 
among the compounds rely on the activation of different receptors in each case 
(see text).
19 Crooke A, Huete-Toral F, Martínez-Águila A, Martín-Gil A, 
Pintor J. Involvement of carbonic anhydrases in the ocular 
hypotensive effect of melatonin analogue 5-MCA-NAT. J 
Pineal Res 2012; 52: 265-270 [PMID: 22107075 DOI: 10.1111/
j.1600-079X.2011.00938.x]
20 Crooke A, Huete-Toral F, Martínez-Águila A, Alarma-
Estrany P, Pintor J. Regulation of ocular adrenoceptor genes 
expression by 5-MCA-NAT: implications for glaucoma 
treatment. Pharmacogenet Genomics 2011; 21: 587-589 [PMID: 
21705965 DOI: 10.1097/FPC.0b013e32834910d1]
21 Crooke A, Huete-Toral F, Martínez-Águila A, Martín-Gil A, 
Pintor J. Melatonin and its analog 5-methoxycarbonylamino-
N-acetyltryptamine potentiate adrenergic receptor-mediated 
ocular hypotensive effects in rabbits: significance for combi-
nation therapy in glaucoma. J Pharmacol Exp Ther 2013; 346: 
138-145 [PMID: 23591996 DOI: 10.1124/jpet.112.202036]
22 Alarma-Estrany P, Guzman-Aranguez A, Huete F, Peral A, 
Plourde R, Pelaez T, Yerxa B, Pintor J. Design of novel mela-
tonin analogs for the reduction of intraocular pressure in 
normotensive rabbits. J Pharmacol Exp Ther 2011; 337: 703-709 
[PMID: 21368006 DOI: 10.1124/jpet.110.178319]
23 Laustsen G, Andersen M. Ramelteon (rozerem) a novel ap-
proach for insomnia treatment. Nurse Pract 2006; 31: 52-55 
[PMID: 16607213 DOI: 10.1097/00006205-200604000-00011]
24 Millan MJ, Brocco M, Gobert A, Dekeyne A. Anxiolytic 
properties of agomelatine, an antidepressant with melatonin-
ergic and serotonergic properties: role of 5-HT2C receptor 
blockade. Psychopharmacology (Berl) 2005; 177: 448-458 [PMID: 
15289999 DOI: 10.1007/s00213-004-1962-z]
25 Martínez-Águila A, Fonseca B, Bergua A, Pintor J. Mela-
tonin analogue agomelatine reduces rabbit’s intraocular 
pressure in normotensive and hypertensive conditions. Eur J 
Pharmacol 2013; 701: 213-217 [PMID: 23270715 DOI: 10.1016/
j.ejphar.2012.12.009]
26 Crooke A, Huete-Toral F, Martínez-Águila A, Colligris B, 
Pintor J. Ocular disorders and the utility of animal models 
in the discovery of melatoninergic drugs with therapeutic 
potential. Expert Opin Drug Discov 2012; 7: 989-1001 [PMID: 
22860991 DOI: 10.1517/17460441.2012.714769]
P- Reviewers: Clement CI, Hong YJ, Nowak MS, Zanon-Moreno V 
S- Editor: Song XX    L- Editor: Roemmele A 
E- Editor: Lu YJ
37 November 12, 2013|Volume 3|Issue 4|WJO|www.wjgnet.com
Alkozi HA et al . Melatonin and analogues reduce IOP
10.1016/j.pharmthera.2006.11.003]
10 Pintor J, Martin L, Pelaez T, Hoyle CH, Peral A. Involvement 
of melatonin MT(3) receptors in the regulation of intraocular 
pressure in rabbits. Eur J Pharmacol 2001; 416: 251-254 [PMID: 
11290376 DOI: 10.1016/S0014-2999(01)00864-0]
11 Pintor J, Peláez T, Hoyle CH, Peral A. Ocular hypotensive 
effects of melatonin receptor agonists in the rabbit: further 
evidence for an MT3 receptor. Br J Pharmacol 2003; 138: 
831-836 [PMID: 12642384 DOI: 10.1038/sj.bjp.0705118]
12 Alarma-Estrany P, Crooke A, Mediero A, Peláez T, Pintor 
J. Sympathetic nervous system modulates the ocular hypo-
tensive action of MT2-melatonin receptors in normotensive 
rabbits. J Pineal Res 2008; 45: 468-475 [PMID: 18673419 DOI: 
10.1111/j.1600-079X.2008.00618.x]
13 Dubocovich ML. Pharmacology and function of melatonin 
receptors. FASEB J 1988; 2: 2765-2773 [PMID: 2842214]
14 Dubocovich ML, Markowska M. Functional MT1 and MT2 
melatonin receptors in mammals. Endocrine 2005; 27: 101-110 
[PMID: 16217123 DOI: 10.1385/ENDO: ]
15 Boutin JA, Saunier C, Guenin SP, Berger S, Moulharat N, 
Gohier A, Delagrange P, Cogé F, Ferry G. Studies of the 
melatonin binding site location onto quinone reductase 2 by 
directed mutagenesis. Arch Biochem Biophys 2008; 477: 12-19 
[PMID: 18502195 DOI: 10.1016/j.abb.2008.04.040]
16 Mailliet F, Ferry G, Vella F, Berger S, Cogé F, Chomarat 
P, Mallet C, Guénin SP, Guillaumet G, Viaud-Massuard 
MC, Yous S, Delagrange P, Boutin JA. Characterization of 
the melatoninergic MT3 binding site on the NRH: quinone 
oxidoreductase 2 enzyme. Biochem Pharmacol 2005; 71: 74-88 
[PMID: 16293234 DOI: 10.1016/j.bcp.2005.09.030]
17 Tan DX, Manchester LC, Terron MP, Flores LJ, Tamura H, Reit-
er RJ. Melatonin as a naturally occurring co-substrate of quinone 
reductase-2, the putative MT3 melatonin membrane receptor: 
hypothesis and significance. J Pineal Res 2007; 43: 317-320 [PMID: 
17910598 DOI: 10.1111/j.1600-079X.2007.00513.x]
18 Alarma-Estrany P, Crooke A, Pintor J. 5-MCA-NAT does not 
act through NQO2 to reduce intraocular pressure in New-
Zealand white rabbit. J Pineal Res 2009; 47: 201-209 [PMID: 
19627460 DOI: 10.1111/j.1600-079X.2009.00702.x]
TRPV4 activation triggers the release of melatonin from human
non-pigmented ciliary epithelial cells
Hanan Awad Alkozi, Jesús Pintor*
Department of Biochemistry, Faculty of Optometry, Universidad Complutense de Madrid, C/ Arcos de Jal!on 118, E281037 Madrid, Spain
a r t i c l e i n f o
Article history:
Received 11 December 2014
Received in revised form
10 March 2015
Accepted in revised form 27 April 2015
Available online 29 April 2015
Keywords:
Aqueous humour
GSK1016790A
Melatonin
RN 1734
TRPV4
a b s t r a c t
Melatonin is a neurohormone mainly produced in the pineal gland; nevertheless, various ocular struc-
tures such as the ciliary body, lens and the retina produce it. One of the roles of melatonin in the eye is
the modulation of intraocular pressure, although little is known about the mechanisms that causes its
presence in the aqueous humour. TRPV4 is a membrane channel which is activated by both physical and
chemical stimuli. Therefore, this channel is sensitive to osmotic and hydrostatic pressure. As a conse-
quence, TRPV4 results as an interesting candidate to study the relation between the activation of the
TRPV4 channel and the production of melatonin. In this sense we have studied the role of the TRPV4
agonist GSK1016790A to modulate the production of melatonin in a cell line derived from human non-
pigmented ciliary epithelial cells. The stimulation of the TRPV4 produced an increase in the extracellular
melatonin levels changing from 8.5 ± 0.6 nM/well/30 min (control) to 23.3 ± 2.1 nM/well/30 min after
10 nM GSK1016790A application, this action being blocked by the selective antagonist RN 1734. The
activation of the TRPV4 by GSK1016790A permitted to observe a melatonin increase which was
concentration-dependent, and provided a pD2 value of !8.5 ± 0.1 (EC50 of 3.0 nM). In conclusion, the
activation of the TRPV4 present in human non-pigmented ciliary epithelial cells can modulate the
presence of extracellular melatonin, this being of relevance since this substance controls the dynamics of
the aqueous humour.
© 2015 Elsevier Ltd. All rights reserved.
Melatonin is a neurohormone produced by the pineal gland, but
also by many ocular structures. These include the ciliary body, lens,
the harderian glands and also the retina (Alarma-Estrany and
Pintor, 2007). As a consequence of its synthesis, it has been
possible to measure melatonin in the aqueous humour of various
species including human beings (Rohde et al., 1985). The role of
melatonin in the anterior pole has been related to the control of the
aqueous humour formation (Osborne, 1994) and therefore with the
regulation of intraocular pressure (IOP) (Pintor et al., 2001; Samples
et al., 1988).
Although it is known that melatonin is present in the aqueous
humour, little is known about what substances and mechanisms
may stimulate its presence in the aqueous humour. An interesting
candidate is the channel TRPV4. It is a membrane protein that be-
longs to the transient receptors, which is a non-selective cation
channel permeable to Ca2þ. In this sense, the Ca2þ inﬂux triggered
after TRPV4 stimulation is probably able to induce the release of
melatonin as it occurs in other cells such as pinealocytes or retinal
cells, although recently it has been demonstrated that melatonin
could be transported bymeans of glucose transporters (Hevia et al.,
2015).
TRPV4 is a channel that participates in the transduction of both
physical (osmotic, mechanical, and heat) and chemical (endoge-
nous, plant-derived, and synthetic ligands) stimuli (Garcia-Elias
et al., 2014). Since this channel is sensitive to mechanical as well
as osmotic pressure, it results of interest to see whether there is a
relation between the activation of the TRPV4 channel and the
production of melatonin. In this sense we have studied the role of
the TRPV4 selective agonist GSK1016790A (Vincent et al., 2009) to
modulate the production of melatonin in non-pigmented human
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ABSTRACT.
Purpose: To study the levels of melatonin in the aqueous humour of normoten-
sive and hypertensive intraocular pressure (IOP) patients and to compare them
to an animal model of glaucoma.
Methods: A total of 37 eyes of 37 patients who underwent cataract surgery were
included in the study and were divided into normotensive patients, with IOP
below 21 mmHg (n = 23), and hypertensive patients, with IOP > 21 mmHg
(n = 14). Glaucomatous DBA/2J (n = 6) and control C57BL/6J (n = 6) mice
presenting 3 and 12 months of age for each strain were also used. Human and
mice aqueous humours were aspirated using a 30-gauge Rycroft cannula on a
tuberculin syringe and further processed to quantify melatonin by high-
performance liquid chromatography analysis.
Results: Melatonin levels in normotensive patients (IOP below 21 mmHg)
presented values as medians (first quartile; third quartile) of 14.62
(5.38;37.99) ng/ml (n = 23), while hypertensive patients (IOP above 21 mmHg)
showed melatonin concentrations of 46.63 (10.28; 167.28) ng/ml (n = 14;
p < 0.039). Glaucoma mice presented melatonin values of 0.37 (0.34; 0.59) ng/
ml (at 3 months of age, before the pathology starts), which increased to 1.55
(0.94; 1.88) ng/ml (at 12 months of age, when the pathology is fully developed
and IOP is maximum; n = 6, p < 0.001). Control mice did not significantly
modified melatonin concentrations between 3 and 12 months of age.
Conclusion: Patients with high IOP present increased concentrations of
melatonin in their aqueous humour compared to normotensive patients. This
has been confirmed in a glaucomatous animal model in which it has been possible
to see a correlation between the development of the pathology, with an increase
in IOP, and a concomitant elevation of melatonin in the aqueous humour.
Key words: aqueous humour – glaucoma – high-performance liquid chromatography –
humans – melatonin – mice
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Introduction
Melatonin is an indoleamine that has
been classically considered as being
only produced by the pineal gland;
nevertheless, this neurohormone is also
synthesized and released by many
ocular structures including the retina,
ciliary body, the lens and the harderian
glands (Alarma-Estrany & Pintor
2007). Although its implications in
ocular physiology is still under investi-
gation, it seems to be clear that this
substance is involved in relevant pro-
cesses such as the control of the aque-
ous humour dynamics (Osborne 1994).
In this sense, melatonin levels are
normally elevated during the night
(Wurtman et al. 1963), which is the
moment in which intraocular pressure
(IOP) is lower. This connection
between melatonin levels and IOP has
been demonstrated on patients that
underwent cataract surgery who were
treated with melatonin to reduce their
IOP (Ismail & Mowafi 2009). There-
fore, this control of IOP carried out by
melatonin has suggested the use of this
compound and its analogues for the
treatment of ocular hypertension and
glaucoma (Mediero et al. 2009). In this
sense, studies performed in animal
models and more recently in humans
suggest that melatonin or any of its
analogues can significantly reduce IOP
in normotensive, in hypertensive ani-
mals (Martinez-Aguila et al. 2013), and
what is more important, in ocular
hypertensive human beings (Pescoso-
lido et al. 2015). All the actions per-
formed by melatonin and analogues to
reduce IOP are mediated by membrane
receptors termed MT1, MT2 and MT3
melatonin receptors present mainly in
the ciliary body (Alarma-Estrany &
Pintor 2007). After activation of such
receptors, mostly MT2 and MT3
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melatonin receptors, IOP decreases
providing normal values of pressure
within the eye and therefore avoiding
possible ocular complications (Pintor
et al. 2001; Alarma-Estrany et al.
2008). The mechanism by which mela-
tonin produces a reduction of IOP in
the ciliary body is mostly due to a
modification in the intracellular levels
of cAMP (Huete-Toral et al. 2015).
Melatonin and its analogue 5-MCA-
NAT activate MT2 and MT3 melatonin
receptors that stimulate adenylate
cyclase with the concomitant activation
of PKA. This activation produces an
inhibition in the eﬄux of chloride
(Huete-Toral et al. 2015), the main
ion governing the movement of water
from the ciliary epithelium to the
posterior chamber (Civan 1998).
Therefore, the reduction in the chloride
eﬄux causes a reduction in aqueous
humour formation (Civan & Mack-
night 2004).
Melatonin is physiologically present
in the aqueous humour, together with
other relevant molecules such as din-
ucleotides (Castany et al. 2011) or
more recently vascular endothelial
growth factor (VEGF) (Wang et al.
2016); the last two elevated in the
aqueous humour of glaucoma
patients. Related to melatonin, one
interesting question is to understand
where and how this substance is
produced, and what factors can mod-
ulate its presence in the aqueous
humour. Recently, a work published
by Alkozi and Pintor has demon-
strated that human non-pigmented
ciliary epithelial cells produce and
release more melatonin when the
TRPV4 channel, present in the mem-
branes of these cells, is activated
(Alkozi & Pintor 2015). This channel
is sensitive, among several stimuli, to
pressure (Garcia-Elias et al. 2014),
and this indicates that an elevation
in IOP can modify the melatonin that
is released to the aqueous humour
(Alkozi & Pintor 2015). This increase
can activate melatonin receptors that
will reduce IOP (Pintor et al. 2001), as
commented above.
Although a connection between
intraocular pressure and melatonin
seems to be possible, there are not so
many works measuring the levels of
this substance in normo- and/or hyper-
tensive patients. Moreover, some
groups have obtained variable and
non-conclusive results indicating that
melatonin concentrations can vary
from the pg/ml to the ng/ml range
(Martin et al. 1992; Chiquet et al.
2006). Under this high variability in
the quantification of melatonin in
human aqueous humour, in the present
experimental work, we have studied the
relationship between melatonin con-
centration in aqueous humour and
IOP in non-glaucomatous patients,
dividing them in those which present
IOP higher than 21 mmHg, and those
whose pressure is below this value.
Also, trying to clarify what happens in
humans, we have performed the same
study in a glaucoma animal model, and
altogether, we demonstrate that there is
an increase in melatonin levels when
intraocular pressure is abnormally ele-
vated.
Patients and Methods
Subject recruitment and aqueous humour
collection
From a sample of 265 patients who
underwent cataract surgery, all hyper-
tensive patients (n = 14), with IOP
>21 mmHg (Tavares et al. 2006) and
23 normotensive patients, with IOP
below 21 mmHg and randomly
selected, were included in the study.
The study protocol was approved by
the clinical research Ethics Committee
of Instituto Balear de Oftalmolog!ıa,
Palma de Mallorca, Spain. Signed
informed consent to the aqueous
humour contribution was obtained
from all patients in accordance with
the Declaration of Helsinki.
Patients with history of primary
acute angle-closure attack, chronic
angle-closure glaucoma, any treatment
for glaucoma or active inflammatory
ocular disease were excluded. Glau-
coma was defined as high intraocular
pressure associated with optic nerve
glaucomatous characteristics consis-
tent with the visual field defect. The
IOP measurements were taken before
the surgery by means of a Perkins
tonometer after instillation of one
drop of double anaesthetic Colircus!ı!
that contains tetracaine 0.1% and
oxybuprocaine 0.4% (Colircus!ı, Alcon
Cus!ı SA, Barcelona, Spain). This
value should be representative of at
least three other previous visits with
non-statistically diﬀerent IOP values
from those presented in the manu-
script. Patients with variations among
visits were not considered in this
study.
Each aqueous humour sample was
taken in the first step of the cataract
surgery with anaesthetic drops (lido-
caine 2%). Through standard clear
corneal microincision (mics 2.2 mm)
under surgical microscope vision, aque-
ous humour was aspirated using a 30-
gauge Rycroft cannula on a tuberculin
syringe (1 ml). Aqueous humour (0.1–
0.2 ml) was collected, immediately
transferred to an Eppendorf and stored
at !20°C and kept protected from light
until the chromatographic analysis was
performed (Castany et al. 2011).
Glaucomatous and non-glaucomatous mice
Aqueous humours were collected from
female C57BL/6J (control, n = 6) and
DBA/2J (glaucomatous, n = 6) mice
obtained from the European distribu-
tor of Jackson Laboratories Mice
(Charles Rivers Laboratories, Barce-
lona, Spain). All animal maintenance
and experimental procedures followed
Spanish and European guidelines for
animal care in the laboratory and
animal research (Guide for the Care
and Use of Laboratory Animals) and
the ARVO Statement for the Use of
Animals in Ophthalmic and Vision
Research. Mice were housed (1–4 mice
per cage) in temperature and light-
controlled rooms maintained according
to a 12-hr light/dark cycle; all animals
were fed ad libitum. DBA/2J and
C57BL/6J mice were studied at 3 and
12 months of age.
Aqueous humour collection was
performed after anesthetizing the mice
with an intraperitoneal (i.p.) injection
of a mixture of ketamine (95 mg/kg,
Imalgene 1000, Merial, Barcelona,
Spain) and xylazine (5 mg/kg,
Romp!un, Bayer, S.A., Barcelona,
Spain). Aqueous humour was pro-
cessed in the same way as with the
human samples. Just before aqueous
humour collection, IOP was measured
by means of a TonoVet! contact
tonometer supplied by Tiolat Oy (Van-
taa, Finland). The application of this
tonometer does not require the use of
any anaesthetic.
High-performance liquid chromatography
(HPLC) analysis
Samples from the aqueous humour
were processed and analysed following
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the protocol described elsewhere
(Alkozi & Pintor 2015). Briefly, the
tubes containing the aqueous humour
were heated in a 98°C bath for 2 min
and transferred to ice 10 min, to pre-
cipitate the proteins. Centrifugation of
the tubes at 22 000 g for 10 min at 4°C
was then performed to pellet the pro-
teins. Melatonin concentrations were
measured by HPLC. The chromato-
graphic system consisted of a Kroma-
phase C18 column 5.0 lm (25 cm in
length, 0.4 cm inner diameter; Schar-
lau, Madrid, Spain), a 1515 Isocratic
HPLC pump, a 2487 dual absorbance
detector and a Rheodyne injector, all
managed by the software Breeze from
Waters (Milford, MA, USA). The sys-
tem was equilibrated overnight with
40% methanol and 60% H2O. Mea-
surements were performed at a flow
rate of 0.8 ml/min fixing the detector at
a wavelength of 244 nm. Quantifica-
tion of melatonin was performed by
comparing the samples with external
standards provided by Sigma (St Louis,
MO. USA).
Statistical analysis
The presented data were analysed using
the statistical software SPSS 22.0 (SPSS,
Inc., Chicago, IL, USA). Normal dis-
tribution of melatonin concentration
was assessed by the Shapiro–Wilk nor-
mality test, resulting in no normality
due to the heterogeneity of the patients.
Then, its values are presented as the
median and quartiles (first quartile;
third quartile) of the experiments per-
formed. The rest of variables are
showed as means ! SD. Therefore,
diﬀerences between before surgery and
after surgery were estimated by non-
parametric test of Wilcoxon for paired
samples. In the animal experiment, the
diﬀerences were also evaluated by Wil-
coxon for paired samples, comparing
between ages of 3 and 12 months. For
correlations, Pearson bivariate regres-
sion was used. p < 0.05 was considered
statistically significant.
Results
Melatonin levels in normotensive and
hypertensive patients’ aqueous humour
All the patients, who underwent catar-
act surgery, not being treated or diag-
nosed of glaucoma were distributed in
two groups. The normotensive group
consisted of all those patients with IOP
values below 21 mmHg, and the hyper-
tensive was formed by those with IOP
values above 21 mmHg. Demographic
details of recruited patients are shown
in Table 1.
After collecting and processing aque-
ous humour samples, the chromato-
graphic analysis clearly showed that
those patients exhibiting IOP higher
than 21 mmHg presented concomi-
tantly higher concentrations of mela-
tonin (Fig. 1, left panel). While
normotensive patients (IOP below
21 mmHg) presented values of 14.62
(5.38; 37.99) ng/ml (n = 23), hyperten-
sive patients showed melatonin concen-
trations of 46.63 (10.28; 167.28) ng/ml
(n = 14), these values being statistically
diﬀerent (p < 0.002). Moreover, a sig-
nificant correlation was found between
the melatonin concentration and IOP
presurgery (p = 0.03), thePearson’s cor-
relation coeﬃcient being 0.441 (Fig. 2).
Melatonin levels in control and
glaucomatous mice’s aqueous humour
The levels of melatonin were also stud-
ied in glaucomatous (DBA2/J) and non-
glaucomatous (C57) mice strains. The
IOPvalues obtained in theDBA2/Jwere
15.05 ! 0.87 mmHg for 3 months and
30.41 ! 1.35 mmHg for 12 months of
age, respectively. For C57 model, the
IOP at 3 months was 11.86 !
0.69 mmHg and 11.13 ! 1.21 mmHg
for 12 months of age.As it can be seen in
Fig. 3, the development of the glauco-
matous pathology in the DBA/2J mice
modified melatonin concentration, its
values changing from 0.37 (0.34;
0.59) ng/ml (at 3 months of age, before
the pathology starts) to 1.55 (0.94;
1.88) ng/ml (at 12 months of age, when
the pathology is fully established and
IOP is maximum; n = 6, p < 0.001).
On the contrary, the levels of mela-
tonin in the control mice (C57), anal-
ysed at the same ages, did not bring
statistically significant diﬀerences,
being 0.47 (0.42; 0.53) ng/ml and 0.42
(0.32; 0.56) ng/ml at 3 and 12 months,
respectively (n = 6, p = 0.418). Mela-
tonin concentration and IOP showed a
strong correlation in mice, the Pear-
son’s correlation coeﬃcient being 0.851
(p < 0.001) for all the animals under
study (Fig. 4).
Discussion
The present experimental work
describes the changes observed in mela-
tonin concentrations in patients pre-
senting normal and high IOP.
According to the present results, those
patients presenting high IOP had also
high melatonin concentrations com-
pared to the melatonin values measured
in normotensive patients, this diﬀerence
being almost threefold. A similar beha-
viour has been observed in a glaucoma-
tous animal model. In the mouse model,
when the pathology has been fully
developed and the pressure is the high-
est (12 months of age), melatonin con-
centrations were also threefold.
Altogether these results indicate that
there is a close relationship between the
levels of melatonin in the aqueous
humour and the IOP values, both in
human and in experimental models.
The use of an animal model such as
the DBA/2J helps to understand the
changes in melatonin levels in the aque-
ous humour before andwhen the pathol-
ogy is established. This is very valuable
due to the impossibility to collect the
aqueous humour of patients before they
develop ocular hypertension.
In the present work, the values of
melatonin found in the aqueous
humour of hypertensive patients, near
50 ng/ml compared to 15 ng/ml in
normotensive, represent an increase of
threefold. This rise is higher than the
increase that can be observed in humans
for melatonin levels in other fluids such
as tears. Human tears contain mela-
tonin that changes in a circadian man-
ner, but when comparing melatonin
Table 1. Demographic characteristics of participants in the study.
Parameter
Non-glaucomatous patients
Total <21 mmHg >21 mmHg
Patients 37 23 14
Mean age (years) ! SD 63.41 ! 13.12 62.13 ! 13.97 66.36 ! 10.81
Age range (years) [24, 84] [35, 82] [35,84]
Gender (male/female) [21, 16] [15, 8] [6, 8]
IOP presurgery (mmHg) 17.70 ! 3.80 15.48 ! 0.48 22.25 ! 0.32
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concentrations during the day, with the
amount during the night, the values in
darkness are 1.6-fold higher than under
light conditions (Carracedo et al. 2016).
This is clearly suggesting that the mela-
tonin concentration in the hypertensive
patients is not only governed by circa-
dian aspects but it may be suggested as
also related to the fact of the pressure
being abnormally high.
The connection between melatonin
and pressure may rely on the existence
of a pressure sensor, the TRPV4 chan-
nel, that after activation triggers the
release of melatonin in the aqueous
humour according to the results already
observed in human non-pigmented cil-
iary epithelial cells (Alkozi & Pintor
2015). The activation of the TRPV4
channel produces changes in the extra-
cellular levels of melatonin, but this
eﬀect requires a continuous stimulation
of this channel. This condition is typical
in glaucoma patients before any treat-
ment starts or in those whose treatments
are not totally eﬀective. Therefore,
finding changes in the aqueous humour
of ocular hypertensive patients could be
a natural process to reduce IOP, as
melatonin is able to reduce IOP as
previously described (Crooke et al.
2012). The question that arises is why,
if the levels of melatonin are higher, IOP
does not return to normal values, as one
should expect. This is a real challenge to
fully understand the role ofmelatonin in
the glaucoma pathology, and although
it deserves further research, some ideas
can be suggested. If melatonin levels are
high and the IOP does not come down,
it might be the case that melatonin
receptors are not fully active or their
number has significantly reduced their
expression with the pathology. The
existence of age-related and region-
specific changes in the expression of
the melatonin receptor subtypes has
already been described in animalmodels
(Guo et al. 2015). It could be the case
that these changes in expression reduc-
ing the presence of melatonin receptors
may happen in some humans, and
therefore, the increased levels of mela-
tonin are not capable to reduce IOP as
one could be expecting. Also, mela-
tonin, besides its function as synchro-
nizer of the biological clock, is a
powerful free radical scavenger and
wide-spectrum antioxidant, and this
role may also appear as the oxidative
damage represents a fundamental step
in the pathogenesis of glaucoma (Sacca
& Izzotti 2014). Therefore, the increase
in melatonin levels could also reflect a
mechanism of protection carried out in
the eye to prevent oxidative damage of
high eﬃciency tissues such as the ciliary
body or the trabecular meshwork
(Sacca et al. 2016). Moreover, if similar
changes regardingmelatonin levels were
occurring in the retina, this molecule
would help to ameliorate the glaucoma-
tous pathology by acting on retinal
glutamate clearance, GABA concentra-
tions, NO synthesis and retinal redox
status (Belforte et al. 2010). More
experiments are necessary to fully con-
firm all these possibilities.
This work has some limitations as it
has focused on patients suﬀering of
ocular hypertension, but it would be
worthy to extend it to those suﬀering
from diagnosed glaucoma. Moreover,
it would be of great interest to see
whether the treatment of such patients
with antiglaucomatous medicines may
modify aqueous humour melatonin
levels in those patients as it happens
with other aqueous humour compo-
nents in experimental animal models
(Reyes et al. 1998). This seems to be
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Fig. 1. Presence of melatonin in the aqueous humour of glaucoma patients. (A) representative
high-performance liquid chromatography elution profiles of human aqueous humour samples of
patients with IOP above 21 mmHg and below 21 mmHg, following the protocol described in
methods. (B) bar plot showing the concentrations of melatonin in the two populations of patients.
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Fig. 3. Melatonin concentrations in the aque-
ous humour of control (normotensive) and
glaucomatous mice. The DBA glaucomatous
mice presented a marked increase in their
aqueous humour melatonin concentrations
when comparing 3 months of age, before the
pathology starts and at 12 month of age, when
the glaucomatous pathology has been fully
established and the pressure in maximal. On
the contrary, control mice, C57, did not change
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*p < 0.001 (Wilcoxon for paired samples).
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interesting because it will help to
understand the connection of antiglau-
comatous drugs with melatonin and,
probably by extension, it will clarify
the best moment of the day to apply
glaucoma medication (Bron 2004).
In summary, patients with high IOP
present higher concentrations of mela-
tonin in their aqueous humours com-
pared to normotensive patients. This
elevation in IOP may trigger the acti-
vation of a TRPV4 channel, this being
the reason of melatonin rise. The lack
of eﬀect of the melatonin present in the
aqueous humour of hypertensive
patients is suggesting an imbalance
between the neurohormone and the
receptors that should reduce IOP.
References
Alarma-Estrany P & Pintor J (2007): Mela-
tonin receptors in the eye: location, second
messengers and role in ocular physiology.
Pharmacol Ther 113: 507–522.
Alarma-Estrany P, Crooke A, Mediero A,
Pelaez T & Pintor J (2008): Sympathetic
nervous system modulates the ocular
hypotensive action of MT2-melatonin recep-
tors in normotensive rabbits. J Pineal Res
45: 468–475.
Alkozi HA & Pintor J (2015): TRPV4 activa-
tion triggers the release of melatonin from
human non-pigmented ciliary epithelial cells.
Exp Eye Res 136: 34–37.
Belforte NA, Moreno MC, de Zavalia N,
Sande PH, Chianelli MS, Keller Sarmiento
MI & Rosenstein RE (2010): Melatonin: a
novel neuroprotectant for the treatment of
glaucoma. J Pineal Res 48: 353–364.
Bron A (2004): [The circadian eﬀects of
antiglaucomatous drugs]. J Fr Ophtalmol
27 Spec No 2: 2S33–2S38.
Carracedo G, Carpena C, Concepcion P et al.
(2016): Presence of melatonin in human
tears. J Optom 9: doi:10.1016/j.optom.
2016.03.00. [Epub ahead of print].
Castany M, Jordi I, Catala J, Gual A, Morales
M, Gasull X & Pintor J (2011): Glaucoma
patients present increased levels of diadeno-
sine tetraphosphate, Ap(4)A, in the aqueous
humour. Exp Eye Res 92: 221–226.
Chiquet C, Claustrat B, Thuret G, Brun J,
Cooper HM & Denis P (2006): Melatonin
concentrations in aqueous humor of glau-
coma patients. Am J Ophthalmol 142: 325–
327.
Civan MM (1998): Transport components of
net secretion of the aqueous humor and their
integrated regulation. Curr Top Membr 45:
1–24.
Civan MM & Macknight AD (2004): The ins
and outs of aqueous humour secretion. Exp
Eye Res 78: 625–631.
Crooke A, Colligris B & Pintor J (2012):
Update in glaucoma medicinal chemistry:
emerging evidence for the importance of
melatonin analogues. Curr Med Chem 19:
3508–3522.
Garcia-Elias A, Mrkonjic S, Jung C, Pardo-
Pastor C, Vicente R & Valverde MA (2014):
The TRPV4 channel. Handb Exp Pharma-
col 222: 293–319.
Guo Q, Dong Y, Cao J, Wang Z, Zhang Z &
Chen Y (2015): Developmental changes of
melatonin receptor expression in the spleen
of the chicken, Gallus domesticus. Acta
Histochem 117: 559–565.
Huete-Toral F, Crooke A, Mart!ınez-!Aguila A
& Pintor J (2015): Melatonin receptors
trigger cAMP production and inhibit chlo-
ride movements in nonpigmented ciliary
epithelial cells. J Pharmacol Exp Ther 352:
119–128.
Ismail SA & Mowafi HA (2009): Melatonin
provides anxiolysis, enhances analgesia,
decreases intraocular pressure, and pro-
motes better operating conditions during
cataract surgery under topical anesthesia.
Anest Analg 108: 1146–1151.
Martin XD, Malina HZ, Brennan MC, Hen-
drickson PH & Lichter PR (1992): The
ciliary body–the third organ found to syn-
thesize indoleamines in humans. Eur J
Ophthalmol 2: 67–72.
Martinez-Aguila A, Fonseca B, Bergua A &
Pintor J (2013): Melatonin analogue agome-
latine reduces rabbit’s intraocular pressure
in normotensive and hypertensive condi-
tions. Eur J Pharmacol 701: 213–217.
Mediero A, Alarma-Estrany P & Pintor J
(2009): New treatments for ocular hyperten-
sion. Auton Neurosci 147: 14–19.
Osborne NN (1994): Serotonin and melatonin
in the iris/ciliary processes and their involve-
ment in intraocular pressure. Acta Neuro-
biol Exp 54(Suppl): 57–64.
Pescosolido N, Gatto V, Stefanucci A &
Rusciano D (2015): Oral treatment with the
melatonin agonist agomelatine lowers the
intraocular pressure of glaucoma patients.
Ophthalmic Physiol Opt 35: 201–205.
Pintor J, Martin L, Pelaez T, Hoyle CH &
Peral A (2001): Involvement of melatonin
MT(3) receptors in the regulation of intraoc-
ular pressure in rabbits. Eur J Pharmacol
416: 251–254.
Reyes MR, Cheng Q, Chuang PY & Lee DA
(1998): The eﬀect of antiglaucoma drugs on
rabbit aqueous humor proteins determined
by gel electrophoresis. J Ocul Pharmacol
Ther 14: 229–237.
Sacca SC & Izzotti A (2014): Focus on
molecular events in the anterior chamber
leading to glaucoma. Cell Mol Life Sci 71:
2197–2218.
Sacca SC, Gandolfi S, Bagnis A, Manni G,
Damonte G, Traverso CE & Izzotti A
(2016): The outflow pathway: a tissue with
morphological and functional unity. J Cell
Physiol 231: 1876–1893.
Tavares IM, Medeiros FA & Weinreb RN
(2006): Inconsistency of the published defi-
nition of ocular hypertension. J Glaucoma
15: 529–533.
Wang J, Gao X, Du S et al. (2016): Aqueous
humor concentration of VEGF and retinal
oxygen saturation after unilateral acute primary
angle closure. Acta Ophthalmol 94: 380–385.
Wurtman RJ, Axelrod J & Phillips LS (1963):
Melatonin synthesis in the pineal gland:
control by light. Science 142: 1071–1073.
Received on May 2nd, 2016.
Accepted on July 31st, 2016.
Correspondence:
Jes!us Pintor, PhD
Department of Biochemistry and Molecular
Biology IV
Faculty of Optics and Optometry
Universidad Complutense de Madrid
C/ Arcos de Jal!on, 118
E-28037, Madrid
Spain
Tel: +34 913946859
Fax: +34 913946885
Email: jpintor@ucm.es
This work has been supported by the research
grants SAF2013-44416-R, RETICS RD12/0034/
0003 and Universidad Complutense PR1/07-
14890. HA is a fellowship holder of the Saudi
Arabia Government. AMA and BF are fellowship
holders of UCM.
y = 14.178x + 7.2274
R2 = 0.7235
0
5
10
15
20
25
30
35
40
0 0.5 1 1.5 2 2.5
Melatonin concentra!on (ng/ml)
IO
P 
(m
m
H
g)
Fig. 4. Relationship between melatonin concentration (ng/ml) in aqueous humour of glaucoma-
tous (DBA2/J) and non-glaucomatous (C57) mice strains and the IOP measured in all times of
experiment. Pearson correlation was statistically significant (p < 0.001; r = 0.851).
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Abstract: Melatonin is a molecule which has gained a great deal of interest in many areas of science;
its synthesis was classically known to be in the pineal gland. However, many organs synthesize
melatonin, such as several ocular structures. Melatonin is known to participate in many functions
apart from its main action regulating the circadian rhythm. It is synthesized from serotonin in two
steps, with a rate-limiting step carried out by arylalkymine N-acetyltransferase (AANAT). In this
report, the role of TRPV4 channel present in human ciliary body epithelial cells in AANAT production
was studied. Several experiments were undertaken to verify the adequate time to reach the maximal
effect by using the TRPV4 agonist GSK1016790A, together with a dose–response study. An increase
of 2.4 folds in AANAT was seen after 18 h of incubation with 10 nM of GSK1016790A (p < 0.001,
n = 6). This increment was verified by antagonist assays. In summary, AANAT levels and therefore
melatonin synthesis change after TRPV4 channel stimulation. Using this cell model together with
human ciliary body tissue it is possible to suggest that AANAT plays an important role in pathologies
related to intraocular pressure.
Keywords: AANAT; ciliary body; eye; melatonin; TRPV4
1. Introduction
Melatonin is an indolamine synthesized by several ocular structures apart from its classical
production in the pineal gland. It is originally known to regulate the circadian rhythm, however, many
studies have indicated further important functions of melatonin, such as its role as an antioxidant,
antidepressant, suppressing carcinogenesis, among other functions [1–4]. Melatonin presence in the
eye is fundamental since it participates in numerous functions such as controlling tear secretion [5],
accelerating corneal wound healing [6], controlling intraocular pressure (IOP) and regulating retinal
physiology [7,8]. All these actions are mediated by melatonin membrane receptors whose presences
have previously been described in the eye [9].
Melatonin is well known for following a circadian rhythm, which has higher levels during
the night and lower levels at daytime [10]. This pattern matches with the changes observed in IOP,
as when melatonin levels rise at night, intraocular pressure comes down [11]. This observation opened
a window of investigation to understand the link between IOP and melatonin.
One of the leading causes of irreversible vision loss is glaucoma, a multifactorial optic neuropathy
that results in progressive blindness. The only risk factor that can be controlled in glaucoma is the
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elevated intraocular pressure. Studies have shown that melatonin and its analogs are able to bring
down IOP by exogenous consumption [12,13]. Surprisingly, a recent study analyzing melatonin levels
in human aqueous humors has demonstrated that those patients with elevated intraocular pressure
present higher melatonin concentrations than healthy subjects [14,15]. These patients should have
lower IOP, nonetheless this does not occur. The reasons that cause it are not yet understood.
Melatonin is synthesized from serotonin through two steps. In the first, serotonin is transformed to
N-acetylserotonin (NAS) through acetylation by an enzyme called arylalkymine N-acetyltransferase
(AANAT). This enzyme catalyzes the transfer of acetyl group from acetyl-CoA to serotonin. In the second
step, to convert NAS to melatonin, the second enzyme called hydroxyindole-O-methyltransferase
(HIOMT) is responsible for the O-methylation [16,17].
The first enzyme in the melatonin synthesis, AANAT, seems to be the key enzyme regulating
melatonin synthesis. Studies have shown that AANAT fluctuate following a circadian rhythm [18–20],
while HIOMT does not seem to change [21]. In fact, this is critical given that melatonin changes
throughout the day; however, it is possible that AANAT is regulated by other environmental factors
such as hormones, food or drug intake [22–24]. AANAT seems to have two ways of regulation. One is
a quick process to protect the enzyme against degradation that happens through its phosphorylation.
This regulatory mechanism also depends on a protein termed 14-3-3 that binds to AANAT and which
has been linked to the activation of PKA after cAMP generation [25]. The second regulation mechanism
is a long-term one, which is also dependent on cAMP/protein kinase A pathway but which activates
gene expression. In rodents, transcriptional activation of aanat gene is the classical mechanism to
induce melatonin biosynthesis. It involves PKA-dependent phosphorylation of the transcription factor
cyclic AMP response element binding protein (CREB) [26] and binding of phosphorylated CREB in the
promoter region of aanat gene.
Very recently, a transient receptor potential vanilloid 4 (TRPV4), a non-selective cation channel
that regulates osmo-, thermo-, mechanosensation was said to play an important role in the ciliary
body epithelium cells [27,28]. This channel activation has led to an increment of the extracellular
level of melatonin [29]. These findings are pharmacologically relevant in the search of new therapies
for glaucoma because melatonin has the ability to lower IOP as previously commented. In this
report, we describe the effect of TRPV4 stimulation on the protein levels of AANAT, one of the
enzymes responsible for melatonin synthesis, as well as its changes in the ciliary body of normal and
glaucomatous patients.
2. Results
2.1. Presence of AANAT in the Human Ciliary Body
Human eyes were first treated for immunflourescent labeling, and the search for possible changes
in the AANAT labeling in the ciliary body was undertaken by analyzing samples of ciliary body tissue
of healthy subjects and comparing them to glaucomatous donors. Ciliary body epithelium presented
a positive labeling in both normal and glaucomatous human samples (Figure 1).
In particular, a stronger fluorescent labeling was observed in the glaucomatous patient sections
(Figure 1B n = 4) when compared to normal samples (Figure 1A, n = 2). This elevation in the expression
of AANAT, in the case of the glaucomatous donors, was “in vitro” established using human ciliary
body epithelial cells which were stimulated by the TRPV4 agonist GSK1016790A, as previously
described [29]. The results obtained with the treated cells were consistent with the human ciliary body
sections obtained from the donors. In this sense, the presence of AANAT was detected in both control
and treated cells (Figure 2), the labeling being stronger in the GSK-treated cells (Figure 2B), than in
the untreated cells (Figure 2A). Positive and negative controls were also performed for AANAT with
human lens epithelial cells and human chondrocytes, respectively (Figure 2C) [30].
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Figure 1. Apparent changes of AANAT in human ciliary body tissue: (A) Representative pictures of 
human ciliary processes (n = 2) of a non-glaucomatous individual (n = 4). From left to right, 
Differential Interference Contrast (DIC) image, nuclei (in red, propidium iodine), AANAT (in green) 
and merge image; (B) Representative image of human ciliary processes of a glaucomatous individual. 
From left to right, DIC image, nuclei (in red, propidium iodine), AANAT (in green) and merge image.  
 
Figure 2. Presence and changes of AANAT in human ciliary body epithelial cells: (A) Untreated 
human ciliary body epithelial cells showing the expression of AANAT (in green) and the nuclei (in 
red); (B) Human ciliary epithelial cells after treatment with 10 nM GSK1016790A for 18 h. AANAT 
expression can be seen in green while nuclei appear in red; (C) Fluorescence quantification of the 
images shown in A and B for the AANAT intensity (green), normalized to control values; (D) Positive 
and negative controls for AANAT performed with human lens epithelial cells (positive) and human 
chondrocytes (negative). The values are the mean ± SEM of six independent experiments (*** p < 
0.001).  
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right, DIC image, nuclei (in red, propidium iodine), AANAT (in green) and merge image.
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2.2. TRPV4 Activation Increases AANAT Protein Expression in Ciliary Body Epithelial Cells
The application of the selective TRPV4 agonist GSK1016790A during different times up to 48 h at
a single dose of 10 nM, showed changes in AANAT expression as observed in Figure 3. The results
indicated that AANAT expression has a clear maximal peak of 2.4 folds above the control value after
18 h of incubation with TRPV4 agonist (Figure 3A, *** p < 0.001, n = 6).
Interestingly, the values of AANAT showed a decrease after that maximal expression of the
enzyme, returning towards the initial levels (Figure 3B).
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Since A NAT is responsible for melatonin synthesis by producing the precursor N-acetyl
serotonin (NAS), HPLC studies were perfor ed to investigate a possible correlation between the
expression levels of AANAT showed in Figure 3 and the production of both, NAS and melatonin.
As can be seen in Figure 4, both the levels of NAS and melatonin presented maximal concentrations at
18 h, with concentrations of 40.24 ± 1.82 nM in the case of NAS and 21.36 ± 1.83 nM for melatonin
(n = 6, *** p < 0.001 vs. control for NAS and ## p < 0.01 vs. control for melatonin). As happened in the
case of AANAT expression, after 18 h, both NAS and melatonin returned to their initial values.
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2.4. Concentration-Response Study of GSK Effect on AANAT Levels in Ciliary Body Epithelial Cells
After adjusting the time necessary to reach the maximal AANAT expression when activating the
TRPV4 channel, a concentration–response assay was performed at this time by applying different
graded concentrations of GSK ranging from 1 nM to 10 µM. In this sense, it was possible to observe that
AANAT expression reached a maximum at GSK concentration of 10 8 M (Figure 5A). Transformation
of Western blots into a dose–response curve allowed the observation of a sigmoidal pattern that
provided a pD2 value for GSK of 8.34 ± 0.30, which was equivalent to an EC50 value of 4.57 nM (n = 5,
Figure 5B).
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2.5. Effect of TRPV4 Anta o ists on AANAT Levels in Ciliary Body Epithelial Cells
Different antagonists were used to onfirm that the effe t shown by GSK1016790A was actually
acting on TRPV4 channel. he application of 10 M of GSK after 18 produc d a significant increase
in AANAT compared to non-treated cells (Figure 6A). This increment was blocked after applying
a non-selective TRPV1/TRPV4 antagonist Ruthenium Red (RR) and by the selective antagonist of the
TRPV4, RN-1734 (p < 0.001 for both compounds vs. GSK alone; n = 5, Figure 6B).
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Figure 6. Effect of TRPV4 antagonists on AANAT phosphorylation triggered by GSK1016790A:
(A) representative Western blot study showing the activity of TRPV4 antagonist Ruthenium Red
(RR) and RN-1734 (RN), both alone and together with GSK1016790A, following the protocol described
in methods; and (B) column plot showing the relative quantification of the Western blots band
intensities. Values represent the mean ± SEM of five independent experiments (*** p < 0.001 versus
GSK1016790A effect).
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3. Discussion
In this study, we have described that the TRPV4 channel stimulation in the ciliary body epithelial
cells is able to increase the expression of the rate-limiting enzyme of melatonin synthesis aralkylamine
N-acetyltransferase (AANAT) (Figure 7). This increment of AANAT is both time and dosage dependent,
and reaches its maximal effect after 18 h of stimulation with the selective TRPV4 agonist GSK1016790A
at 10 nM concentration [31]. This effect was blocked by TRPs antagonist Ruthenium Red and with the
selective TRPV4 antagonist RN-1734 [32].
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Figure 7. Possible mechanism of action of GSK acting on the TRPV4 channel in the ciliary body. After
the activation of the TRPV4 the influx of Ca2+ will bind to calmodulin (CM) which activates adenylate
cyclase and later protein kinase A (PKA). This kinase will finally produce the phosphorylation of
CREB (cAMP response element-binding) than may stimulate the synthesis of the enzyme AANAT.
This protein together with HIOMT will finally augment the production of melatonin in ciliary body
epithelial cells. TRPV4 channel can be stimulated by the abnormal elevation in IOP that often occur in
glaucoma pathology.
In a previous study, it was possible to demonstrate the presence of the TRPV4 channel in human
ciliary epithelial cells and the effect, after its stimulation, was an increment of melatonin levels [29].
In fact, in a different study carried out in our lab, it has shown that patients with elevated intraocular
pressure actually have higher melatonin levels in the aqueous humor compared to healthy subjects [15].
Moreover, in this study, and supporting the previous observation, it has been possible to visualize
the changes in AANAT expression in the ciliary body when comparing normal and glauco atous
individuals (Figure 7). This increase may explain the rise of melatonin in glaucomatous patients and
opens the question of why, as melatonin concentrations are abnormally elevated in glaucomatous
individuals, this substance cannot reduce IOP s should be expected. In this sense, many studi s have
reported the hypotensive acti n of melatonin and analogs either in norm tensive and glaucomatous
animal models [33,34] as well as in norm tensive and ocular hypertensive human beings [12,35].
The reason why the exogenously added melatonin or analogs, produce a r duction in IOP, seems to
be related to the dose reached in the aqueous humor. In the glaucomatous patient´s ciliary body and
in the human ciliary epithelial cells the elevation of AANAT explains the rise in melatonin in their
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aqueous humor as if the eye wanted to counteract the IOP by acting on melatonin receptors, as the
melatonin is unable to perform its hypotensive effect [15]. More studies are necessary to understand
why melatonin cannot reduce IOP in glaucomatous patients.
Glaucoma pathology is known as the silent thief of sight, as it progressively damages the retinal
cells. Nevertheless, themain risk factor of this disease is, in fact, the elevated intraocular pressure which
can occur either by an increment of the aqueous humor production from the non-pigmented ciliary
body cells or by a decrease in its drainage through the uveoscleral outflow pathway or the conventional
way through the trabecular meshwork [36]. Previous studies in search of finding new treatments for
glaucoma have shown that TRPV4 is linked to trabecular meshwork cells. TRPV4 activation mediates
Ca2+ influx in the trabecular meshwork which, after the use of an antagonist for this channel, resulted
in a decrease in IOP in a murine model of glaucoma [37]. This would imply that the antagonism
of the TRPV4 in the trabecular meshwork could protect the retinal ganglion cells from mechanical
stress [38,39]. However, different studies have shown the opposite effect on IOP after TRPV4 activation
in Lowe syndrome patients. In this sense, TRPV4 activation lowered IOP by acting on the cilia present
in the trabecular meshwork [40].
In this study, together with previous ones [15], it has been possible to establish a clear link between
melatonin synthesis and the TRPV4, pressure sensor channel, which could lead the ciliary epithelium
cells to produce more AANAT in order to synthesize melatonin, which may modify the physiology of
those tissues bathed by the aqueous humor.
4. Materials and Methods
4.1. Cells
Non-pigmented ciliary epithelial cells (59HCE), a human immortalized cell line was kindly
supplied by Miguel Coca-Prados. Cells were grown in high glucose Dulbecco’s modified Eagle’s
medium (Gibco/Invitrogen, Carlsbad, CA, USA) containing 10% fetal bovine serum (Sigma-Aldrich,
St. Louis, MO, USA) and 0.05 mg/mL Gentamicin (Gibco/Invitrogen) at 37  C in humidified
atmosphere 5% CO2–95% air. After the culture reached the confluence, cells were detached with 0.25%
trypsin and seeded into 6-well plates and/or to 4-well chamber slides, respectively. All the experiments
were performed using cells comprising numbers 10–15 passages to assure assays reproducibility.
4.2. Human Eye Tissues
Donor Human eyes were obtained from the Fundación Banco de Sangre y Tejidos de las Islas
Baleares (Blood and tissue bank Foundation from Baleares Islands). This has been approved by
the Ethics Committee of the Universidad Complutense de Madrid with reference C.P.-C.I. 16/249-E
(21 June 2016). Six donor eyes were used for this assay, two of a healthy normal subject and another
four of glaucoma patients. Eyes were enucleated and collected without the cornea in sterile tubes and
maintained in 4% paraformaldehyde in 0.1 M phosphate buffer (PB) (pH 7.2–7.4) at 4  C until posterior
processing. Eyes were dissected under stereomicroscope (Zeiss) and with the 0.8 mm tip curved
forceps and sterile dissecting scissors, the iris and ciliary processes were collected. Several washes in
phosphate buffer saline (PBS) were performed and then, the specimens were cryoprotected in a sucrose
gradient (from 11% to 33%) and were embedded in tissue freezing medium (Tissue-Tek® OCT, Qiagen,
Barcelona, Spain) until frozen with liquid nitrogen. Vertical sections of control and glaucomatous
human samples (10 µm thick) were collected using a cryostat (Microm, Walldorf, Germany) and
mounted from the same region. Samples were maintained in a  20  C until use.
4.3. Immunofluorescent Studies
Frozen sections were rinsed in PBS 1X and permeabilized with PBS-0.05% Tx-100 solution for
30 min. Afterwards, to avoid non-specific staining, sections were incubated in a blocking solution with
a 10% normal donkey serum (NDS, Jackson Immunoresearch, West Grove, PA, USA) during 1 h at
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room temperature. Then, the primary antibody rabbit anti-serotonin N-acetyltrasnferase (AANAT,
ab3505, Abcam, Cambrigde, UK) was incubated at a 1:500 dilution at 4  C overnight. Sections were
washed in PBS1X-0.1% Tx-100 and incubated with donkey anti-immunoglobulin IgG rabbit antibody
conjugated with fluorescein isothiocyanate (FITC; green, Jackson ImmunoResearch, West Grove)
at 1:100 dilution in PBS-0.1% Tx-100 for 1 h in a dark chamber at a room temperature. The nuclei
were stained with propidium iodide (red, Sigma-Aldrich, St. Louis, MO, USA) diluted 1:500 in
PBS for 10 min. Finally, sections were rinsed and mounted in Vectashield (Vector Laboratories, Palex
Medical, Barcelona, Spain) and coverslipped. The samples were examined under a confocal microscope
(Zeiss LSM 5, Jena, Germany) at 40⇥magnification. For ciliary epithelial cells immunostaining, similar
protocol was done for immunostaining of ciliary epithelium cells after incubating them with TRPV4
agonist GSK1016790A using a rabbit anti-TPRV4 (ab94868, 1:1000 Abcam) primary antibody.
4.4. TRPV4 Experiments
Non-pigmented ciliary body epithelial cells were seeded in multiwells of 6 at a density of 1.2⇥ 106
cells and then treated with the TRPV4 agonist GSK1016790A (Tocris Bioscience, Bristol, UK), for
different durations starting from 1, 3, 6, 18, 24, and 48 h to establish a time course at a concentration of
10 nM. The supernatants at the indicated times were collected for melatonin quantification by HPLC
as described below. After the corresponding times cells were submitted to lysis as described below for
Western blot assays.
In different multiwells, after choosing the best time to see an increase of AANAT, a dose–response
curve was obtained by incubating the cells with GSK1016790A at different concentrations ranging
from 1 nM to 10 µM, for 18 h (according to the time-course results). Then, cell lysis was performed to
quantify AANAT (see below).
For antagonists studies, the compounds ruthenium red (RR) and RN-1734 (RN) [29], were assayed
at concentrations of 1 nM and 10 nM respectively, either alone or 30 min before the application of
the TRPV4 agonist GSK1016790A. The supernatants at the indicated times were taken for melatonin
quantification by HPLC as described below, as well as lysed cells for AANAT detection.
4.5. AANAT Western-Blot Studies
Cells were removed and homogenized in ice with RIPA buffer (1:5 v/v) containing 50 mMHEPES,
pH 8, 150 mM NaCl, 1% NP-40 (w/v), 0.5% sodium deoxicolate, 0.1% SDS and Halt Protease and
Phosphate Inhibitor Cocktail (Thermo Fisher Scientific, Madrid, Spain). The lysates were centrifuged
at 15,000⇥ g for 15 min at 4  C. The supernatant was stored at  20  C until use.
Protein concentration was determined by Pierce BCA Protein Assay Kit (Thermo Fisher Scientific,
Madrid, Spain). Cell samples (60 µg proteins) were diluted in Laemmli´s sample buffer, loaded on
a 15% SDS-PAGE gels and transferred to nitrocellulose membrane. Blots were blocked with 5%
non-fat dry milk (Bio-Rad, Madrid, Spain) for 1 h at room temperature and then they were incubated
overnight at 4  C in TBS1X 0.1% Tween 20 containing 5% non-fat milk (Bio-Rad) (blocking buffer) and
AANAT primary antibody (ab3505, 1:1000, Abcam). Mouse monoclonal glyceraldehyde-3-phosphate
dehydrogenase (anti-GAPDH 1:500) (Santa Cruz, Dallas, TX, USA) served as a loading control.
Membranes were incubated with a goat anti Ig G-rabbit or a goat anti-Ig G mouse conjugated
with horseradish peroxidase secondary antibody (Jackson ImmunoResearch, West Grove, PA, USA)
for 1 h at room temperature. Then, proteins were revealed by chemiluminiscence using enhanced
chemiluminiscence (ECL) detection (Amersham Phamacia Biotech, Barcelona, Spain). Films were
scanned with Gel Logic 200 Imaging System (Kodak). The densitometric analysis was performed by
using Kodak Molecular Imaging software (v 4.0.3, Kodak, Rochester, NY, USA). The densitometry
values of each sample were normalized to respective densitometric GAPDH values.
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4.6. HPLC Analysis
N-acetyl serotonin measurements were performed by HPLC following the protocol described
by Alkozi and co-workers [28]. Before injection, the supernatants were heated in a 98  C dry bath
for 2 min before being transferred to ice for 10 min. To eliminate proteins, tubes were centrifuged at
13,000⇥ g for 10 min at 4  C. The analysis by HPLC to detect NAS was carried out using a SunFire18
column (5 µ, 25 cm in length, 0.4 cm inner diameter) from Waters (Milford, MA, USA) equilibrated
with a mobile phase consisting of 15% acetonitrile, 0.1% acetic acid and at a flow rate of 0.75 mL/min,
detecting NAS at the wavelength of 244 nm.
Melatonin measurements were carried out by HPLC as previously described. Briefly, the HPLC
was connected to column Kromaphase C18 with 5.0 µmparticle (25 cm in length, 0.4 cm inner diameter)
from Scharlau, Madrid, Spain. The HPLC consisted of a 1515 Isocratic HPLC pump, a 2487 dual
absorbance detector, and a Reodyne injector, ruled by the program Breeze from Waters (Milford, MA,
USA). The mobile phase was obtained with 40% methanol, 60% H2O. Chromatograms were obtained
at a flow rate of 0.8 mL/min measuring melatonin at a wavelength of 244 nm [27,28].
Quantification of NAS and melatonin was performed by comparing the samples with external
standards provided by Sigma (St. Louis, MO, USA).
4.7. Statistical Analysis
The data represent the mean ±SEM of 4–6 independent experiments (indicated in each case).
Statistical significance was calculated by student t-test or ANOVA test when necessary. GraphPad
Prism, v 5 for MAC (GraphPad Software Inc., San Diego, CA, USA) was used to obtain the plots and to
fit nonlinear regression curves in order to obtain the pD2 value (EC50).
5. Conclusions
TRPV4 channel activation, which is present in the human ciliary body and ciliary body epithelial
cells, increases the expression of the enzyme AANAT, which elevates the concentration of NAS and
melatonin. Elevated intraocular pressure can stimulate this channel too promoting the presence of
higher concentrations of melatonin in the aqueous humor of patients with glaucoma as previously
observed [15]. Altogether, we can suggest that melatonin and AANAT play an important role in
pathologies related to intraocular pressure, although more research is necessary to fully understand
the role of melatonin in the homeostasis of the aqueous humor.
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a b s t r a c t
Melatonin is a substance synthesized in the pineal gland as well as in other organs. This substance is
involved in many ocular functions, giving its synthesis in numerous eye structures. Melatonin is syn-
thesized from serotonin through two enzymes, the ﬁrst limiting step into the synthesis of melatonin
being aralkylamine N-acetyltransferase (AANAT). In this current study, AANAT phosphorylation after the
activation of TRPV4 was studied using human non-pigmented epithelial ciliary body cells. Firstly, it was
necessary to determine the adequate time and dose of the TRPV4 agonist GSK1016790A to reach the
maximal phosphorylation of AANAT. An increase of 72% was observed after 5 min incubation with 10 nM
GSK (**p < 0.05, n ¼ 6) with a concomitant rise in N-acetyl serotonin and melatonin synthesis. The
involvement of a TRPV4 channel in melatonin synthesis was veriﬁed by antagonist and siRNA studies as a
previous step to studying intracellular signalling. Studies performed on the second messengers involved
in GSK induced AANAT phosphorylation were carried out by inhibiting several pathways. In conclusion,
the activation of calmodulin and calmodulin-dependent protein kinase II was conﬁrmed, as shown by the
cascade seen in AANAT phosphorylation (***p < 0.001, n ¼ 4). This mechanism was also established by
measuring N-acetyl serotonin and melatonin levels. In conclusion, the activation of a TRPV4 present in
human ciliary body epithelial cells produced an increase in AANAT phosphorylation and a further
melatonin increase by a mechanism in which Ca-calmodulin and the calmodulin-dependent protein
kinase II are involved.
© 2017 Elsevier Ltd. All rights reserved.
1. Introduction
Melatonin is the substance that was discovered in the pineal
gland and is responsible for the control of those processes related to
light/darkness cycles (Reiter et al., 2014). This molecule can also be
synthesized in other organs and tissues such as the eye and the gut
(Balemans et al., 1980; Bertrand et al., 2010; Rohde et al., 1985). The
effects observed in the eye are related to the control of several
relevant physiological aspects including tear secretion (Hoyle et al.,
2006), corneal wound healing (Crooke et al., 2015), intraocular
pressure (IOP) regulation (Pintor et al., 2001; Samples et al., 1988)
and retinal physiology (Tosini et al., 2012). All these actions are
mainly mediated bymembranemelatonin receptors that have been
classiﬁed as MT1, MT2 (Zlotos et al., 2014) and the putative MT3
(Pintor et al., 2003; Serle et al., 2004) which have been also iden-
tiﬁed in some tissues such as the enzyme quinone reductase-2
(Nosjean et al., 2000).
Melatonin synthesis depends on 5 hydroxy-tryptamine (5-HT or
serotonin) levels. 5-HT is transformed in two steps catalysed by the
enzymes aralkylamine N-acetyltransferase (AANAT) and ace-
tylserotonin O-methyltransferase (HIOMT) (Bernard et al., 1999).
Although both enzymes are necessary for the synthesis of mela-
tonin, AANAT seems to be the limiting step in terms of regulation
(Kim et al., 2007; Tosini et al., 2006). This is a critical aspect when
considering the circadian ﬂuctuations of melatonin throughout the
day, but this does not discard the possibility of AANAT being
regulated by other environmental factors different from the light/
darkness changes such as other hormones, food or even alcohol
intake (Garcia-Marin et al., 2015; Kashani et al., 2015; Peres et al.,
2011; Schomerus and Korf, 2005).
Independently of the cause, regulation of AANAT occurs in two
main ways, by regulating the expression of the gene that encodes
for this enzyme or by a quick process, which involves
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a b s t r a c t
Melanopsin is a non-image forming photoreceptor known to be present in the retina and it is considered
to have light regulated tasks among other functions. In the present work, melanopsin presence in human
lens epithelial cells as well as in human lens tissue is described for the ﬁrst time. Moreover, studying the
concentration of melatonin and its synthesising enzyme AANAT proved a clear link between melanopsin
activation and the suppression of melatonin synthesis. Melanopsin sensitivity to speciﬁc wavelength
(465e480 nm, blue) was conﬁrmed after making temporal studies incubating lens epithelial cells under
light, red, green, blue and total darkness for 2, 4, 8, 12 h and analysing the concentration of both
melatonin and its synthesising enzyme AANAT, discovering that melatonin levels after submitting cells to
total darkness are signiﬁcantly higher to ones submitted to white or speciﬁcally blue light (***p < 0.001,
n ¼ 6). The involvement of melanopsin in the regulation of melatonin was also determined by using a
speciﬁc inhibitor AA92593 and by inhibiting melanopsin-induced phospholipase C activation. Under this
situation neither AANAT nor melatonin levels changed under light conditions (n ¼ 4, ***p < 0.001). The
discovery of melanopsin in the lens opens the possibility of regulating melatonin synthesis with the
corresponding implication as an antioxidant substance.
© 2016 Elsevier Ltd. All rights reserved.
1. Introduction
The most important environmental changes for almost any
living organism are associated with earth's daily rotation. Thus, the
ability to grab occurring changes is critical to survival. Accordingly,
light is considered to provide the most reliable source of informa-
tion about time of the day in order for the organism to adapt its
physiology in accordance with the internal clock (Arbab, 2009). In
such a way, photoreception is essential for the regulation of the
circadian system (Haniﬁn and Brainard, 2007).
Beside object recognition, eyes serves as the sensory organ
which detects the presence or absence of light and eye loss in hu-
man or other mammals results in a failure of photoentrainment
(Bellingham and Foster, 2002). In this sense, melanopsin emerges
as a non-image forming photoreceptor protein in which one of its
functions is a light-regulated task (Provencio et al., 1998).
Melanopsin is a member of the G-protein-coupled receptor
family, a vitamin A-based opsin in the vertebrate retina that has
been shown to be involved in the synchronization of the circadian
rhythms, pupillary light reﬂex, and melatonin suppression (Foster
and Bellingham, 2002; Gooley et al., 2003; Ruby et al., 2002). It is
localized in the intrinsically photosensitive retinal ganglion cells
(ipRGC) and it is known to be speciﬁcally sensitive to blue light
(Hattar et al., 2002). Melanopsin receptors capture this speciﬁc
wavelength and send signals through the suprachiasmatic nucleus
until reaching the pineal gland to supress the synthesis of the
hormone melatonin during the day (Baver et al., 2008; Wurtman
et al., 1963).
Melatonin is synthesized from serotonin through two steps. In
the ﬁrst, serotonin is catalysed by the enzyme Aralkylamine N-
acetyltransferase (AANAT), then the product, N-acetyl-serotonin
(NAS) is taken by the last enzyme in the melatonin synthesis,
Hydroxyindole O-methyltransferase (HIOMT) (Bernard et al., 1999;
Ganguly et al., 2002; Menendez-Pelaez et al., 1987). Both enzymes
are necessary for melatonin formation; nevertheless, AANAT ap-
pears to be the limiting step for its synthesis (Ganguly et al., 2001,
2005).
Melatonin is a neurohormone mainly synthesised by the pineal
gland as indicated, but it is also present in many ocular structures
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Short Commentary
Melatonin is a neurohormone synthesized in the pineal gland as 
well as in other organs and it plays an important role in many ocular 
functions, as it is synthesized in numerous eye structures. Melatonin 
found to reduce the intraocular pressure and in serves as an antioxidant 
preventing against free radicals, hence cataract formation as well as retinal 
damage due to glaucoma, among other functions. Ocular pharmacology 
is a challenging field giving the difficulties of drug delivery inside the eye 
due to its low bioavailability. In this sense, the present brief commentary 
is summarizing the latest advances in non-invasive ocular drug delivery 
focused on the effect of melatonin in different ocular diseases. 
Melatonin is an ancient molecule which was first identified in the 
late 1950s [1]. It exists in almost every organism starting from the 
primitive ones as prokaryotes to the very complex organisms as the 
humans. Melatonin is known as a circadian rhythm regulator [2]. This 
indoleamide is a neurohormone considered classically to be secreted by 
the pineal gland, nonetheless, it is currently known to be synthesized 
in other organs and tissues such as the retina and cerebellum [3,4], 
iris, ciliary body [5], crystalline lens [6,7], Harderian gland [8] and the 
lacrimal gland [9], spleen, heart, skeletal muscle, liver, stomach, gut, 
placenta, testes, ovaries, cerebral cortex and striatum [10].
Melatonin levels in the body are variable giving the time of the 
day, it increases at night and when light enters the eye and reach the 
retina, melatonin is suppressed [11], such photoreception being due to 
specific ganglion cells in the retina containing the pigment melanopsin 
[12]. This neurohormone is of great importance in the eye, apart from 
the retina it has numerous functions, such as working as an antioxidant 
protecting ocular structures against free radicals, for instance, melatonin 
intraperitoneal injection on rats instantly following an oxidative stress 
has shown to protect the lens against cataract [13]. Melatonin is inversely 
related to intraocular pressure since IOP decreases at night while 
melatonin increases [14]. It also has been proved to reduce intraocular 
pressure (IOP) by decreasing the rate of aqueous humour secretion by 
the non-pigmented ciliary epithelium, resulting in a modulation of IOP 
[15]. More importantly, melatonin is important for the cornea, studies 
showed that melatonin accelerate corneal wound healing, and it has 
been possible to demonstrate that the effect of melatonin is to increase 
the rate of cell migration rather than mitosis [16]. Besides, melatonin 
has the ability to potentiate the effect of diadenosine tetraphosphate, a 
tear secretion inducer, being suitable to treat one of the most prevalent 
ocular conditions: Dry eye [17].
Treating ocular conditions have many challenges due to poor drug 
delivery because of effective multiple barriers to drug entry, comprising 
nasolacrimal drainage, epithelial drug transport barriers and clearance 
from the vasculature in the conjunctiva [18]. While topical ocular 
bioavailability is extraordinary poor, in the order of 5% or less, sustained 
delivery systems for diseases of the posterior segment such as various 
vitreoretinal disorders through intraocular delivery systems are used 
via implantable devices or injections [19]. However, independently of 
the fact that intraocular drug delivery systems are invasive, up to date, 
long-term drug delivery for diseases of the anterior segment of the eye 
does not exist.
Improving Melatonin Delivery Within the Eye
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There are several ways for drugs to reach the ocular system, for 
instance, melatonin orally administered at a concentration of 10 mg 
to patients before performing cataract surgery have shown to lower 
intraocular pressure, consequently, they had better operating condition 
[20]. Melatonin was also investigated for the treatment of uveitis in 
hamsters, experiments were done by injecting 5 mg of melatonin before 
the induction of uveitis, and results suggested that melatonin prevents 
the clinical and biochemical consequences of this disorder [21]. 
Among several factors leading to poor bioavailability of drug 
administered topically, the cornea is the primary barrier for anterior 
segment due to lipophilicity and tight junctions which restrain the 
entrance of pharmacological substances [22]. In this sense, experiments 
have demonstrated that when melatonin or any of its analogues is 
topically applied, the amount that appears within the eye was between 
3 and 4 orders of magnitude lower than the instilled amount [23]. This 
relevant fact is suggesting that it is necessary to improve the delivery 
ways to permit better results with less amount of melatonin. 
There are three main ideas that can be highlighted: One can be to 
facilitate the entrance through the cornea by modifying the barrier effect. 
Second, to permit melatonin to remain longer on the ocular surface to 
allow a slow but a sustained entrance of this substance. Third to induce 
the intraocular synthesis of melatonin by modulating light wavelength.
Concerning the first idea, an interesting study showed that the 
molecule diadenosine tetraphosphate (Ap4A), has the ability to make 
transiently disappear the corneal tight junctions permitting efficient 
drug delivery to the eye. A study showed that 5-MCA-NAT, a melatonin 
analog, had more hypotensive effect when instilled topically on New 
Zealand white rabbits when diadenosine tetraphosphate was applied 
two hours before the melatonin analogue. Indeed, when 5-MCA-
NAT was topically applied after using diadenosine tetraphosphate, the 
amount of this melatonin analogue found within the eye was 3-fold the 
one measured when it was instilled alone [24]. This is indicating that 
the transient elimination of the corneal tight junctions is an effective 
mechanism to permit the entrance of molecules into the eye [25].
The second idea consists of permitting melatonin to remain longer 
on the ocular surface. A possible alternative for a long-term drug 
delivery is the use of contact lenses, in such a way, ocular bioavailability 
will be improved considering reduced tear mixing between the lens 
and the cornea besides the extended drug release [26]. The traditional 
method is to soak the lens in drug solution in order for the drug to be 
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absorbed into the polymeric lenses, this way permit limited and slow 
release of the drugs into the post-lens lacrimal fluid [18,27]. Melatonin 
and analogues can be soaked in contact lenses overnight and the lenses 
can be fitted to obtain a sustained release of these substances. In this 
way, when melatonin is topically instilled it lasted no more than 2 min 
on the ocular surface as happens with all compounds applied in this way 
[18] (Kompella, Kadam et al. 2010). When melatonin and analogues 
are released from contact lenses the maximal release occurs 2 hours 
after the lens fitting their presence being measurable for more than 300 
min, as it happens with other naturally occurring substances [27]. This 
slow but sustained release of melatonin will permit the entry of this 
substance and therefore a more robust intraocular effect. 
The third idea is based on modifying the light that enters the eye in 
order to induce the natural production of melatonin in the lens, instead 
of applying it exogenously. Recently, it has been possible to describe 
the presence of melanopsin in the lens epithelium [28]. This pigment 
abolishes the synthesis of melatonin when the lens is illuminated with 
blue light (including the blue component of white light). Therefore, it 
is possible to induce the synthesis of melatonin by reducing the blue 
component of white light (460-490 nm wavelength) by means of filters. 
Interestingly, white light permits a discrete synthesis of melatonin 
in lens epithelial cells (about 20 pmol/106 cells), but the blockade of 
blue light permits levels which are 3-fold higher (60 pmol/106 cells) 
[28]. This regulation of the local synthesis of melatonin by filtering 
light, could be an interesting approach to induce melatonin synthesis 
intraocularly and to help in processes such as the reduction of IOP and 
cataract prevention. 
In summary, melatonin has proven effective for several ocular 
disorders and it could be interesting to investigate the best possible way 
for its delivery giving the challenges ophthalmologists are facing due to 
limited non-invasive drug delivery systems to the eye.
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